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Autoimmunity can occur when self-reactive lymphocytes of the adaptive immune system are 
activated upon encounter with antigen.  This can lead to the development of debilitating and 
potentially life-threatening autoimmune diseases such as type-1 diabetes, rheumatoid arthritis 
and multiple sclerosis.  Regulatory T cells (Tregs) are a subset of CD4+ T cells that express 
the lineage-specific transcription factor Foxp3 and exert dominant peripheral tolerance to 
maintain immune homeostasis.  It is therefore important to fully understand the underlying 
mechanisms of Treg development, homeostasis and function due to the positive and negative 
effects that therapeutic manipulation could have on this essential T lymphocyte population.   
 
Many effector molecules have been proposed to have a central role in regulatory T cell 
function, and it is now clear that Tregs are equipped with multiple mechanisms by which to 
exert suppressive function.  It has been reported that the cytotoxic T lymphocyte antigen-4 
(CTLA-4) receptor is constitutively expressed by regulatory T cells and a role for this 
molecule in Treg suppression has been suggested.  
 
This investigation revealed a role for CTLA-4 in maintaining homeostasis of the peripheral 
regulatory T cell compartment.  In addition, using a transgenic mouse model that permitted 
the development of antigen-specific Ctla-4-deficient Tregs, a role for the CTLA-4 receptor in 
Treg suppressive function was identified.  The data obtained suggest that the CTLA-4 
receptor may function on regulatory T cells by modulating CD80/CD86 co-stimulatory 
molecule expression by antigen-presenting cells, and hence their capacity to activate 
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All organisms are at risk of infection and disease caused by invasion of unwanted, foreign 
pathogens.  Therefore, various mechanisms of immunity have evolved to provide protection.  
The vertebrate immune system is a highly effective biological defence mechanism; potentially 
pathogenic microorganisms are continually encountered on a daily basis, but illness is a 
relatively rare occurrence.  Immunity in vertebrates consists of complex, highly regulated 
interactions between many types of tissues, cells and proteins, which are divided into two 
parts: the innate and the adaptive immune responses. 
 
1.1.1 The Innate Immune System.   
Innate immunity is a basic, first line of defence against infection.  Innate defence mechanisms 
actively exist within an organism prior to encounter with pathogens, and therefore act quickly 
and efficiently to eliminate invading microorganisms and prevent infection.  The physical and 
chemical mechanisms of the mammalian innate immune system are evident throughout the 
evolution of multicellular organisms.  The epithelial surfaces of the skin and internal mucosa 
provide a physical barrier to infection.  Additionally, pathogen invasion is inhibited by the 
secretion of anti-microbial enzymes and peptides in, for example, saliva and tears [1].  If 
pathogens do manage to overcome the physical epithelial barrier and enter the organism this 
can trigger the activation of an enzymatic cascade known as the complement system [2].  
Effector functions of complement include the direct lysis of bacteria- or virus-infected cells 
and promotion of pathogen clearance by the phagocytic cells of the innate immune system.        
 
In addition to physical and chemical elements, there is also a cellular component of innate 
immunity.  Cells of the innate immune system are leucocytes of myeloid origin; this includes 
macrophages, neutrophils and dendritic cells (DCs) which ingest and destroy invading 
pathogens by phagocytosis.  Innate immune cells recognise conserved structures which are 
common to many pathogens, but not found on host cells [3].  These pathogen-associated 
molecular patterns (PAMPs) are identified by pattern-recognition receptors (PRRs) on the 
surface of innate leucocytes [4], for example, toll-like receptors (TLRs) [5].  Innate immunity 
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depends on invariant, germ-line encoded receptors which trigger an almost immediate attack 
on pathogens.  However, infectious microorganisms are not always successfully eliminated by 
the innate immune system because pathogens evolve to escape detection by the 
genome-specified pattern-recognition receptors.  When innate immunity is bypassed, evaded 
or overwhelmed, there is also the adaptive immune response to control infection.             
 
1.1.2 The Adaptive Immune System.   
Adaptive immunity has evolved to overcome the constraints of innate immunity in that a 
specific immune response is generated to a particular pathogen and results in immunological 
memory to provide enhanced protection against re-infection.  The adaptive immune system 
consists of leucocytes of lymphoid origin, namely T lymphocytes and B lymphocytes.  The 
importance of adaptive immunity is illustrated by the severe immuno-compromised 
phenotypes associated with defects in the adaptive immune system [6].   
 
The clonal selection theory, first hypothesised by Macfarlane Burnet in the 1950s, describes 
the basic principle of the adaptive immune response [7].  Each lymphocyte has cell-surface 
antigen-receptors of a single specificity, and upon encounter with its specific antigen the 
particular lymphocyte is activated to proliferate.  This generates many progeny cells, all with 
the same cell-surface antigen-receptors specific for a particular pathogen, which differentiate 
into either effector lymphocytes to eliminate the infection or memory lymphocytes that are 
primed to produce a rapid response if the particular pathogen is encountered again.  In order 
to generate a population of individual, specific lymphocytes capable of recognising diverse 
pathogens, the cell-surface antigen-receptors are not germ-line encoded but formed by the 
random recombination of variable receptor gene segments [8].                 
 
The adaptive immune system is initiated by the innate immune system upon infection by a 
pathogen.  Peripheral lymphoid organs such as the spleen and lymph nodes (LNs) are highly 
organised structures specialised to promote the interaction of innate immune cells with 
lymphocytes to activate the adaptive immune response.  Dendritic cells are long-lived, 
specialised phagocytic cells present in most tissues where they provide surveillance against 
infecting pathogens.  In addition to pattern-recognition receptor-mediated phagocytosis of 
pathogens, dendritic cells continually sample the local extracellular environment by the 
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receptor-independent process of macropinocytosis.  Uptake of a pathogenic agent activates 
tissue-resident dendritic cells to migrate to nearby draining lymph nodes, mature into a 
specialised antigen-presenting cell (APC) and interact with re-circulating T lymphocytes, 
thereby initiating an adaptive immune response [9].                    
 
1.1.3 T Lymphocytes.   
All lymphocytes originate from haematopoietic stem cell progenitors in the bone marrow.  
T cell precursors then migrate to the thymus where they undergo maturation into naïve 
T lymphocytes [10], which are then exported to re-circulate in the peripheral blood and 
lymphatic system.  Two broad classes of T lymphocytes develop in the thymus from a 
common CD4+CD8+ precursor; CD4+ helper T cells which activate other cells of the 
immune system, and CD8+ cytotoxic T cells that destroy virally infected cells.       
 
T cell receptors (TCRs) recognise antigens as peptide fragments displayed on the surface of 
antigen-presenting cells, such as dendritic cells.  Antigen-presenting cells process antigens 
which are then delivered to the cell surface and presented by specialised glycoproteins called 
major histocompatibility complex (MHC) molecules that bind the CD4 and CD8 co-receptors 
on T cells.  CD8+ T cells are MHC class I restricted, which is expressed on all nucleated cells 
and displays endogenously derived peptides from intracellular pathogens infecting the cell.  
CD4+ T cells are MHC class II restricted which displays exogenously derived peptides from 
extracellular pathogens [11].  However, the binding of an antigen-specific T cell receptor and 
CD4 or CD8 co-receptor to a peptide:MHC complex is not sufficient for naïve T cell 
activation.  A second, independent co-stimulatory signal is also required.  The 
antigen-presenting cell displaying the peptide:MHC complex simultaneously expresses the 
ligands, CD80 and CD86, that interact with the co-stimulatory receptor CD28 on the T cell 
surface to deliver an activation signal alongside the antigen-specific signal via the T cell 
receptor [12]. 
         
Upon full T cell activation following T cell receptor stimulation by antigen and 
CD28-mediated co-stimulation, naïve T cells differentiate into effector T cells (Teff).  
Effector T cells can be classified into functional groups that detect antigen from different 
types of pathogen and therefore eliminate it accordingly.  Activated CD8+ T cells 
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differentiate into cytotoxic T lymphocytes (CTLs) and have the ability to kill infected target 
cells.  Apoptosis of an infected target cell is induced by one of two main mechanisms [13].  
Cytotoxic T lymphocytes can release cytotoxins; perforin disrupts the target cell membrane 
allowing entry of granzyme.  Alternatively, CD8+ T cells can express the FAS ligand which 
interacts with the death receptor FAS on the target cell.  To ensure that cytotoxic 
T lymphocytes only target infected cells, exogenously derived peptide antigens are excluded 
from the MHC class I pathway [14].  CD4+ helper T lymphocytes produce cytokines to 
recruit and activate other immune cells.  TH1 CD4+ T cells express the transcription factor 
T-bet and secrete interferon-gamma (IFN-γ) to activate macrophages as part of an 
inflammatory response [15], whereas production of interleukin-4 (IL-4), IL-5 and IL-13 by 
GATA3-expressing TH2 CD4+ T cells initiates a B cell-mediated humoral response [16].  
More recently, an additional CD4+ helper T cell subset has been identified to be involved in 
orchestrating the inflammatory response.  TH17 cells express the transcription factor RORγt 
and produce the cytokines IL-17, IL-21 and IL-22 [17, 18].  The TH17 immune response is 
thought to protect against fungal infections and Gram-negative bacteria through the 
recruitment and activation of neutrophils [19].        
 
It takes several days for clonal expansion and differentiation into effector T cells, therefore an 
important element of the adaptive immune response is the generation of immunological 
memory.  During the differentiation of effector T lymphocytes, CD4+ and CD8+ memory 
T cells are also generated.  Memory T cells are long-lived and ensure the rapid instigation of a 
secondary, antigen-specific adaptive immune response upon subsequent infection with the 
same pathogen [20].        
 
1.1.4 B Lymphocytes.   
In addition to the cellular T lymphocyte response, adaptive immunity consists of the humoral 
immune response in which antibody-producing B cells protect the extracellular spaces from 
pathogenic infection.  B lymphocytes, like T cells, originate from haematopoietic stem cell 
progenitors in the bone marrow.  However, unlike T cells, B cells remain in the bone marrow 
to mature.  Antigen recognition activates B cells to differentiate into plasma cells that secrete 
antibody; the effector molecule of humoral immunity.  Similar to the T lymphocyte response, 
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memory B cells are also generated to provide long-term immunity to re-infection with the 
same pathogen [21].   
 
The B cell receptor (BCR) is a membrane-bound antibody (immunoglobulin) that upon 
antigen-recognition transmits an activation signal into the B cell to initiate plasma cell 
differentiation.  Like T lymphocytes, B cells require more than simply antigen alone for full 
activation to differentiate into antibody-secreting plasma cells; CD4+ helper T cells provide 
the requisite accessory signals [22].  Therefore, the B cell receptor also delivers bound antigen 
into the B cell for degradation and processing, and MHC class II molecules then present the 
peptides on the B cell surface to CD4+ helper T cells.  An example accessory signal provided 
by helper T cells is CD40 ligand (CD40L), that upon interaction with CD40 on B cells drives 
resting B cells into cell cycle and increases expression of CD80 and CD86 co-stimulatory 
molecules which enhance the mutual T-B lymphocyte interaction by sustaining T cell growth 
and differentiation [23].    
 
Upon encounter with antigen in the presence of helper T cells, naïve B cells differentiate into 
antibody-producing plasma cells at sites within lymphoid tissues known as germinal centres 
(GCs) [24, 25].  Germinal centres are areas of intense proliferation where B cells undergo 
somatic hypermutation of the antigen recognising, variable portion of antibody to create 
immunoglobulin diversity and improve antibody affinity for antigen.  Antibodies are versatile 
as effector molecules; the effector function of antibodies is determined by the Fc tail region, 
and therefore different isotypes of antibody are produced to confer functional diversity to the 
humoral response.  Different cytokines preferentially induce immunoglobulin class switching 
in the germinal centre reaction to produce different isotypes of antibody such as IgG and IgE.  
Secreted antibody functions in three main ways to mediate the humoral response to infection 
[26].  Firstly, antibodies can neutralise a pathogen or toxin by blocking adherence to host cells 
and consequent infection.  Secondly, recognition of antigen by antibody creates an 
immunoglobulin coat which opsonises the bound pathogen or toxin for identification and 
destruction by phagocytic cells of the immune system.  Lastly, antibodies bound to pathogens 
can also activate the complement system that results in the formation of a membrane attack 




Highly specific, adaptive immune responses towards such a variety of pathogenic antigens are 
possible due to the random generation of many diverse lymphocyte receptors.  However, in 
order to ensure that the immune receptor repertoire is large enough to recognise a significant 
amount of the almost infinite number of potentially pathogenic antigens, some self-reactive 
lymphocytes are predictably generated.  Autoimmunity can occur when an immune response 
is mounted against self-tissue antigens as opposed to invading, foreign pathogens.  
Pathologically, autoimmune disease results from this immune-mediated attack of self-tissues.  
Consequently, there are immunological tolerance mechanisms that actively prevent 
autoimmunity but still allow the effective control of infection [27].      
 
1.2.1 Immunological Tolerance.   
The random generation of many diverse lymphocyte receptors to provide effective immunity 
against the almost infinite number of pathogens that could be encountered inevitably 
generates some that recognise self-antigens.  Immunological tolerance is the active failure to 
mount an immune response to a particular antigen, and therefore protects against 
autoimmunity.  
 
Self-reactive T and B lymphocytes can be generated; therefore both T cells and B cells can be 
made immunologically tolerant.  During B lymphocyte development, self-reactive B cell 
receptors are deleted by undergoing negative selection upon recognition of self-molecules 
present in the bone marrow [28].  Peripheral tolerance mechanisms that control any 
self-reactive B cells which escaped clonal deletion are not that well understood.  Upon 
encounter with self-antigen, peripheral B cells can be induced to undergo apoptosis [29, 30] 
or become anergic [27].  B cell activation and differentiation into antibody-producing plasma 
cells requires T cell help, consequently T cell tolerance is much more rigorous.             
 
Similar to B cell tolerance, T cell tolerance involves both central tolerance mechanisms that 
occur within the thymus during T cell development, and peripheral tolerance mechanisms to 
control any self-reactive T cells that circumvent central tolerance and are exported to the 
























Figure 1.01.  A diagram to illustrate immunological T cell tolerance.  In the 
thymus (left) T lymphocytes develop bearing T cell receptors that recognise an 
almost infinite repertoire of different antigens.  Central tolerance mechanisms exist 
to delete highly self-reactive T cells by negative selection.  Mature thymocytes are 
exported to the periphery to provide immunity against invading pathogens (right).  
Peripheral tolerance mechanisms such as regulatory T cells control the unwanted 
activation of any self-reactive T cells, that escaped negative selection in the thymus, 
upon encounter with their self-antigen.        
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T lymphocytes undergo both positive selection to ensure self-MHC is recognised and negative 
selection to delete T cells that recognise self-antigens [31].   
 
Positive selection occurs in the thymic cortex and is mediated by cortical thymic epithelial 
cells (cTECs).  CD4/CD8 double positive thymocytes are positively selected on their ability 
to recognise self-MHC molecules.  Developing thymocytes that fail to bind self-MHC 
molecules on the thymic stroma within the cortex are induced to undergo programmed cell 
death.  The MHC gene is highly polymorphic which increases the range of antigens that can 
be presented to T cells.  However, this MHC allelic diversity means that T lymphocytes are 
MHC-restricted in their antigen recognition.  Thus, positive selection identifies 
T lymphocytes that are capable of responding to infected host cells.  During positive 
selection, CD4/CD8 double positive thymocytes are also coordinated to express the CD4 or 
the CD8 co-receptor according to recognition of MHC class II or MHC class I molecules, 
respectively.       
 
Following positive selection in the thymic cortex, T lymphocytes with strongly self-reactive 
receptors are deleted in the medulla by negative selection.  The autoimmune regulator AIRE 
(a transcription factor) promotes the expression of self-antigens by medullary thymic 
epithelial cells (mTECs) [32].  This promiscuous gene expression of tissue-specific antigens 
within the thymus identifies any highly self-reactive T cells that have been generated and 
those that pose the greatest threat are induced to undergo apoptosis.  There is also now 
evidence for intercellular self-antigen transfer between thymic epithelial cells and thymic 
dendritic cells within the medulla microenvironment which would increase the efficacy of 
negative selection by broadening the cellular basis of self-antigen presentation for tolerance 
induction [33].       
 
There is a fine balance between the elimination of highly self-reactive T lymphocytes and the 
development of a diverse T cell receptor repertoire to provide efficient protection against 
pathogenic infection.  Consequently, some self-reactive T cells evade central tolerance and 
are exported to the periphery.  Thus, peripheral tolerance mechanisms exist to control 
potentially self-reactive T cells and the development of autoimmunity.  One mechanism of 
peripheral tolerance is the generation of immunoprivileged sites where anatomical barriers 
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prevent lymphocytes encountering antigen and the cytokine environment inhibits the 
development of an immune response [34].  These are generally tissues that upon mal-function 
could hinder the survival of an organism, such as the central nervous system (CNS), eye and 
placenta.  Also, T cells can be made unresponsive upon antigen encounter by the induction of 
anergy.  T cell stimulation with antigen via the T cell receptor in the absence of CD28 
co-stimulation has been reported to induce an anergic state of unresponsiveness [35-38].  
Finally, peripheral tolerance is actively maintained by a subset of T lymphocytes called 
regulatory T cells (Tregs) [39].  This specialised population of CD4+ T cells is thought to 
maintain immune homeostasis by suppressing the inappropriate activation of T cells, such as 
any self-reactive T cells that encounter antigen to thereby prevent autoimmunity and the 
development of autoimmune disease.  In addition to these natural mechanisms of peripheral 
tolerance, immunological tolerance can be induced or acquired in the periphery [40].  For 
example, in oral tolerance, continually encountered, non-self food proteins induce the immune 
system to adapt to external antigens that pose no threat, and failure to acquire tolerance can 
lead to the development of inflammatory bowel disease (IBD).  Clinically, the induction of 
tolerance is of key importance in tissue transplantation.                  
 
1.2.2 Type-1 Diabetes.   
Dysregulated immune homeostasis can result upon loss of immunological tolerance and lead 
to the development of autoimmunity.  There are many different types of autoimmune diseases 
mediated by both self-reactive T and B lymphocytes.  Autoimmune diseases are broadly 
classified as systemic when the self-antigens are ubiquitous, for example systemic lupus 
erythematosus (SLE) and rheumatoid arthritis (RA), or organ-specific when disease is limited 
to auto-antigens of a particular organ, such as type 1 diabetes (T1D) and multiple sclerosis 
(MS) [41]. 
 
Type-1 diabetes is one of three main forms of diabetes.  It is a T cell-mediated autoimmune 
disease in which insulin-producing beta-cells of the islets of langerhans in the pancreas are 
destroyed by the immune system.  Upon islet cell destruction, the decrease in production of 
insulin by the pancreas results in a loss of control over blood glucose homeostasis and 
consequently hyperglycemia.  Long-term, chronic disease can result in limb amputation due 
to gangrene, renal failure, blindness, coma and stroke [42].   
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Susceptibility to type-1 diabetes is thought to be genetically inherited [43].  However, 
environmental stimuli such as viral infection or stress seem to trigger disease onset [44].  
Particularly in the developed western world the incidence of type-1 diabetes is on the increase 
[45].  Currently there is no true, complete cure for type-1 diabetes.  Kidney-pancreas organ 
transplants have proved to be successful in making patients insulin-independent [46].  This 
treatment does however require long-term immunosuppressive drug therapy.  Thus, at present 
treatment of type-1 diabetes requires that patients control the disease with regular insulin 
injections to maintain glucose homeostasis.   
 
The pathological mechanisms that lead to the development of type-1 diabetes are not fully 
understood; although there is strong evidence that disease is associated with loss of 
immunological self-tolerance.  Due to their function of mediating immunological peripheral 
tolerance, defects in regulatory T cell number or function may be critically involved in the 
development of type-1 diabetes and many other autoimmune diseases.  Early studies reported 
reduced numbers of regulatory T cells in type-1 diabetic patients [47].  However, subsequent 
studies have found no difference in the frequency of CD4+ CD25+ Tregs between type-1 
diabetic subjects and normal controls [48-50], even when FOXP3 was used as a more specific 
lineage marker for regulatory T cells [42].  One of these studies found that even though type-1 
diabetic patients had normal numbers of peripheral regulatory T cells, these Tregs were 
defective in their functional ability to suppress effector T cell proliferation during in vitro 
co-culture [48].  On the other hand, isolation of regulatory T cells as only the CD4+ CD25hi 
population did not identify a difference in in vitro Treg suppressive capacity between type-1 
diabetic patients and normal controls [49].  Type-1 diabetes is difficult to study in humans as 
clinical diagnosis of loss of blood glucose control by insulin occurs after manifestation of 
widespread pancreatic islet destruction.  Therefore animal models of type-1 diabetes have 
been valuable tools for studying the onset and progression of the disease.   
 
1.2.3 Transgenic, Adoptive Transfer Mouse Model of Autoimmune Diabetes. 
The non-obese diabetic (NOD) mouse which spontaneously develops diabetes similar to the 
human disease is frequently used to study type-1 diabetes and the role of regulatory T cells in 
autoimmunity [51].  However, the Tregs present in these model animals have to be analyzed 
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as whole heterogeneous populations because their antigen-receptor repertoire recognizes a 
huge variety of self-antigens encountered in the thymus during development.  Our laboratory 
has developed a transgenic mouse model to facilitate the study of regulatory T cells with a 
single antigen specificity [52, 53] (Fig. 1.02). 
 
DO11.10 Rag2-/- transgenic mice contain CD4+ T lymphocytes that possess the DO11.10 
transgenic T cell receptor, which can be specifically identified using a fluorescently labeled 
monoclonal antibody (KJ-126).  The DO11.10 transgenic TCR recognizes the chicken egg 
glycoprotein ovalbumin (OVA).  In RIP-mOVA transgenic mice expression of the 
membrane-bound form of OVA is under the control of the rat insulin promoter (RIP), 
therefore these mice specifically express the OVA protein on the β cells of the pancreas.  
Consequently, adoptive transfer of DO11.10 Rag2-/- CD4+ T cells into RIP-mOVA mice, 
which are also Rag2-/- and therefore T and B lymphocyte deficient, causes pancreatic islet 
destruction and development of overt diabetes, which can be monitored by blood glucose 
readings.  Additionally, antigen-specific (KJ-126+) CD4+ CD25+ regulatory T cells can be 
obtained from DO11.10 Rag2-/- x RIP-mOVA Rag2-/- mice because the rat insulin promoter 
also drives mOVA expression in the thymus, therefore in these double positive mice a 
regulatory T cell population develops with a single DO11.10 TCR specificity.  Co-transfer of 
antigen-specific (KJ-126+) CD4+ CD25+ regulatory T cells with DO11.10 Rag2-/- CD4+ 
T cells into RIP-mOVA Rag2-/- mice suppresses the development of diabetes.  This 
transgenic, adoptive transfer mouse model of autoimmune diabetes is therefore a very useful 
tool for studying antigen-specific Tregs in-vivo [52] as 100% of these mice spontaneously 



















Figure 1.02. Transgenic, adoptive transfer mouse model of autoimmune diabetes.  Adoptive transfer of TCR- 
transgenic (DO11.10) CD4+ CD25- T cells, that specifically recognise the model antigen ovalbumin, into RIP- 
mOVA Rag2-/- host mice, which express the model antigen ovalbumin under the control of the rat insulin promoter, 
causes pancreatic islet destruction and development of overt diabetes in around 3 weeks.  Co-transfer of TCR- 
transgenic (DO11.10) CD4+ CD25+ Tregs suppresses the development of diabetes.   
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1.3 Regulatory T Cells 
Regulatory T cells are a subset of CD4+ T cells specialised to exert dominant immunological 
tolerance in the periphery, by suppressing the activation of effector T cells, to maintain 
homeostasis.  The concept of specialised suppressor T cells was an active area of cellular 
immunology research in the 1970s.  However, with the molecular biology revolution of the 
1980s; CD4+ helper T cells and CD8+ cytotoxic T cells were cloned, but no suppressor T cell 
subset could be identified [54].  This led to widespread questioning of the very existence of a 
specialised suppressor T cell subset.  Almost 15 years ago, there came a renaissance in the 
suppressor T cell field when Sakaguchi and colleagues demonstrated the existence of 
naturally occurring, thymus-derived CD4+ T cells that expressed the interleukin-2 (IL-2) 
receptor α-chain (CD25+), and which protected from autoimmunity to maintain peripheral 
immunological tolerance [39].  This CD4+ CD25+ T cell subset was subsequently found to 
inhibit effector T cell responses both in vitro and in vivo [55-57], and are now termed 
regulatory T cells.   
 
Regulatory T cells were firmly established as a distinct T cell subset with the identification of 
the lineage-specific forkhead box P3 transcription factor, FOXP3 [58-60].  Foxp3 encodes a 
member of the forkhead / winged-helix family of transcription factors, also known as Scurfin.  
Genetic mutations of Foxp3 in both mice and humans leads to the development of severe, 
fatal autoimmune disease; scurfy and immunodysregulation polyendocrinopathy enteropathy 
X-linked syndrome (IPEX), respectively [61, 62].  Since the identification of Foxp3 as a 
regulatory T cell-lineage marker, it has been established that FOXP3 has an essential role in 
maintaining the transcriptional and function programs of Tregs (reviewed in [63]).  More 
recently, the molecular mechanisms that maintain Foxp3 expression in Tregs have begun to 
be elucidated; for instance a complex of the transcription factors RUNX and CBFbeta has 
been implicated [64].       
 
CD4+ FOXP3+ regulatory T cells critically control unwanted effector T cell responses, such 
as those towards self-antigens during autoimmune diseases and those towards non-harmful 
foreign antigens during allergic reactions.  Therefore, it is important to fully understand the 
development, homeostasis and function of the regulatory T cell subset due to the therapeutic 
potential to treat autoimmunity and allergy [65].  Modulation of the regulatory T cell 
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population also has therapeutic implications in the promotion of tolerance following 
transplantation [66].  Additionally, the CD4+ FOXP3+ regulatory T cell population is one of 
the main barriers to overcome in cancer therapy as Tregs function to suppress anti-tumor 
immune responses.  Murine studies have shown that Treg depletion leads to enhanced tumor 
immunity [67-70], and CD4+ FOXP3+ Tregs have been found to be increased in the 
peripheral blood and, in some instances, tumor infiltrating lymphocytes of human cancer 
patients [71].        
 
1.3.1 Development of Natural Regulatory T cells in the Thymus. 
Natural CD4+ FOXP3+ regulatory T cells constitute 5-10% of the peripheral CD4+ T cell 
population.  It was realised that natural Tregs develop in the thymus and migrate to the 
periphery as studies in mice found that neonatal thymectomy resulted in lethal autoimmunity 
and a lack of peripheral regulatory T cells [72].  It is still not completely understood how 
CD4+ FOXP3+ regulatory T cells develop in the thymus.  It was initially proposed that 
differentiation into the FOXP3+ Treg lineage is determined according to TCR-signal strength 
during thymic development.  As discussed previously, during thymic development all 
T lymphocytes that receive a weak TCR-signal are positively selected to survive and develop, 
but a very strong TCR-signal induces apoptosis and the self-reactive T cells undergo negative 
selection.  An intermediate TCR-signal was hypothesised to up-regulate Foxp3 expression 
and commit the developing T cell to the Treg lineage (reviewed in [73]).   
 
Studies using TCR-transgenic mice support the requirement of intra-thymic self-antigen 
encounter for FOXP3+ regulatory T cell differentiation as Tregs do not develop in mice that 
express a single, transgenic TCR unless the cognate antigen for the transgenic TCR is 
expressed in the thymus [74, 75].  Analysis of conventional and regulatory T cell receptor 
genes originally identified minimal overlap between the two T cell populations with 
regulatory, but not conventional, T cells expressing self-antigen specific TCRs [76].  In 
contrast, more recent analyses of conventional and regulatory T cell receptor sequences, by 
the same laboratory, suggest that Tregs express a polyclonal TCR repertoire which does not 
preferentially recognise self-antigens, but is comparable to the polyclonal TCR repertoire of 
conventional T cells (Tconv) [77].        
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As discussed above, positive selection of developing thymocytes occurs in the cortical region 
of the thymus, and then AIRE-induced, promiscuous self-antigen expression in the thymic 
medulla mediates negative selection of self-reactive T lymphocytes.  Some studies suggest 
that FOXP3+ regulatory T cells arise at the CD4 single-positive stage, alongside negative 
selection, in the thymic medulla [78, 79].  Consistent with this, FOXP3+ cells can only be 
found in the medullary region of Foxp3-GFP reporter mice thymi [80].  On the other hand, it 
has also been found that differentiation into the FOXP3+ Treg lineage may be initiated in 
cortical CD4/CD8 double-positive thymocytes earlier in thymic development [81-84].  In 
addition to induction of Treg differentiation by cortical thymic epithelial cells, medullary 
thymic epithelial cells or thymic dendritic cells, it has recently been proposed that 
developmental control of immature thymocyte differentiation into the regulatory T cell 
lineage is T cell-intrinsic and does not require a dedicated antigen-presenting cell [85].                        
              
In addition to antigen-encounter, CD28-mediated co-stimulation has been found to be 
required for CD4+ FOXP3+ regulatory T cell thymic development.  Analysis of 
CD28-deficient mice and anti-CD80/anti-CD86 antibody treated mice identified a significant 
decrease in the percentage and number of CD4 single-positive CD25+ thymocytes [86].  A 
role for the CD28 co-stimulatory receptor homologue, CTLA-4, in FOXP3+ Treg 
development has not been specifically addressed.  However, no overall defects in thymic 
selection and thymocyte development have been identified in Ctla-4-deficient mice [87, 88].    
 
Regulatory T cells constitutively express the IL-2 receptor α-chain, CD25, and there is 
substantial evidence that IL-2 signalling plays a role in Treg development.  IL-2-knockout and 
IL-2Rα/β-knockout mice have a substantially reduced CD4+ CD25+ Treg population and 
exhibit similar severe and fatal autoimmunity to Foxp3-deficient mice [89-93].  Adoptive 
transfer experiments or generation of mixed bone marrow chimeras to correct the deficient 
Treg population inhibited the lethal autoimmunity [94-96].  Furthermore, thymus-specific 
expression of IL-2Rβ in IL-2Rβ-/- mice restored the production of functional CD4+ CD25+ 
Tregs and prevented fatal autoimmunity [93, 97].  The IL-2 cytokine is a T cell growth factor, 
and it has been proposed that IL-2 signalling functions in regulatory T cell thymic 
development to drive expansion of this population following initial production of thymic 
CD4+ CD25+ Tregs [98]. 
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Transforming growth factor-beta (TGF-β) is another cytokine that has been extensively 
studied in determining the molecular mechanisms involved in thymic Treg differentiation as 
mice deficient in TGF-β also have a similar severe autoimmunity phenotype to 
Foxp3-deficient and IL-2-deficient mice [99, 100].  Initial analysis of TGF-β-knockout and 
TGF-βRII-knockout mice found an unaltered, or if anything augmented, thymic FOXP3+ 
population [101-104].  However, it has recently been proposed that TGF-β signalling plays a 
formerly unrecognised role in the thymic development of CD4+ CD25+ FOXP3+ regulatory 
T cells that was previously masked by the increased IL-2 present in TGF-βRI-knockout mice 
[105].        
 
1.3.2 Adaptive Regulatory T Cells in the Periphery. 
In addition to natural regulatory T cells that develop in the thymus and are exported to the 
periphery to exert dominant immunological tolerance, Foxp3 expression can be induced in 
peripheral CD4+ FOXP3- conventional T cells to generate adaptive Tregs (also called 
TH3 cells).  It is thought that adaptive regulatory T cells have a functional role in controlling 
allergic inflammation and maintaining mucosal tolerance to continuously encountered, 
non-harmful environmental and food antigens (reviewed in [106]).  Induction of Foxp3 
expression in vivo by foreign antigen has been demonstrated by a number of different 
methods [107-110], and more recently the adaptive Tregs generated have been shown to 
functionally exert suppressive activity [111-113].  
 
The requirements and molecular mechanisms of Foxp3 induction to generate adaptive Tregs 
are still not completely understood.  In vitro, TGF-β has been found to induce Foxp3 
expression [114].  Consistent with this, neutralisation of TGF-β in vivo has been found to 
impair oral tolerance and inhibit the differentiation of antigen-specific adaptive Tregs [110, 
115].  Specifically in the gut-associated lymphoid tissue (GALT), retinoic acid present in this 
microenvironment has been suggested to play an important role in the TGF-β induction of 
Foxp3 expression and generation of adaptive Tregs [116-118].  However, more recent 
evidence has found that retinoic acid may facilitate TGF-β induction of FOXP3+ Tregs by 
inhibiting the generation of effector TH17 cells [119].  Recently, the Runt-related transcription 
factors RUNX1 and RUNX3 have been demonstrated to bind to the Foxp3 promoter as the 
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molecular link between TGF-β receptor signalling and induction of Foxp3 expression in the 
generation of adaptive Tregs [120].           
 
Similar to the differentiation of natural FOXP3+ Tregs in the thymus, the co-stimulatory 
receptor CD28 has been found to be required for the in vitro TGF-β-mediated induction of 
Foxp3 expression [121].  It was established that the requirement for CD28 in adaptive Treg 
generation was mediated by IL-2, which is in line with experiments using IL-2-deficient 
T cells and IL-2 neutralisation that demonstrated a requirement for IL-2 in TGF-β-mediated 
in vitro Foxp3 induction [122].  In contrast to natural Treg generation, it has been suggested 
that the homologue of the CD28 receptor, CTLA-4, has an essential role in the TGF-
β-mediated in vitro induction of Foxp3 [123].  Another inhibitory signalling pathway has also 
been proposed to regulate the generation of adaptive Tregs as programmed death 1 ligand 
(PD-L1) was found to be required for the TGF-β-mediated in vitro induction of Foxp3 
expression [124].  On the other hand, an additional co-stimulatory pathway mediated by 
OX40 has been identified as an inhibitor of the induction of Foxp3 expression [125], data 
suggest that this is due to the induction of memory T cells in vivo [126].          
 
In addition to the induction of Foxp3 by TGF-β to generate the adaptive regulatory T cells 
discussed above (TH3 cells), IL-10 has been found to induce CD4+ T cells to become type 1 
regulatory T cells (Tr1 cells).  Tr1 cells do not express Foxp3 [127], but produce high levels 
of the inhibitory cytokines IL-10 and TGF-β to mediate suppression [128].  Tr1 cells have 
been shown to play a critical role in the prevention of inflammatory bowel disease and 
regulation of allergic responses [129].   
 
1.3.3 Peripheral Homeostasis of Regulatory T Cells. 
There have been major advances in knowledge and understanding of CD4+ FOXP3+ natural 
and adaptive Treg generation in the thymus and periphery, respectively.  However, relatively 
little is known about the mechanisms that control the size and stability of the peripheral Treg 
population.  To date similar factors to those involved in the development of regulatory T cells 
have been implicated in peripheral Treg homeostasis, such as CD28 co-stimulation and the 
cytokines IL-2 and TGF-β (reviewed in [130]).        
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As discussed above, CD28-mediated signaling has been implicated in the thymic development 
of regulatory T cells.  CD28 signals are also required for the peripheral homeostasis of Tregs 
[131] as the reduced thymic Treg numbers observed in CD28-deficient mice are not restored 
in the periphery.  Peripheral CD4+ CD25+ Tregs are also decreased upon 
anti-CD80/anti-CD86 blocking antibody treatment.  It is unclear from these experiments 
whether the requirement for CD28 directly controls Treg survival and proliferation, or 
indirectly regulates production of the T cell growth factor IL-2 from conventional T cells.  
Although, an investigation found that upon adoptive transfer into CD28-/- mice, wild type 
Treg survival was impaired [86].         
 
Consistent with the potential role of the cytokine IL-2 in Treg homeostasis implicated by 
studies on the role of the CD28 receptor, IL-2-knockout and IL-2Rα/β-knockout mice have a 
decreased CD4+ CD25+ Treg population and develop severe autoimmunity [89-93].  
Furthermore, a role for IL-2 in the peripheral maintenance of regulatory T cells is suggested 
by a competitive setting model in which in the presence of wild type FOXP3+ Tregs, 
IL-2Rα-/- FOXP3+ Tregs do not survive [80].  Similarly, TGF-β has been proposed to 
function in peripheral Treg homeostasis because both TGF-βI-/- and TGF-βRII-/- mice have 
been found to have reduced numbers of peripheral FOXP3+ Tregs [101, 103, 104].   
 
More recently, other molecules have been proposed to function in the maintenance of 
peripheral regulatory T cell homeostasis.  The Wiskott-Aldrich syndrome protein (WASp) is 
essential for optimal T cell activation and WAS patients are immunodeficient.  However, 
WAS patients are also susceptible to systemic autoimmunity, and even though thymic Tregs 
develop normally in WASp-/- mice the peripheral CD4+ FOXP3+ Treg population is reduced 
[132].  Mice deficient for the cellular adhesion molecule LFA-1 also have a significantly 
reduced peripheral Treg population.  Although, in this study, the decreased number of 
peripheral Tregs was attributed to a reduced capacity of LFA-1-/- conventional T cells to be 
induced to become adaptive Tregs [133].   
 
1.3.4 Mechanisms of Regulatory T Cell Function. 
Since the identification of the CD4+ CD25+ FOXP3+ regulatory T cell subset there has been 
numerous studies investigating the mechanism(s) of Treg suppression due to the huge 
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therapeutic potential in the modulation of Treg function to improve treatment for 
autoimmunity, allergy and cancer.  From both in vitro and in vivo studies, it has become clear 
that regulatory T cells do not rely on just one mechanism of suppression, but rather there are 
multiple mechanisms by which Tregs can exert suppressive function (Fig. 1.03) (reviewed in 
[134-137]).   
 
There is debate over the cellular target of Treg-mediated suppression.  In vitro suppression 
assays of effector T cell responses can be performed in the absence of antigen-presenting cells 
using bead-coupled, plate-bound or soluble antibodies to provide the necessary TCR and 
CD28 activation stimulus.  This suggests that regulatory T cells target responder, effector T 
cells directly to achieve suppression.  Due to the constitutive expression of the IL-2 receptor 
α-chain (CD25) by regulatory T cells, it has been suggested that Tregs may compete with 
FOXP3- conventional T cells for the T cell growth factor IL-2, thereby inhibiting Tconv 
proliferation and inducing apoptosis due to cytokine deprivation [138].  In line with this 
hypothesis, IL-2 has been found to be essential for Treg homeostasis in vivo [139] and Tregs 
do not produce IL-2 as FOXP3 suppresses IL-2 transcription [140], therefore regulatory 
T cells could act as a sink for the IL-2 cytokine.  However, CD25 is the low-affinity receptor 
for IL-2 and expression of the high-affinity IL-2 receptor complex has not been quantified on 
FOXP3+ regulatory T cells compared to activated, effector FOXP3- conventional T cells 
(reviewed in [136]). 
 
It has also been hypothesised that other cytokines could mediate Treg suppressive function.  
CD4+ FOXP3+ regulatory T cells produce inhibitory cytokines such as IL-10, IL-35 and 
TGF-β.  In vivo adoptive transfer studies using Tregs from IL-10-/- mice provided evidence of 
a role for IL-10 in regulatory T cell suppressive function as IL-10-deficient Tregs failed to 
prevent inflammatory bowel disease [141] or protect against experimental autoimmune 
encephalomyelitis (EAE) [142].  IL-35 is a newly proposed inhibitory cytokine and is a 
member of the IL-12 heterodimeric cytokine family, composed of Epstein-Barr virus-induced 
gene 3 (Ebi3) and IL-12a (p35).  In vitro Ebi3-/- and IL-12a-/- Tregs were found to have 
reduced suppressive activity over responder effector T cells, and neither Ebi3-/- nor IL-12a-/- 
Tregs were able to protect against inflammatory bowel disease in vivo [143].  However, it has 





























Figure 1.03. A diagram to illustrate the proposed mechanisms of regulatory T cell function.  Decreased APC 
antigen-presentation and co-stimulation by
 
CD39 hydrolysis of ATP to ADP or AMP, Nrp-1-mediated long 
Treg:APC
 
interaction, LAG-3 ligation of MHC II, CTLA-4 binding of CD80/CD86.  Induction of IDO.  Induction 
of T cell apoptosis by Galectin-1 binding of CD45, granzyme
 
and perforin-mediated cytolysis.  Treg production of 
inhibitory cytokines (IL-10, IL-35, TGF-β).  T cell cytokine deprivation by CD25-mediated IL-2 consumption.    
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express IL-35 [144].  As discussed previously, mice deficient in TGF-β suffer from a fatal, 
autoimmune diseased phenotype and TGF-β has been found to induce Foxp3 expression.  
However, there is controversy over the role of TGF-β as an effector molecule of regulatory 
T cell suppressive function.  Initially, in vitro Treg suppression was shown to be reversed by 
anti-TGF-β antibody [145].  However, later studies found that anti-TGF-β or soluble 
TGF-βRII did not abrogate Treg suppressive function [146].  In vivo, abrogation of wild-type 
Treg protection against inflammatory bowel disease with anti-TGF-β neutralizing antibodies 
suggests TGF-β is involved in Treg control of intestinal homeostasis [147].  On the other 
hand, anti-TGF-β was also found to abrogate the function of TGF-β1-/- Tregs which suggests 
that TGF-β is required to control intestinal inflammation, but can be produced by another, 
non-regulatory T cell source [102].                                                  
 
In addition to the secretion of inhibitory cytokines by FOXP+ regulatory T cells to induce cell 
cycle arrest in FOXP3- effector T cells, it has been proposed that Tregs can express surface 
molecules such as Galectins which induce cell cycle arrest, apoptosis and inhibit 
pro-inflammatory cytokine production by effector T cells upon interaction with many 
responder cell surface glycoproteins such as CD45.  In vitro, both mouse and human Treg 
suppressive function was reduced upon blockade of galectin-1, and suppression by regulatory 
T cells isolated from galectin-1-deficient mice was also impaired [148].  Another potential 
mechanism by which it has been hypothesised that Tregs could induce apoptosis and directly 
target responder, effector T cells to achieve suppression is granzyme-mediated cytolysis.  For 
instance, activated human CD4+ CD25+ FOXP3+ regulatory T cells have been shown to 
express granzyme A and induce the apoptosis of CD4+ and CD8+ responder T cells in a 
perforin-dependent manner [149]. 
 
However, as well as directly affecting the effector T cells, regulatory T cells could also 
control an immune response by targeting the antigen-presenting cells.  As explained 
previously, antigen-presenting cells such as dendritic cells present peptides complexed to 
MHC molecules, along with co-stimulatory molecules, to activate T cells via TCR ligation 
and CD28 co-stimulation.  Two-photon laser-scanning microscopy studies demonstrated in 
lymph nodes in situ that direct interactions occur between Tregs and antigen-presenting cells, 
and this was associated with decreased antigen-presenting cell capacity to stimulate effector 
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T cells [150].  A number of mechanisms have been proposed by which effector molecules on 
CD4+ FOXP3+ regulatory T cells modulate the capacity of antigen-presenting cells to prime 
FOXP3- conventional T cells.   
 
It has been suggested that pro-longed interaction of regulatory T cells with antigen-presenting 
cells can prevent maturation of the dendritic cells; this restricts conventional T cell access to 
peptide:MHC complexes and limits their activation.  Neuropilin-1 (Nrp-1) is a receptor that is 
preferentially expressed by regulatory T cells and recently been shown to promote long 
interactions between Tregs and immature dendritic cells, and blockade of which abrogates 
Treg-mediated suppression in vitro [151].  Another cell surface receptor expressed by 
regulatory T cells that has been proposed to maintain dendritic cells in an immature state and 
limit their capacity to present antigen to and co-stimulate T cells is LAG-3.  LAG-3 binds to 
MHC class II molecules and induces an inhibitory signal which prevents dendritic cell 
maturation [152].  It has also been hypothesised that regulatory T cell expression of CD39 
functions to limit the co-stimulatory capacity of antigen-presenting cells.  Adenosine 
triphosphate (ATP) can up-regulate CD86 expression by dendritic cells during inflammation 
in response to cell damage.  However, Tregs express the ectoenzyme CD39 which modulates 
extracellular ATP by hydrolysis to adenosine diphosphate (ADP) or adenosine 
monophosphate (AMP) [153].   
 
Constitutive expression of CTLA-4 by CD4+ CD25+ regulatory T cells [154, 155] and the 
severe lymphoproliferative disease observed in Ctla-4 knockout mice [156, 157] suggest that 
the CTLA-4 receptor is a good candidate effector molecule for Treg function.  CTLA-4 binds 
the same ligands on antigen-presenting cells as the CD28 co-stimulatory receptor (CD80 and 
CD86) with a 20-100 fold higher affinity [158].  It has therefore been hypothesised that the 
binding of CTLA-4 on Tregs to CD80 and CD86 on antigen-presenting cells could also 
prevent the priming and co-stimulation required to activate conventional T cells by ligand 
competition.  It has also been proposed that this interaction of CTLA-4 on Tregs with its 
ligands on antigen-presenting cells prevents dendritic cell maturation, or even down-regulates 
CD80 and CD86 expression [159, 160].  In addition it has been suggested that upon binding 
of CTLA-4 on Tregs to its ligands on antigen-presenting cells, CD80 and CD86 can 
back-signal into the dendritic cell to stimulate production of the enzyme 
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indoleamine 2,3-dioxygenase (IDO) [161, 162].  IDO catabolises an essential amino acid for 
T cell proliferation, tryptophan, therefore it has been proposed that induction of active IDO 
negatively affects T cell survival [163]. 
 
Another receptor that is constitutively expressed by regulatory T cells compared to being 
up-regulated by conventional T cells upon activation is the co-stimulatory and survival 
glucocorticoid-induced tumor necrosis factor receptor, GITR.  It has been proposed that GITR 
functions to negatively regulate Treg-mediated suppression [164, 165].  However, 
GITR-deficiency does not alter immune homeostasis [166] and it seems more likely that 
antibody-mediated modulation of GITR targets and enhances effector T cell responses rather 
than abrogate regulatory T cell function [167, 168].    
 
Very recently, a role for microRNAs (specifically miRNA 155 [169]) in the maintenance and 
function of regulatory T cells has been revealed [170, 171].  However, the detailed molecular 

















1.4 The Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Receptor 
The Ctla-4 gene was originally identified during the screening of mouse cytotoxic 
T cell-derived cDNA libraries for T cell specific genes [172], hence the name cytotoxic 
T lymphocyte associated antigen.  The Ctla-4 gene is homologous to the CD28 co-stimulatory 
receptor gene; there is a high degree of nucleotide sequence similarity and the genes map to a 
similar chromosomal location [173].  The CTLA-4 receptor (also known as CD152) is a 
type-1 transmembrane glycoprotein member of the immunoglobulin superfamily and exists as 
a disulphide-linked homodimer [174].  In addition to homology with CD28, CTLA-4 was 
identified as a second receptor for the CD28 co-stimulatory receptor ligands (CD80 and 
CD86) [175-178].  The cell surface expression levels of CTLA-4 on resting T cells are very 
low.  It is difficult to measure CTLA-4 expression as this receptor largely exists 
intracellularly, and upon cell activation is translocated to the cell surface.  However, cell 
surface expression levels of CTLA-4 on activated T cells are limited due to rapid 
clathrin-mediated endocytosis of the CTLA-4 receptor [179].  A soluble form of CTLA-4 
(sCTLA-4) has also been described which is a splice variant that lacks the 
membrane-tethering region of the CTLA-4 receptor [180].   
 
1.4.1 The CD28 Co-Stimulatory Receptor and CD80/CD86 Ligands.  
The CD28 co-stimulatory receptor is a 44kDa, disulphide-linked homodimeric member of the 
immunoglobulin superfamily constitutively expressed on the surface of both CD4+ and 
CD8+ T cells.  As discussed previously, CD28 receptor ligation, by the binding of the ligands 
CD80 and CD86, along with TCR-stimulation, by antigen presented on MHC, results in the 
full activation of naïve T cells [181].  A number of different T cell responses occur following 
CD28-costimulated activation such as proliferation, enhanced cell survival by the 
up-regulation of the anti-apoptotic protein Bcl-xL, and increased cytokine (IL-2, TNF-α, IFN-γ 
and GM-CSF) production via mRNA stabilisation [182].  CD28 gene ablated mice have a 
much reduced frequency of peripheral T cells which could be attributed to defective survival 
and proliferation upon the loss of CD28-mediated co-stimulation.  Interestingly, it has been 
reported that CD28-deficient mice can still generate T cell responses to viruses and allografts 
[183, 184], which is indicative of a CD28-independent element to T cell responses [185].  
However, CD28-mediated co-stimulation is essential for the activation of T cells that provide 
B cell help for germinal centre and antibody class switching responses as CD28-deficient 
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mice lack germinal centres [186] due to an inability to optimally induce the chemokine 
receptor CXCR5, which directs T cell migration into B follicles [187].        
 
The CTLA-4 receptor binds the same ligands as the CD28 co-stimulatory receptor, namely 
CD80 and CD86.  Like the CD28 and CTLA-4 receptors, CD80 and CD86 are members of 
the immunoglobulin superfamily.  CD80 and CD86 are cell surface glycoproteins expressed 
by antigen-presenting cells and the level of CD80 and CD86 expression seems to depend on 
the activation state of the cells (reviewed in [188]).  Both CD80 and CD86 bind the same 
receptors and it was initially thought that these ligands were functionally equivalent [189, 
190].  Both the CD28 and CTLA-4 receptors preferentially bind to CD80 over CD86, but the 
CTLA-4 receptor has a 20-100 fold higher affinity for both ligands compared to the CD28 
co-stimulatory receptor [158].  However, the functional roles of CD80 and CD86 are still not 
fully understood.  CD80 and CD86 are only about 25% identical in sequence (reviewed in 
[191]) and structural data suggest that CD80 exists as a dimer [192], whereas this has not 
been shown for CD86.  Additionally, studies using knockout mice revealed that 
CD86-deficient mice were more severely immunocompromised than CD80-deficient mice, 
which suggests differential stimulatory and inhibitory functions for the two ligands [190].  
However, when investigating the functional differences between CD80 and CD86 in vivo, 
blocking antibody studies have yielded conflicting results [193-195].  More recently, studies 
using Chinese hamster ovary (CHO) cell transfectants that express either CD80 or CD86 have 
revealed that CD80 is a more potent co-stimulator than CD86 [196].     
 
1.4.2 CTLA-4 Receptor Function. 
It is now regarded that the CTLA-4 receptor functions opposite the CD28 co-stimulatory 
receptor to negatively regulate T cell responses.  Early studies implicated the CTLA-4 
receptor in the augmentation of CD28-mediated co-stimulation as anti-CTLA-4 monoclonal 
antibodies were found to enhance the proliferation of anti-CD3/anti-CD28 activated T cells 
[197, 198].  However, it was soon realised that the stimulatory effects observed upon 
blockade of CTLA-4 could be attributed to the disruption of T cell negative control as the 
CTLA-4 receptor was found to inhibit antigen-driven, CD28 co-stimulated proliferation and 
IL-2 production by CD4+ T cells [199-202].  
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Negative regulation of T cell responses is clearly illustrated by Ctla-4 gene ablated mice  
which develop a lethal lymphoproliferative disease and die by 3 to 4 weeks of age [156, 157].  
Ctla-4-/- mice exhibit a massive expansion of polyclonal T cells leading to lymphocytic 
infiltration and tissue destruction of multiple organs, such as the heart, liver and pancreas.  It 
has been demonstrated that the lymphoproliferative phenotype of Ctla-4-/- mice is mediated 
by CD4+ T cells as CD4+ T cell depletion abrogated disease [203].  Additionally, CD28 
co-stimulation is required for this CD4+ T cell-mediated lymphoproliferative syndrome as 
CTLA-4-Ig treatment of Ctla-4-deficient mice prevents the fatal disease [204] and Ctla-4-/- 
mice that are also deficient in CD80 and CD86 do not develop the lymphoproliferative 
disorder [190, 205].  Similarly, this lethal disease is abrogated in mice deficient in both Ctla-4 
and CD28 [206].      
 
Using anti-CTLA-4 blocking antibodies and a murine model of experimental autoimmune 
encephalomyelitis (EAE), a role for the CTLA-4 receptor in mediating the inhibition of an 
ongoing immune response and regulating autoimmunity has been suggested [207].  This 
functional role of CTLA-4 in regulating the development of EAE was later attributed to 
control over the frequency of the primed CD4+ T cell population [208].  It has been proposed 
that the CTLA-4-mediated restriction of proliferating CD4+ T cell clonal expansion is 
cell-autonomous and regulated by the induction of CTLA-4 expression upon T cell activation 
[209].  A role for the CTLA-4 receptor in the maintenance of T cell homeostasis has also been 
shown using TCR-transgenic Ctla-4-/- mice in which the lethal lymphoproliferative disease 
associated with Ctla-4-deficiency was delayed and the antigen-specific CD4+ T cell 
population was activated and expanded [210].      
 
Studying CTLA-4 is severely hampered by the fatal lymphoproliferative syndrome of 
Ctla-4-/- mice and research into the CTLA-4 receptor is therefore often carried out using 
blocking antibodies and in vitro tissue culture systems.  Alternatively, in-vivo, disease in 
Ctla-4-/- mice is delayed or prevented by CTLA-4-Ig injection, anti-CD80/86 blocking 
antibody treatment or breeding onto a CD80/86-/- background.  However, these methods also 
interfere with CD28 signalling, so results cannot be attributed directly to the loss of CTLA-4.  
To overcome the lethal lymphoproliferative syndrome that develops in Ctla-4-/- animals it is 
also possible to breed Ctla-4-deficient mice onto a TCR-transgenic background, directing 
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TCR specificity to a non-self antigen.  To preclude rearrangements of second T cell receptors 
that might recognise self-antigens these animals can be maintained on a Rag2-deficient 
background, and accordingly TCR-transgenic Ctla-4-/- Rag2-/- mice do not develop 
lymphoproliferative disease and their peripheral T cells bear a naïve phenotype [210, 211].  
This model system has proved useful in dissecting the role of CTLA-4 in non-regulatory 
T cells [52, 210, 211], although it cannot be used to elucidate the role of CTLA-4 in FOXP3+ 
Tregs since TCR-transgenic Rag2-/- animals do not develop Tregs due to the absence of 
cognate antigen expression in the thymus [212].     
 
1.4.3 Mechanisms of CTLA-4 Receptor Function.   
The underlying mechanism(s) of CTLA-4 receptor function are still not fully understood.  
Both cell-intrinsic and cell-extrinsic models of CTLA-4 receptor function have been 
proposed.  Early studies with antibodies to CTLA-4 found that CTLA-4 ligation inhibited 
T cell proliferation and IL-2 production [199-202].  Following on from these results, it has 
been proposed that upon ligand-binding, the CTLA-4 receptor transduces a negative signal 
within the T cell that inhibits TCR / CD28 signalling and T cell activation.  It has been 
suggested that the transduction of TCR and CD28 activating signals by protein kinases is 
regulated by the CTLA-4-mediated recruitment of phosphatases [213, 214].  More recently, 
another mechanism by which it has been hypothesised that the CTLA-4 receptor negatively 
affects TCR signalling is the inhibition of microcluster formation in T cells [215] because 
following TCR ligation, signalling molecules such as the protein kinase ZAP70 form clusters 
to transduce an activating signal to induce T cell proliferation and effector cytokine 
expression.  In addition, two other cell-intrinsic models for CTLA-4 receptor function have 
been proposed that suggest the T cell response is negatively regulated by the disruption of 
immunological synapse formation.  Firstly, it has been reported that CTLA-4 could block 
lipid-raft formation in response to TCR ligation, thereby disturbing the recruitment of 
adhesion and signalling molecules required to form a stable immunological synapse for T cell 
activation [216-218].  Secondly, it has been hypothesised that the CTLA-4 receptor is 
involved in reversing the TCR-induced ‘stop’ signal which is normally required to reduce 
T cell motility and allow the formation of a stable interaction with an antigen-presenting cell 
(reviewed in [219]).        
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Cell-intrinsic, negative signalling models of CTLA-4 receptor function are not consistent with 
the ability of CTLA-4-expressing cells to exert dominant tolerance over CTLA-4-deficient 
cells in mixed bone marrow chimeras [220, 221].  Furthermore, using mixed bone marrow 
chimeras, it has been shown that CTLA-4 is not involved in the down-regulation of specific 
T cell responses in a T cell-autonomous fashion because following viral infection, activated 
and expanded antigen-specific CTLA-4-deficient T cells contracted indistinguishably from 
antigen-specific CTLA-4-sufficient T cells [222].  Cell-extrinsic models of CTLA-4 receptor 
function in the down-regulation of T cell responses have also been proposed.  As discussed 
above, not only does the CTLA-4 receptor share its ligands with the CD28 co-stimulatory 
receptor, but both CD80 and CD86 have preferential affinity for CTLA-4 compared with 
CD28.  This has formed the basis of the ligand competition model for CTLA-4-mediated 
inhibition of T cell activation in which preferential binding of CTLA-4 to CD80 and CD86 
would deprive T cells of CD28 co-stimulatory signals.  Consistent with this hypothesis, 
transgenic expression of a truncated CTLA-4 receptor that lacks the cytoplasmic domain 
needed for signal transduction, ameliorated the severe lymphoproliferative disease seen in 
Ctla-4 knockout mice [223].  Upon ligand binding, it has also been suggested that the 
CTLA-4 receptor could function in a cell-extrinsic manner by ‘back-signalling’ via CD80 and 
CD86 into antigen-presenting cells.  CD80/CD86 engagement of CTLA-4 has been reported 
to up-regulate expression of the enzyme indoleamine 2,3-dioxygenase (IDO) in dendritic cells 
[224, 225].  IDO degrades the essential T cell proliferation metabolite, tryptophan and has 
therefore been proposed as an immunosuppressive mechanism [163].  However, Ido knockout 
mice do not exhibit the same severe lymphoproliferative syndrome phenotype as 
Ctla-4-deficient mice [226].       
 
1.4.4 CTLA-4 and Regulatory T Cells.   
It was first suggested that the CTLA-4 receptor may have a role in regulatory T cell function 
when it was found that CD4+ CD25+ Tregs constitutively express CTLA-4 [155].  The severe 
lymphoproliferative syndrome exhibited by Ctla-4-deficient mice is also consistent with a 
role for the CTLA-4 receptor in immune regulation and is similar to the Foxp3-/- scurfy 
mouse phenotype [60].  Moreover, a role for CTLA-4 in Treg suppressive function would be 
in line with the observation that CTLA-4 and FOXP3 need to be expressed by the same cell to 
provide optimal protection from the lethal lymphoproliferative diseases associated with 
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deficiency of both pathways [227].  In addition polymorphisms in the Ctla-4 gene have been 
associated with several autoimmune diseases such as type 1 diabetes, thyroiditis, systemic 
lupus erythematosus and rheumatoid arthritis (reviewed in [228, 229]).  However, functional 
studies into the role of CTLA-4 in Treg-mediated suppression have yielded contradictory 
results.   
 
In-vitro analysis has found that that Ctla-4-deficient Tregs retain suppressive function [230].  
Although, to circumvent the lymphoproliferative and activated cellular phenotype associated 
with Ctla-4-/- mice, this study carried out experiments with CD25+ CD4 single positive 
thymocytes rather than peripheral Tregs.  It has also been demonstrated that Ctla-4-deficient 
regulatory T cells exert suppressive function in vitro because they develop a compensatory 
suppressive mechanism involving the production of TGF-β [231].  However, in this 
investigation Ctla-4-/- mice were treated with anti-CD80 and anti-CD86 monoclonal 
antibodies or expressed the Ctla-4-Ig transgene in order to delay the overt lymphoproliferative 
syndrome.  Therefore, these regulatory T cells that were analysed for suppressive function 
developed in the absence of CD28 signalling, and it has been discussed above that a 
requirement for the CD28 co-stimulatory receptor in Treg development and homeostasis has 
been identified.   
 
In vivo the role of the CTLA-4 receptor in regulatory T cell suppression of colitis has been 
investigated [232].  Ctla-4-/- Tregs were found to prevent colitis in vivo, however these Tregs 
were isolated from Ctla-4-/- mice that were also CD80- and CD86-deficient.  Although, to 
circumvent this issue Ctla-4-deficient Tregs were isolated from mixed bone marrow chimeras 
using a congenic marker and these Tregs were similarly found to prevent the development of 
colitis in vivo.  In contrast, in this same study, anti-CTLA-4 blocking antibody treatment 
abrogated Treg mediated suppression of colitis in vivo, even when appropriate measures were 
taken to ensure the monoclonal antibody only targeted the Treg population and did not 
simultaneously affect the conventional T cell population.  The NOD mouse model of 
autoimmune diabetes has also been used to assess the role of the CTLA-4 receptor in 
regulatory T cell suppressive function [233].  Blocking anti-CTLA-4 antibody treatment was 
found to accelerate progression of diabetes in NOD mice.  Control adoptive transfer 
experiments using NOD-SCID mice found that the anti-CTLA-4 monoclonal antibody 
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preferentially targeted the Treg population as antibody treatment following adoptive transfer 
of effector cells alone did not accelerate diabetes progression, whereas antibody treatment 
abrogated the suppressive function of co-transferred Tregs.   
 
Overall, the role of the CTLA-4 receptor in regulatory T cell suppressive function is still not 
clear.  Also, it is not known if, like its homologue CD28, the CTLA-4 receptor has a 
functional role in the generation of regulatory T cells.  Although, it has been reported that 
CD25+ cells isolated from Ctla-4-deficient mice express Foxp3 mRNA [231].  Additionally, 
if the CTLA-4 receptor has a role on regulatory T cells it is not known whether this is 
mechanistically Treg-intrinsic to modulate TCR signalling or Treg-extrinsic to modulate 
antigen-presenting cells.  Many of the studies into the mechanism of CTLA-4 receptor 
function that have been discussed above in 1.4.2 investigated activated (CTLA-4-expressing) 
CD4+ FOXP3- conventional T cells or the CD4+ T cell population as a whole and did not 
specifically analyse the CD4+ FOXP3+ regulatory T cell population.  It is clear that many of 
the proposed mechanisms for CTLA-4 receptor inhibition of T cell activation could also be 
applicable to regulatory T cell suppressive function.  For instance, CD4+ CD25+ regulatory 
T cells have been shown to down-regulate CD80 and CD86 on dendritic cells [159].  Also, 
CD4+ CD25+ Tregs have been reported to modulate tryptophan catabolism via the induction 
of IDO in dendritic cells [161].  Therefore, there are still many unanswered questions 













1.5 Aims and Objectives 
CD4+ FOXP3+ regulatory T cells are a key lymphocyte population in the maintenance of 
immunological tolerance.  It is therefore important to understand the molecular pathways that 
control regulatory T cell homeostasis and function.  This investigation focused in particular 
on the role of the CTLA-4 receptor in regulatory T cell biology.  The main objectives of this 
project were to understand the contribution of the CTLA-4 receptor to Treg selection in the 
thymus, peripheral Treg homeostasis (cellular proliferation and FOXP3 induction) and Treg 
suppressive function.  Overall, this project aimed to provide new insight into the role of 
CTLA-4 in the regulation of T cell immune responses, in particular those that could result in 

















2.0 MATERIALS AND METHODS 
 
2.1 Mice 
2.1.1 Mice.  BALB/c, DO11.10 TCR transgenic and CD28-/- mice were purchased from the 
Jackson Laboratory (Bar Harbor, ME).  Rat insulin promoter (RIP)-mOVA mice on a BALB/c 
background expressing membrane OVA under the control of the rat insulin promoter (from 
line 296-1B) were a gift from W. Heath (Walter and Eliza Hall Institute, Melbourne, 
Australia).  Rag2-/- mice were purchased from Taconic Laboratories (Germantown, NY).  
Ctla-4-/- mice were provided by Arlene Sharpe (Harvard, Boston, MA).  Ctla-4-/- mice were 
bred heterozygously.  DO11.10 mice and RIP-mOVA mice were bred to a Rag2-/- background 
to generate DO11.10 Rag2-/- and RIP-mOVA Rag2-/- mice.  Ctla-4-/- and CD28-/- mice were 
backcrossed with DO11.10 Rag2-/- mice to generate DO11.10 Rag2-/- Ctla-4-/- and DO11.10 
Rag2-/- CD28-/ mice.  DO11.10 Rag2-/- and DO11.10 Rag2-/- Ctla-4-/- were crossed with 
RIP-mOVA Rag2-/- to generate DO11.10 x RIP-mOVA Rag2-/- and DO11.10 x RIP-mOVA 
Rag2-/- Ctla-4-/- progeny.  Foxp3+/- females were kindly provided by A. Rudensky and used 
to obtain Foxp3-/- mice.  OX40-/- mice were provided by M. Bachmann.  CD30-/- mice were 
provided by H. Takimoto.  OX40-/- CD30-/- mice were generated by breeding the two single 
knockout strains and backcrossing heterozygote offspring.  Rank-/- mice on the C57BL/6 
background were provided by J. Penninger.  C57BL/6 mice were used from the Birmingham 
Biomedical Services Unit stock.     Mice were housed at the Birmingham Biomedical Services 
Unit and were used according to Home Office regulations. 
 
2.1.2 Adoptive T Cell Transfers.  For assessment of Ctla-4-/- Treg pathogenicity: 1-2 x 106 
Ctla-4-/- lymphocytes or high speed cell sorted (Mo-Flo, DakoCytomation) CD4+ CD25- 
conventional T cells and CD4+ CD25hi regulatory T cells from lymph nodes of BALB/c wild 
type and Ctla-4-/- mice were adoptively transferred into Rag2-/- mice. These were injected 
intravenously in 400μl of phosphate buffered saline (PBS) (Sigma).  For assessment of wild 
type Treg control of  Ctla-4-/- disease: Ctla-4-/- lymphocytes alone or plus 0.6 x 106 MACS 
separated CD4+ CD25- conventional T cells or CD4+ CD25+ regulatory T cells from lymph 
nodes of BALB/c wild type mice were adoptively transferred into Rag2-/- mice. These were 
injected intravenously in 400μl of PBS.  For adoptive transfer of Ctla-4-/- lymphocytes into 
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BALB/c or CD28-/- mice: 50 x 106 Ctla-4-/- lymphocytes were injected intravenously in 
400μl of PBS into BALB/c and CD28-/- mice.  For adoptive transfer model of autoimmune 
diabetes: 0.2 x 106 high speed cell sorted CD4+ CD25- from lymph nodes of DO11.10 x 
RIP-mOVA Rag2-/- were injected intravenously in 400µl of PBS into RIP-mOVA Rag2-/- 
mice alone or plus 0.2 x 106 high speed cell sorted CD4+ CD25+ from lymph nodes of 
DO11.10 x RIP-mOVA Rag2-/- or DO11.10 x RIP-mOVA Rag2-/- Ctla-4-/- mice.  Weight 
loss is expressed as a percentage of maximal weight, and LN counts refer to pooled axillary, 
inguinal, brachial and mesenteric lymph nodes. 
 
2.1.3 Bone Marrow Chimeras.  8 x 106 THY1 depleted bone marrow (MACS depletion) 
from BALB/c or Ctla-4-/- mice was injected intravenously in 400μl of PBS into Rag2-/- mice 
(irradiated with 5Gy) either alone or as a BALB/c : Ctla-4-/- 50:50 mix.       
 
2.1.4 In Vivo Anti-CTLA-4 / Anti-ICOSL Blocking Antibody Treatment.  Six to eight 
week old BALB/c mice were administered with 500μg of blocking anti-CTLA-4 monoclonal 
antibody (4F10, gift from J. Bluestone, University of California, San Francisco) or 200µg of 
anti-ICOSL blocking antibody (HK5.3, ebioscience) or control hamster IgG by 
intra-peritoneal injection twice weekly.  4F10 was grown in Miniperm bioreactors (Grenier 
Bio-One) using IgG-depleted FCS and purified by passing over staphylococcal protein A (GE 
Healthcare).   
 
2.1.5 In Vivo OVA Treatment.  Six to eight week old DO11.10 Rag2-/-, DO11.10 Rag2-/- 
Ctla-4-/- and DO11.10 Rag2-/- CD28-/- mice were injected (intra-peritoneal) with 50μg 
Imject Ovalbumin (Thermo Scientific) in 100ul PBS or equivalent volume of PBS as a 
control.  Treatment was administered on day 0, 1, 2, 5 and 6 and tissue was harvested on 
day7.      
 
2.1.6 In Vivo BrdU Treatment.  Two week old BALB/c mice were given 1mg 
5-bromo2’-deoxy-uridine (BrdU) (BD Pharmingen) in 100μl by intra-peritoneal injection 
every twenty-four hours for three days.  Mice were harvested twenty-four hours following last 
injection.   
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2.1.7 Diabetes Monitoring.  Blood glucose was measured using Ascensia Elite XL blood 
glucose meter (Bayer, USA).  Overt diabetes was classed as having a blood glucose 




























2.2.1 Section Preparation.  Spleens were flash frozen in liquid nitrogen and stored at -80°C 
until use.  Tissue was sectioned by cryostat at -20°C. Serial sections 5μm in thickness were 
cut onto glass slides (Hendley-Essex). Sections were air dried for 30 minutes, fixed in 100% 
cold acetone (Scientific and Chemical supplies) at 4°C for 20 minutes and dried at room 
temperature for 10 minutes. Slides were stored in sealed polyethylene bags at -20°C until use.  
 
2.2.2 Immunochemistry.  Slides were re-hydrated in PBS before use.  Sections were then 
stained with primary antibodies directed against murine epitopes for one hour at room 
temperature (Table 1).  Sections were washed in TRIS (pH7.2) (Sigma) and biotin- or 
HRP-conjugated secondary antibodies pre-adsorbed with normal mouse serum added for 
45minutes at room temperature (Table 2).  HRP-conjugated antibodies were finally detected 
with Diaminobenzidine (DAB) solution (Sigma). Biotinylated antibodies were detected with 
streptavidinABComplex-alkaline phosphate (DakoCytomation), followed by Naphthol 
AS-MX Phosphate–substrate and Fast Blue BB salt with Levamisole (all Sigma).  Images 
were taken with a Nikon eclipse E400 light microscope and Nikon coolpix 950 digital camera 
and red, green, blue levels adjusted in Adobe Photoshop version 8.0.  Images processed for 
presentation with ImageJ ( Rasband W.S., ImageJ, U.S. National Insitute of Health, Bethesda, 
Maryland, USA, http://rsb.info.nih.gov/ij/ 1997-2009) 
 
2.2.3 Immunofluorescence.  As for immunochemistry, slides were re-hydrated in PBS before 
use.  Sections were then blocked with 10% goat serum (Sigma) or if goat primary antibodies 
were used sections were blocked with 10% donkey serum (Sigma).  Sections were then 
stained with primary antibodies directed against murine epitopes for one hour at room 
temperature (Table 1).  Sections were washed in PBS (Sigma) and secondary antibodies 
pre-adsorbed with normal mouse serum added for 45minutes at room temperature (Table 2).  
For three-step amplifications, tertiary antibodies were added for 40minutes at room 
temperature (Table 2). Slides were mounted with Vectorshield (Vector Laboratories) and 
images were obtained by confocal microscopy (Zeiss LSM 510).  Images processed with 




2.2.4 H & E Staining.  Tissue was placed in 10% formalin (Sigma, 4% formaldehyde w/v) at 
4°C for 5 days.  Processing of tissue, cutting of sections and hematoxylin and eosion staining 
was kindly carried out by the pathology department. 
 
2.2.5 Antibodies. 
Specificity Clone Host Conjugate Supplier Dilution 
CD11c N418 Hamster Purified Purified from 
Supernatant 
1/10 
CD4 GK1.5 Rat Purified BD 1/1000 
CD4  Rat AF-647 Conjugated by 
D. Withers  
1/100 
CD86 GL1 Rat FITC BD 1/100 
FOXP3 FJK-16s Rat Biotinylated ebioscience 1/50 
IgD  Sheep Purified The Binding Site, 
Birmingham, UK 
1/200 
Ki67  Rabbit Purified J. Gerdes, Borstel, 
Germany 
1/500 
PNA   Biotinylated Vector Labs 1/150 
Table 1.  Primary antibodies used in immunohistology.   
 
Specificity Host Conjugate Supplier Amount / 
Dilution 
biotin  Streptavidin AF555 Invitrogen 1/1000 
FITC Rabbit Purified Dako 1/500 
Hamster Goat Cy5 Jackson Labs 1/60 
Rabbit Donkey AF488 Invitrogen 1/100 
Rat Rabbit Biotinylated Dako 1/600 
Sheep / Goat Donkey Peroxidase The Binding Site, 
Birmingham, UK 
1/100 




2.3 Flow Cytometry 
2.3.1 Cell Isolation.  Single cell suspensions were isolated from peripheral lymph nodes 
(LNs), spleens and thymi by mashing through a wire mesh with cold PBS containing 2% FCS 
(Sigma).  For spleens and thymi this was followed by red blood cell removal by incubation 
for ten minutes at 37°C in 3-7ml of lysis buffer (see appendix), cells were washed thoroughly 
in ice-cold PBS containing 2% FCS to stop the reaction.  In some instances spleens were 
digested with 0.5mg/ml collagenase / dispase (Roche), 0.25mg/ml Liberase (Roche) and 
0.1mg/ml DNase (Sigma) in complete medium (C10) (see appendix) for 45minutes at 37°C 
prior to mashing though a wire mesh and red blood cell lysis.  To isolate non-thymocytes 
thymi were teased apart and digested with 0.5mg/ml collagenase / dispase (Roche) in C10 for 
45minutes at 37°C on a shaker.  A second digest with 1X trypsin (Sigma) in 0.02% EDTA 
(Sigma) was carried out at 37°C for ten minutes.  Samples were filtered by passing through a 
40μm cell strainer (BD Biosciences).  Lymphocytes from the pancreas were obtained by 
tearing the pancreas in cold PBS containing 5% FCS, 56mM glucose (Sigma), 2µg/ml 
aproptinin (Roche) and 50µg/ml TLCK (Roche).  Following centrifugation, samples were 
resuspended in 2ml pre-warmed PBS containing 15% FCS and Liberase CI (Roche). Samples 
were passed through a 40μm cell strainer (BD) and lymphocytes were recovered by 
centrifugation at 1000 x g, 4°C for 20 minutes over lympholyte-M (Cedarlane Laboratories, 
Ontario, Canada) and then washed in PBS containing 2% FCS.  Cells from the draining and 
non-draining pancreatic lymph nodes (PanLNs) were obtained by tearing open the tissue in 
PBS containing 2% FCS.   
 
2.3.2 Staining Protocol.  Cells were surface stained for fifteen minutes at 4°C with 5% goat 
serum and washed with 1ml PBS containing 2% FCS.  For intracellular CTLA-4, Ki67, 
FOXP3 and cytokine staining, cells were fixed and permeabilised according to the 
manufacturer’s instructions (eBioscience) with reagents containing paraformaldehyde and 
saponin and then intracellular antibodies were added.  For intracellular cytokine staining 
2 x 106 cells per well (24 well plate) were cultured with 50ng/ml Phorbol Myristate Acetate 
(PMA) (Sigma) and 1.5µM Ionomycin (Sigma) for 4-6hours.  After one hour 1µl/ml of Golgi 
Stop (BD Pharmingen) was added per well.  For intracellular BrdU staining, cells were fixed 
and permeabilised according to the manufacturer’s instructions (BectonDickinson) with 
reagents containing paraformaldehyde and saponin.  100µl of 300μg/ml DNase (BD 
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Pharmingen BrdU Kit) was added and cells incubated for one hour at 37°C in a water bath 
and then intracellular antibodies were added.  For Annexin V staining, cells were resuspended 
in 100ul of cold binding buffer (see appendix) and incubated with annexin V antibody for 15 
minutes at room temperature before another 500ul of cold binding buffer was added before 
analysis.  All cell samples were analysed by flow cytometry (FACScalibur™ or 
DakoCytomation™ and FlowJo™ software) (BectonDickinson).  
 
2.3.3 Antibodies. 
Specificity Clone Conjugate Supplier Dilution 
ANNEXIN V  FITC BD 556419 5µl 
B220 RA3-6B2 PE BD 553090 1/100 
Bcl-2  FITC BD 51-15024X 18µl 
Biotin  Streptavidin APC BD 554067 1/100 
Biotin  Streptavidin PE BD 554061 1/100 
CD11c N418 FITC ebioscience 11-0114-82 1/50 
CD11c N418 PE ebioscience 12-0114-82 1/50 
CD19 1D3 APC BD 550992 1/200 
CD19 1D3 FITC BD 553785 1/200 
CD25 PC61 APC BD 557192 1/100 
CD25 PC61.5 PE-Cy7 ebioscience 25-0251-82 1/50 
CD25 PC61 PE BD 553866 1/100 
CD27 LG.7F9 APC ebioscience 17-0271-82 1/50 
CD28 37.51 Biotin BD 553296 1/10 
CD3e 145-2C11 PerCP BD 553067 1/75 
CD3e 145-2C11 PE-Cy5.5 ebioscience 35-0031-82 1/75 
CD4 RM4-5 PerCP BD 553052 1/50 
CD4 GK1.5 FITC BD 553729 1/100 
CD40 1C10 Biotin  ebioscience 13-0401-85 1µl 
CD45.2 104 FITC ebioscience 11-0454-82 1/200 
CD62L MEL-14 APC BD 553152 1/50 
CD62L MEL-14 PE-Cy7 ebioscience 25-0621-82 1/50 
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CD69 H1.2F3 FITC BD 553236 1/50 
CD69 H1.2F3 PE BD 553237 1/50 
CD8 53-6.7 FITC BD 553031 1/100 
CD80 16-10A1 FITC BD 553768 1/50 
CD80 16-10A1 PE BD 553769 1/50 
CD86 GL1 FITC BD553691 1/50 
CD86 GL1 PE BD 553692 1/50 
CD8a 53-7.6 APC ebioscience 17-0081-82 1/100 
CTLA-4 UC10-4F10-11 PE BD 553720 1µl 
CXCR5 2G8 Biotin BD 551960 2.5µl 
EpCam G8.8 AF-647 Hybridoma gift from 
Moon Kim  
1/700 
FAS  PE  1/75 
FOXP3 FJK.16S APC ebioscience 17-5773-82 2µl 
FOXP3 FJK.16S Pacific Blue ebioscience 57-5773-80 2µl 
FOXP3 FJK-16S PE ebioscience 12-5773-82 1.5µl 
FOXP3 FJK-16S FITC ebioscience 11-5773-82 1µl 
I-Ad AMS-32.1 Biotin  BD 553546 1/200 
ICOS 7E.17G9 Biotin  ebioscience 13-9942-81 1/50 
ICOS 7E.17G9 PE ebioscience 12-9942-82 1/50 
ICOSL HK5.3 PE ebioscience 12-5985-81 1/50 
IFN-γ XMG1.2 APC BD 554413 1µl 
IFN-γ XMG1.2 PE BD 554412 1µl 
IFN-γ XMG1.2 AF-488 BD 557724 1µl 
IL-17 TC11-18H10 PE BD 559502 1µl 
IL-17 TC11-18H10 FITC BD 560221 1µl 
IL-2 JES6-5H4 FITC BD 554427 1µl 
IL-2 JES6-5H4 PE BD 554428 1µl 
IL-4 11B11 APC BD 554436 1µl 
KJ DO11.10 PE CALTAG mm7504 1/50 
PD-1 J43 PE ebioscience 12-9985-82 1/50 
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THY1.1 H1551 APC ebioscience 17-0900-82 1/400 
THY1.2 53-2.1 APC ebioscience 17-0902-83 1/400 
TRANCE IK2215 Biotin ebioscience 13-5952-82 1µl 


























2.4 Cell Separation / Sorting 
2.4.1 Magnetic Cell Separation (MACS).  Single cell suspensions were obtained from 
spleen or lymph nodes as described.  For positive selections cells were labelled with 10ul 
microbeads (Miltenyi Biotec) per 107cells and passed through an LS column. The 
magnetically labelled cells were retained in the column, and eluted to give the desired 
fraction.  For negative selections cells were labelled with 15µl of biotin-conjugated antibody 
cocktail (Miltenyi Biotec) per 107 cells, and passed through an LD column.  The magnetically 
labelled cells were retained in the column and the flow-through collected as the desired 
fraction.     
 
2.4.2 Fluorescent Activated Cell Sorting (FACS).  Single cell suspensions were isolated 
from lymph nodes as described.  Cells were surface stained in 600μl C10, for 10 minutes on 
ice before being passed through a 40μm cell strainer (BD Biosciences).  Desired cell 
populations were purified by high speed cell sorting (Beckman Coulter High Speed Cell 

















2.5 In Vitro Cell Culture  
2.5.1 Overnight Cultures. 
For CD28-depedency assays 1 x 105 wild type BALB/c or CD28-/- MACS separated CD4+ 
lymphocytes were cultured overnight in a 96-well, round-bottomed plate plus or minus 
500ng/ml anti-CD3 (BD Pharmingen) and 1µg/ml anti-CD28 (BD Pharmingen) at 37°C, 5% 
CO2.  The next day wells were harvested by washing with PBS and stained with CD4, ICOS, 
CD69, TRANCE and intracellular FOXP3, CTLA-4 for analysis by flow cytometry as 
described above. 
For in vitro overnight culture with lipopolysaccharide (LPS) 1 x 105 wild type BALB/c 
splenocytes were cultured overnight in a 96-well, round-bottomed plate with 10µg/ml LPS 
(Sigma) at 37°C, 5% CO2.  The next day wells were harvested by washing with PBS and 
stained with CD3, CD19, CD80 and CD86 for analysis by flow cytometry as described above. 
For analysis of ICOS expression in a ‘Ctla-4-/- environment’ 3 x 105 lymphocytes from 18 
day old BALB/c or Ctla-4-/- mice were cultured in a 96-well, round-bottomed plate at 37°C, 
5% CO2 for two days.  Supernatants were removed and added to 2 x 105 wild type BALB/c 
lymphocytes which were cultured overnight in a 96-well, round-bottomed plate at 37°, 5% 
CO2.  The next day wells were harvested by washing with PBS and stained with CD4, ICOS, 
CD69 and intracellular FOXP3 for analysis by flow cytometry as described above. 
      
2.5.2 CTLA-4 Cycling. 
Wild type BALB/c lymphocytes were surface stained with CD4 and CD25 for analysis by 
flow cytometry as described above.  1 x 106 lymphocytes were cultured in a 96-well, round 
bottomed plate plus or minus 50ng/ml Phorbol Myristate Acetate (PMA) (Sigma) and 1.5µM 
Ionomycin (Sigma) with 1µl anti-CTLA-4-PE antibody at 37°C, 5% CO2 for various lengths 
of time.  For harvest wells were washed with PBS and stained intracellular with CD4 and 
FOXP3 for analysis by flow cytometry as described above. 
     
2.5.3 TGF-β Induction. 
A 48-well, flat-bottomed plate was pre-coated with 10µg/ml anti-CD3 (BD Pharmingen) in 
PBS and stored at -4°C overnight.  The anti-CD3 was removed to leave plate-bound anti-CD3 
and 2.5 x 105 lymphocytes from DO11.10 Rag2-/- mice that were either wild type, Ctla-4-/- 
or CD28-/- were cultured in the pre-coated 48-well plate with 1.25 x 106 irradiated BALB/c 
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splenocytes (20Gy) plus or minus 3ng/ml TGF-β (Peprotech) and 100 I. U. recombinant IL-2 
(Peprotech) at 37°C, 5% CO2 for 3 days.  For harvest wells were washed with PBS and 
stained with CD4, KJ-126, CD25 and intracellular FOXP3 for analysis by flow cytometry as 
described above. 
            
2.5.4 Suppression Assays.  Cells were cultured in triplicate in round-bottomed 96 well plates 
in complete medium (see appendix). CD4+ CD27+ CD25- conventional T cells were added at 
2.5 x 104 per well. In co-culture experiments, purified CD4+ CD27hi CD25hi Tregs were 
added at a ratio of 1:1, 0.5:1 or 0.25:1 (Tregs:Tcells). CD19+ purified APCs were added at a 
ratio of 1:6 (Tcells:APCs). Cells were stimulated with 1µg/ml of soluble anti-CD3 (BD 
Pharmingen). After 72 hours cells were harvested and stained with CD4, THY1.1 and 
intracellular FOXP3 for analysis by flow cytometry as described above. 
 
2.5.5 Anergy Assay. 
Congenically marked THY1.1+ MACS separated CD4+ CD25- conventional T cells were 
co-cultured with wild type BALB/c or Ctla-4-/- CD4+ CD25hi CD27hi Tregs at a 1:1 ratio as 
described for the suppression assays above.  On day 3, THY1.1+ conventional T cells were 
re-isolated by MACS positive selection (THY1.1-PE antibody 1/300, 10µl anti-PE MACS 
beads) and 2.5 x 104 cells re-stimulated in 96-well, round-bottomed plates with 1 x 105 
irradiated BALB/s splenocytes (20Gy), 1µg/ml anti-CD3 (BD Pharmingen) and 100 I.U. 
recombinant IL-2 (Peprotech) at 37°C, 5% CO2 for 3 days, 1µCi tritiated thymdine 
(Amersham, GE Healthcare) was added for the last 6 hours  of culture before harvest.          
 
2.5.6 T Cell / Treg and B Cell / DC Co-cultures. 
4 x 106 MACS separated BALB/c splenic CD19+ or CD11c+ cells were co-cultured with 
8 x 104 MACS separated BALB/c CD4+ CD25- T cells or CD4+ CD25+ Tregs or both, plus 
or minus 50µg/ml anti-CTLA-4 blocking antibody (4F10, gift from J. Bluestone, University 
of California, San Francisco) at 37°C, 5% CO2.  Cells were harvested and stained with CD3, 





2.6 Molecular Biology 
2.6.1 RNA Isolation.  
Frozen cell pellets were thawed and the RNA was isolated from the cells by RNAzol 
(Biogenesis Ltd) homogenisation (800µl at room temperature), chloroform extraction (80µl 
for 5minutes on ice) and isopropanol precipitation (15minutes at -20°C).     
 
2.6.2 cDNA Preparation. 
Immediately following RNA extraction, samples were heated to 70°C for 5 minutes before 
transferring to ice. Reverse transcription PCR was then performed by using M-MLV avian 
reverse transcriptase and oligo(dT) primers (Invitrogen, Paisley, UK). 
 
2.6.3 qPCR.  Primers and probes of pre-made TaqMan Gene Expression Assays purchased 
from Applied Biosystems (see table 4) and used in accordance with manufacturers’ 
instructions.  Primer and probe titrations were determined and reactions made with PCR 2x 
mastermix (ABI) in 96 well microAmp plates (ABI). Gene expression was quantified using a 
Mx3000 PCR machine (Stratagene) and normalised to β-actin levels.  β-actin primer and 
probe (Eurogentec): F: 5’ CGT GAA AAG ATG ACC CAG 3’ (0.07µm). R: 5’ TGG TAC 
GAC CAG AGG CAT 3’ (0.05µm).  1 cycle 50°C for 2minutes, followed by 1 cycle 95°C for 
10minutes, followed by 40 cycles 95°C for 15seconds and 60°C for 1minute.     
Quantitative SYBR Green PCR with RANK primers was conducted with SensiMix No-Ref 
SYBR Green Kit (Quantace) and used in accordance with the manufacturer’s instructions and 
normalised to β-actin levels.  RANK primers: F: 5’ GCT GGC TAC CAC TGG AAC TC 3’ 
(0.2µm). R: 5’ GTG CAG TTG GTC CAA GGT TT 3’ (0.2µm).  1 cycle 95°C for 10minutes, 
followed by 39 cycles 95°C for 15seconds, 62°C for 20seconds and 72°C for 5 seconds.  Then 
melting curve of 30seconds up to 73°C, then next 37 cycles 5seconds increasing 1°C each 








2.6.4 TaqMan Gene Expression Assays. 






























Unpaired T-tests were performed using GraphPad Prism version 4.00 for Windows 
(GraphPad Software, San Diego California USA). All tests were two-tailed with 95% 


































CTLA-4 was first thought to be a co-stimulatory receptor because early studies using 
anti-CTLA-4 monoclonal antibodies interpreted enhanced proliferation of 
anti-CD3/anti-CD28 activated T cells as evidence for augmented CD28-mediated 
co-stimulation [197, 198].  It is now realised that the stimulatory effects observed upon 
blockade or loss of CTLA-4 can be attributed to the disruption of T cell negative control [199, 
200].  The two receptors CD28 and CTLA-4 are now regarded to have functionally opposite 
roles in T cell responses.       
 
Like the CD28 co-stimulatory receptor, CTLA-4 is predominantly found to be expressed by 
T lymphocytes.  It is now known that CTLA-4 is constitutively expressed by the 
CD4+ CD25+ regulatory T cell subset [154, 155].  However, the role of CTLA-4 in Treg 
development and homeostasis is unclear.  CTLA-4 binds to the same ligands (CD80 and 
CD86) as the CD28 co-stimulatory receptor.  CD28 signalling has been shown to control both 
the thymic development and peripheral homeostasis of Tregs [86, 131].  On the other hand, it 
has previously been shown that thymic selection and thymocyte development is grossly 
normal in Ctla-4-deficient mice [87, 88].  However, these studies did not specifically assess 
the development of FOXP3+ Tregs in Ctla-4 knockout mice as they were carried out prior to 
the identification of the transcription factor Foxp3 as a specific marker for Tregs [60]. 
   
Due to the fatal lymphoproliferative disease that Ctla-4 knockout mice succumb to around 
three weeks of age [156, 157], frequently, CD28 signalling is simultaneously abrogated by 
CD80/86 blockade or deficiency when studying Ctla-4-deficient mice [231, 232].  As 
discussed above, CD28 co-stimulation has been found to be required for the thymic 
generation and peripheral maintenance of regulatory T cells [86], therefore the results of these 
studies cannot be solely attributed to a lack of CTLA-4.  Consequently, to investigate the role 
of CTLA-4 in regulatory T cell development and homeostasis, Ctla-4-deficient mice with 




3.2.1 Cellular expression of the CD28 and CTLA-4 receptors, and their ligands CD80 
and CD86. 
In order to understand a potential role for CTLA-4 on regulatory T cells, it was important to 
study the CTLA-4 receptor in the context of its ligands, CD80 and CD86, and also its 
homologue; the CD28 co-stimulatory receptor.  An early objective of the project was 
therefore to analyse the cellular distribution of CTLA-4, CD28 and their ligands (CD80 and 
CD86).  Since Tregs were to be identified by expression of the FOXP3 transcription factor, 
the specificity of the FOXP3 monoclonal antibody was first validated by staining wild type 
C57BL/6 mice and Foxp3-/- lymphocytes for analysis by flow cytometry.  CD28 and CTLA-4 
antibodies were similarly assessed using Ctla-4-/- and CD28-/- lymphocytes along with 
appropriate wild type BALB/c controls.  It can be seen in Fig. 3.01 that the FOXP3 (A), CD28 
(B) and CTLA-4 (D) antibodies all specifically stained wild type, control lymphocytes as 
opposed to lymphocytes from the respective knockout mice.  Also, the streptavidin secondary 
conjugate used to detect CD28 showed negligible non-specific binding (C).  As well as 
validating the specificity of the monoclonal antibodies, this data confirmed gene ablation in 
the Foxp3, CD28 and Ctla-4 knockout mice.   
 
It is known that T cells constitutively express the CD28 co-stimulatory receptor (reviewed in 
[188]).  Flow cytometry was used to investigate the distribution of CD28 expression among 
the various T cell subtypes.  It can be clearly seen in Fig. 3.02 that CD4+ FOXP3- 
conventional T cell, CD4+ FOXP3+ regulatory T cell (A) and CD8+ T cell (B) populations all 
constitutively expressed a similar amount of the CD28 co-stimulatory receptor.  The level of 
CD28 expression on CD8+ T cells was slightly higher than CD4+ T cells as indicated by the 
median fluorescent intensity of CD28-specific staining by flow cytometry.  Within the CD4+ 
T cell population the median fluorescent intensity of CD28-specific staining on FOXP3+ cells 
was slightly lower than on FOXP3- cells.                   
 
CD28 is constitutively expressed by T cells, whereas CTLA-4 is not highly expressed by 
resting conventional T cells.  Rather, upon activation de novo transcription of CTLA-4 is 








Figure 3.01.  Validation of FOXP3, CD28 and CTLA-4 monoclonal antibodies 
by flow cytometry.  Single cell suspensions from peripheral lymph nodes were 
surface stained with CD4, CD28 and intracellularly with CTLA-4 and FOXP3 for 
analysis by flow cytometry. Representative FACS plots of (A) three week old wild 
type C57BL/6 mice (left) and Foxp3-/- mice (right), (B) adult wild type BALB/c 
mice (left) and CD28-/- mice (right), (C) adult wild type BALB/c mice for secondary 
alone and (D) 15-18 day Ctla-4+/- mice (left) and Ctla-4-/- mice (right).  All FACS 
















Figure 3.02.  Cellular distribution of CD28 co-stimulatory receptor expression.  
Single cell suspensions from peripheral lymph nodes were surface stained with CD4, 
CD8, CD28 and intracellularly with FOXP3 for analysis by flow cytometry. 
Representative FACS plots for (A) CD4+ gated lymphocytes of adult wild type 
BALB/c mice (left) and for secondary alone (right) and (B) CD8+ gated 
lymphocytes of adult wild type BALB/c mice (left) and for secondary alone (right).  





mechanisms [234].  It is known that CD4+ CD25+ Tregs constitutively express the CTLA-4 
receptor [154, 155].  However, these studies were carried out prior to the identification of the 
transcription factor Foxp3 as a specific marker for Tregs, and the development of 
FOXP3-specific monoclonal antibodies.  Therefore, Tregs were previously identified as the 
CD4+ CD25+ T cell population, which could include some activated (CD25+) conventional 
T cells (CD4+ FOXP3-).  Consequently, the surface and intracellular expression of CTLA-4 
by Tconv and Treg populations identified as CD4+ FOXP3- and CD4+ FOXP3+, 
respectively, was analysed by flow cytometry.  Additionally, CTLA-4 expression by other 
lymphocyte populations (CD8+ T cells and B cells) was assessed by flow cytometry to 
investigate the cellular distribution of the CTLA-4 receptor.  The FACS plots in Fig. 3.03 
show that neither FOXP3- nor FOXP3+ CD4+ T cells expressed CTLA-4 at the cell surface.  
On the other hand, intracellular CTLA-4 was detected in some CD4+ FOXP3- Tconv and the 
majority of CD4+ FOXP3+ Tregs (A).  Only a small minority of CD8+ T cells expressed 
CTLA-4 (C).  It has been suggested that CTLA-4 may be expressed by B cells [235-237].  
However, CTLA-4 was not detected in CD19+ B cells (Fig 3.03 D).     
 
As mentioned above, the CTLA-4 receptor is not highly expressed by resting conventional 
T cells.  The up regulation of CTLA-4 by Tconv upon activation is thought to be 
CD28-dependent [202, 234], whereas the mechanistic control of CTLA-4 expression in Tregs 
is not known.  It has previously been reported that CD28 co-stimulation was required to 
induce CTLA-4 expression in CD4/CD8 double positive thymocytes as part of Treg thymic 
development [238].  Using lymphocytes isolated from CD28-deficient mice and agonistic 
antibodies to CD3 and CD28, the CD28-dependency of intracellular CTLA-4 expression by 
CD4+ FOXP3- Tconv and CD4+ FOXP3+ Tregs was investigated by in vitro overnight 
culture.  As predicted there were fewer CD4+ lymphocytes in CD28-/- mice, however both 
CD4+ FOXP3- Tconv and CD4+ FOXP3+ Tregs expressed intracellular CTLA-4 like 
lymphocytes from wild type mice (Fig. 3.04 A).  Fig. 3.04 B shows that fewer CD28-deficient 
CD4+ FOXP3- conventional T cells expressed intracellular CTLA-4 compared to wild type 
(left graph).  Intracellular CTLA-4 expression in Tconv increased in response to 
TCR-stimulation by anti-CD3 in both wild type and CD28-deficient lymphocytes.  In wild 









Figure 3.03. Cellular distribution of CTLA-4 receptor expression.  Single cell 
suspensions from peripheral lymph nodes were surface stained with CD4, CD8, 
CD19, CTLA-4 and intracellularly with FOXP3, CTLA-4 and Control antibody for 
analysis by flow cytometry. Representative FACS plots for (A) CD4+ gated 
lymphocytes of adult wild type BALB/c mice for surface CTLA-4 (left) and 
intracellular CTLA-4 (right), (B) CD4+ gated lymphocytes of adult wild type 
BALB/c mice for intracellular control antibody, (C) CD8+ gated lymphocytes of 
adult wild type BALB/c mice for intracellular CTLA-4 and (D) CD19+ gated 
lymphocytes of adult wild type BALB/c mice for intracellular CTLA-4.  Data 





























































































































































































Figure 3.04. CD28-dependency of intracellular CTLA-4 expression by CD4+ 
FOXP3- Tconv and CD4+ FOXP3+ Tregs. (A)  Single cell suspensions from 
peripheral lymph nodes were surface stained with CD4 and intracellularly with 
CTLA-4 and FOXP3 for analysis by flow cytometry.   Representative FACS plots 
for CD4+ gated lymphocytes of adult wild type BALB/c mice for iCTLA-4 (left) and 
adult CD28-/- mice for iCTLA-4 (right).  2 X 105 cells adult BALB/c wild type 
(blue) or CD28-/- (red) single cell suspensions from peripheral lymph nodes were 
cultured overnight plus or minus 500ng/ml anti-CD3 and 1µg/ml anti-CD28.  Cells 
were then surface stained with CD4 and intracellularly with CTLA-4 and FOXP3 for 
analysis by flow cytometry.  (B) percentage iCTLA-4+ of gated CD4+ FOXP3-
Tconv (left) and gated CD4+ FOXP3+ Tregs (right).  (C)  iCTLA-4 median 
fluorescence intensity of gated CD4+ FOXP3- Tconv (left) and gated CD4+ 
FOXP3+ Tregs (right).  Representative graphs from three independent experiments 
are shown.
anti-CD3 further increased intracellular CTLA-4 expression, although CD28 co-stimulation 
alone had no affect.  As predicted, the anti-CD28 antibody had no synergistic affect with 
anti-CD3 on CD28-/- lymphocytes.  Collectively, these data suggest that a combination of 
TCR and CD28 signalling drive the up regulation of CTLA-4 in conventional T cells.    
 
Parallel analyses were carried out on the CD4+ FOXP3+ regulatory T cell subset.  
Intracellular CTLA-4 expression by CD28-deficient CD4+ FOXP3+ Tregs (Fig. 3.04 B and 
C) was increased in both proportion and intensity compared to wild type.  Similar to 
conventional T cells, Treg intracellular CTLA-4 expression increased upon TCR-stimulation 
with anti-CD3.  However, CD28 co-stimulation had no synergistic affect with 
TCR-stimulation on intracellular CTLA-4 expression by CD4+ FOXP3+ Tregs.  Overall, the 
data suggest that up regulation of intracellular CTLA-4 expression by CD4+ FOXP3- Tconv 
is CD28-dependent and CD28-independent for CD4+ FOXP3+ Tregs.   
 
Any effect of CTLA-4 on the homeostasis of regulatory T cells would presumably depend 
upon encounter with one of its natural ligands; CD80 or CD86.  The CD28 / CTLA-4 ligands, 
CD80 and CD86, are expressed by dendritic cell and B cell antigen-presenting cells (APCs) to 
provide T cell co-stimulation when antigen is presented to T cells via MHC molecules on 
APCs [239].  To examine the distribution of CD80 and CD86 expression by APCs flow 
cytometry was used to analyse wild type splenocytes.  Fig. 3.05 A shows that CD3- CD11c+ 
MHC II+ dendritic cells constitutively expressed both CD80 and CD86.  On the other hand, 
only a relatively small proportion of CD19+ B cells expressed CD80 and CD86 (Fig. 3.05 B).  
Nevertheless, B cells were capable of up regulating CD86 expression following activation by 
overnight culture with LPS (Fig. 3.05 C). 
 
3.2.2 CTLA-4 receptor endocytosis. 
As discussed above, it is known that CTLA-4 is poorly expressed at the cell surface (see Fig. 
3.03).  Upon T cell activation, CTLA-4 is thought to be translocated to the cell surface, but 
cell surface expression levels are limited due to rapid clathrin-mediated endocytosis of the 
CTLA-4 receptor [179].  Phorbol myristate acetate (PMA) T cell activation has been shown to 
increase CTLA-4 trafficking to the plasma membrane via a phospholipase D-dependent 




















Figure 3.05.  Cellular distribution of CD80/CD86 ligand expression. Splenocytes 
were surface stained with CD3, CD11c, CD19, CD80, CD86 and I-Ad for analysis 
by flow cytometry. (A)  CD3- I-Ad+ CD11c+ gated lymphocytes of adult wild type 
BALB/c mice for CD80 (left) and control antibody (right).  (B)  CD3- I-Ad+ 
CD11c+ gated lymphocytes of adult wild type BALB/c mice for CD86 (left) and 
control antibody (right).  (C)  CD19+ gated lymphocytes of adult wild type BALB/c 
mice for CD80 (left) and CD86 (right).  (D) 1 X 105 wild type BALB/c splenocytes 
were cultured overnight plus or minus 10µg/ml LPS.  Cells were then surface stained 
with CD19, CD80 and CD86 for analysis by flow cytometry.  Left histogram shows 
CD80 of gated CD19+ cultured plus (red) and minus (blue) LPS, and right histogram 
shows CD86 of gated CD19+ cultured plus (red) and minus (blue) LPS.
CD4+ FOXP3- conventional T cells and CD4+ FOXP3+ regulatory T cells, in vitro culture 
with PMA, ionomycin and extracellularly provided, fluorescently conjugated anti-CTLA-4 
antibody was used.  To investigate CTLA-4 receptor cycling in CD4+ FOXP3- Tconv and 
CD4+ FOXP3+ Tregs whole lymphocytes were cultured plus or minus PMA and ionomycin 
with exogenous, fluorescently conjugated anti-CTLA-4 antibody.  Over time, any CTLA-4 
that trafficked to the cell surface would be fluorescently labelled by the exogenous 
anti-CTLA-4 and quantified upon analysis by flow cytometry.   
 
The data in Fig. 3.06 shows that over time the CTLA-4 receptor cycled in response to PMA 
and ionomycin as the proportion of cells positive for CTLA-4 increased from the minimal 
surface level of CTLA-4 expression towards the level of constitutively expressed, intracellular 
CTLA-4 upon fresh ex vivo staining.  In the time-frame studied, Treg CTLA-4 expression was 
always greater than Tconv CTLA-4 expression.  The CTLA-4 receptor cycling kinetics of 
Tconv and Tregs was similar; after 2hrs incubation with PMA and ionomycin there was a 
shift in the proportion of cells that had bound the fluorescently-conjugated anti-CTLA-4 
antibody.  For both Tconv and Tregs, the level of bound fluorescently-conjugated 
anti-CTLA-4 antibody after culture in medium alone did not increase above the minimal 
surface level of CTLA-4 expression.  The data obtained suggest that the CTLA-4 receptor 
cycles in Tregs in a similar manner to Tconv, but the intracellular store of CTLA-4 in Tregs is 
constitutively larger than in Tconv.   
 
3.2.3 CTLA-4 normally functions to restrict the proliferation of Tregs in the periphery. 
To examine the role of CTLA-4 in Treg homeostasis, first, BALB/c mice genetically deficient 
for the Ctla-4 gene were analysed.  Mice in which the Ctla-4 gene has been ablated succumb 
to a fatal lymphoproliferative syndrome by around 3 weeks of age [156, 157].  Fig. 3.07 A 
illustrates how homozygous Ctla-4-deficient mice were smaller than heterozygous littermate 
controls and exhibited lymphadenopathy and splenomegaly.  The graph of Fig. 3.07 B shows 
how in addition to looking larger by eye, the spleen from a Ctla-4 knockout mouse was also 
of greater mass.  The absolute cell counts of pooled peripheral lymph nodes and spleen of a 




Figure 3.06. CTLA-4 receptor cycling in CD4+ FOXP3- conventional T cells 
and CD4+ FOXP3+ Tregs.  Wild type adult BALB/c single cell suspensions from 
peripheral lymph nodes were stained with CD4.  1 X 106 lymphocytes were cultured 
for time stated plus or minus 50ng/ml PMA and 1.5µM Ionomycin and 2µg/ml 
CTLA-4-PE.  Cells were then stained intracellularly with FOXP3 for analysis by 
flow cytometry.  For fresh ex-vivo wild type adult BALB/c single cell suspensions 
from peripheral lymph nodes were surface stained with CD4, CTLA-4 and 
intracellularly CTLA-4 and FOXP3.  Top graph shows CD4+ FOXP3- gated Tconv 
and bottom graph shows CD4+ FOXP3+ gated Tregs.  Bars represent mean and 
standard deviation is shown for three independent experiments.  Note the different 





























































































































































































































































































































































































































































































Figure 3.07. Ctla-4-/- mouse phenotype.  (A) Day 18 Ctla-4+/- and Ctla-4-/- mice 
(left).  Centre shows brachial (top), axillary (middle) and inguinal (bottom) lymph 
nodes dissected from day 18 Ctla-4+/- and Ctla-4-/- mice.  Day 18 Ctla-4+/- and 
Ctla-4-/- spleens (right).  (B)  Graph shows weight of 15-18 day old BALB/c, Ctla-
4+/- and Ctla-4-/- spleens.  (C)  Graph shows absolute cell number for all lymph 
nodes and spleen from 15-18 day old BALB/c, Ctla-4+/- and Ctla-4-/- mice.  (D)  
Graphs show percentage of CD4+ (top), CD8+ (middle) and CD19+ (bottom) in 
lymph nodes and spleen of 15-18 day old Ctla-4+/- and Ctla-4-/- mice.  (E) Graphs 
show absolute number of CD4+ (top), CD8+ (middle) and CD19+ (bottom) in lymph 
nodes and spleen of 15-18 day old Ctla-4+/- and Ctla-4-/- mice.  Bars represent 
mean values and standard deviation is shown for >5 mice.  p values calculated by 
two-tailed, unpaired T-test for the means.   
Phenotyping of Ctla-4-deficient mice was carried out by flow cytometry to investigate the 
cellular composition of the lymphocytes within the lymph nodes and spleen.  Since no overt 
difference was observed between wild type and Ctla-4 heterozygous mice, Ctla-4+/- 
littermate controls were used as a comparison for the Ctla-4 knockout mice.  Due to the large 
increase in lymph node and spleen size of Ctla-4-deficient mice, it can be seen in Fig. 3.07 E 
that the absolute numbers of CD4+ T cells, CD8+ T cells and CD19+ B cells was increased in 
the lymph nodes and spleen of Ctla-4-/- mice compared to littermate controls.  However, the 
T cell and B cell percentage compositions of lymph nodes and spleen varied (Fig. 3.07 D).  
The percentage of CD4+ T cells was slightly decreased in the lymph nodes and increased in 
the spleen of Ctla-4 knockout mice compared to littermate controls.  These differences were 
small, but statistically significant.  Whereas, the percentage of CD8+ T cells were decreased 
in Ctla-4-/- lymph nodes, but unaltered in the spleen.  With the decreased CD4 and CD8 
T cell proportion in the Ctla-4-/- lymph nodes there was a concurrent increase in 
CD19+ B cells.  The B cell proportions in the Ctla-4-/- spleen however remained similar to 
that of the littermate controls.     
 
The original phenotyping studies of Ctla-4-deficient mice when they were generated in the 
mid-1990s identified an augmented CD25+ T cell population [156, 157].  Due to alterations in 
other T cell activation markers such as increased CD69 and decreased CD62L, at the time, the 
increase in CD25+ T cells was attributed to an increase in activated T cells.  These studies 
were carried out prior to the resurgence of CD4+ CD25+ Tregs and the identification of the 
transcription factor Foxp3 as a specific marker for this T cell population.  To test whether the 
augmented CD4+ CD25+ population in Ctla-4-deficient mice represented activated 
conventional T cells or regulatory T cells, FOXP3 expression was analysed in lymphocytes 
from Ctla-4 knockout mice by flow cytometry.  The FACS plots of Fig. 3.08 A show that in 
Ctla-4-/- mice there was an increase in the percentage of CD25+ FOXP3+ lymphocytes [241].  
The phenotyping data of the Ctla-4-/- mice in Fig. 3.07 D suggested that there was not much 
change in the proportion of CD4+ T cells as a whole.  The graphs of Fig. 3.08 B show the 
proportion of CD4+ T cells that were FOXP3- or FOXP3+, and it can be seen that there was a 
shift within the CD4+ T cell population in which the FOXP3+ lymphocytes were augmented 





































































































































































































Figure 3.08. Ctla-4-deficient mice have increased CD4+ FOXP3+ cells.  Day 15-
18 Ctla-4+/- and Ctla-4-/- single cell suspensions from peripheral lymph nodes were 
surface stained with CD4, CD25 and intracellularly with FOXP3 for analysis by flow 
cytometry.  (A)  CD25 and FOXP3 expression by day 15-18 Ctla-4+/- (left) and 
Ctla-4-/- (right) lymphocytes.  (B)  Graphs show percentage of CD4+ that are 
FOXP3- (red) or FOXP3+ (blue) in the lymph nodes (top) and spleen (bottom) of 
Ctla-4+/- and Ctla-4-/- mice.  (C) Graphs show absolute number of CD4+ FOXP3-
and CD4+ FOXP3+ in the lymph nodes (left) and spleen (right) of Ctla-4+/- (blue) 
and Ctla-4-/- (red) mice.  (D)  Fold increase in the absolute number of CD4+ 
FOXP3+ Tregs (blue) and CD4+ FOXP3- Tconv (red) in the lymph nodes and spleen 
of Ctla-4-/- versus Ctla-4+/- mice.  Bars represent mean and standard deviation is 
shown for ≥5 mice.
numbers of both CD4+ FOXP3- and CD4+ FOXP3+ lymphocytes was increased in 
Ctla-4-deficient mice (Fig. 3.08 C).  One possible explanation for the augmentation of 
CD4+ FOXP3+ lymphocytes in the periphery of Ctla-4-deficient mice is that thymocyte 
selection could be altered in the absence in Ctla-4, such that a greater proportion of CD4+ 
thymocytes are induced to express Foxp3 and are then exported to the periphery.  FOXP3 
expression by Ctla-4-/- thymocytes was therefore analysed by flow cytometry.  Fig. 3.09 A 
shows the gating strategy used to identify the four main thymocyte populations based on CD4 
and CD8 expression.  The proportions of CD4 single positive, CD8 single positive, 
CD4 / CD8 double negative and CD4 / CD8 double positive thymocytes were unaltered in the 
thymi of mice lacking Ctla-4.  Within the CD4 single positive thymocyte gate, the percentage 
of FOXP3+ CD4+ thymocytes was similar in Ctla-4-deficient thymi compared to littermate 
controls (Fig. 3.09 B).  The graph of Fig. 3.09 C represents combined data for four different 
Ctla-4-/- mice and four different Ctla-4+/- littermate controls, and shows that the percentage 
of CD4 single positive FOXP3+ thymocytes was unchanged.  The data of Fig. 3.09 was 
obtained using a piece of thymus as opposed to a whole thymus because due to the 
lymphadenopathy in Ctla-4-/- mice it was difficult to obtain single cell thymocyte 
suspensions from whole thymi that were not contaminated by parathymic lymph nodes (as 
previously reported by others [88]).  Therefore, flow cytometry data was only used when no 
CD19+ B cell contamination was observed (illustrated in Fig. 3.09 D).  Together the data 
suggest that the size of the CD4+ FOXP3+ regulatory T cell population selected 
intra-thymically is not modulated by the CTLA-4 pathway.   
 
To compliment the above studies into a possible role of CTLA-4 in thymic selection, the 
distribution of intracellular CTLA-4 expression among the four main thymocyte subsets, 
based on CD4 and CD8 expression, was analysed by flow cytometry.  Fig. 3.10 A shows that 
like for peripheral T cells, CD4 single positive thymocytes expressed intracellular CTLA-4 
and this mainly corresponded to the FOXP3+ subset.  CD8 single positive, CD4 / CD8 double 
positive and CD4 / CD8 double negative thymocyte populations expressed negligible amounts 
of intracellular CTLA-4.   
 
As a comparison of CTLA-4 deficiency, mice lacking the homologous co-stimulatory 
receptor CD28 were also examined.  It is known that CD28 is required for the thymic  
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Figure 3.09. Normal proportion of CD4+ FOXP3+ Tregs in the thymus of Ctla-
4-/- mice.  Single cell suspensions from 15-18 day old Ctla-4+/- or Ctla-4-/- thymi 
were surface stained with CD4, CD8, CD19 and intracellularly with FOXP3 for 
analysis by flow cytometry.  (A)  Representative FACS plots showing the 
proportions of CD8 single positive, CD4 / CD8 double positive, CD4 / CD8 double 
negative and CD4 single positive thymocytes for Ctla-4+/- (left) and Ctla-4-/-
(right).  (B)  Representative FACS plots for FOXP3 expression by CD4 SP-gated 
Ctla-4+/- (left) and Ctla-4-/- (right) thymocytes.  (C)  A graph to show the mean 
percent of CD4 SP-gated thymocytes that are FOXP3+ with standard deviations.  (D) 
Histogram to illustrate the presence of CD19+ cells in the whole thymus of Ctla-4-/-
(red) compared to Ctla-4+/- (black) and a carefully dissected piece of Ctla-4-/-
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Figure 3.10. Distribution of CTLA-4 in wild type thymus and analysis of CD4+ 
FOXP3+ Tregs in CD28-/- thymus. Single cell suspensions from adult wild type 
BALB/c or CD28-/- thymi were surface stained with CD4, CD8 and intracellularly 
with CTLA-4 and FOXP3. Representative FACS plots showing (A)  Intracellular
CTLA-4 expression by the various CD4 and CD8 thymocyte subsets of adult wild 
type BALB/c thymus. (B) the proportions of CD8 single positive, CD4 / CD8 double 
positive, CD4 / CD8 double negative and CD4 single positive thymocytes for wild 
type BALB/c (left) and CD28-/- (right), (C)  FOXP3 expression by CD4 SP-gated 
wild type BALB/c (left) and CD28-/- (right) thymocytes.  Data represent ≥3 mice.   
selection of CD4+ FOXP3+ Tregs [86, 131, 238].  Thymi from CD28-deficient mice were 
analysed for FOXP3 expression by flow cytometry as done previously for Ctla-4-deficient 
thymi.  Fig. 3.10 B illustrates that similar to Ctla-4-deficient thymi, CD28-deficient thymi had 
unaltered proportions of CD4 single positive, CD8 single positive, CD4 / CD8 double 
negative and CD4 / CD8 double positive thymocytes to wild type thymi.  The proportion of 
CD4 single positive thymocytes that was FOXP3+ on the other hand was significantly 
reduced in thymi lacking CD28 (Fig. 3.10 C).  Thus, the published observation that CD28 
signalling controls FOXP3+ Treg selection in the thymus was repeatable, but a role for 
CTLA-4 in this process was not found.       
 
The molecules, CD80 and CD86, are common ligands to both the CTLA-4 and CD28 
receptors.  Within the thymus it is hypothesised that medullary thymic epithelial cells 
(mTECs) present antigen to developing thymocytes as part of negative selection and FOXP3+ 
Treg differentiation [79, 242].  Therefore, the expression of the ligands, CD80 and CD86, was 
analysed on non-thymocytes by flow cytometry.  Thymi were teased apart to remove the 
majority of thymocytes and digested with collagenase, dispase and trypsin so that EpCam+ 
(pan-epithelial cell marker) non-thymocytes (CD45-) could be identified.  Using an isotype 
control to set the flow cytometry analysis gates Fig. 3.11 shows that CD80 and CD86 
expression by EpCam+ non-thymocytes was similar in wild type, CD28-deficient and 
Ctla-4-deficient thymi.         
 
No thymic defect in Treg development was observed in the absence of Ctla-4, therefore the 
peripheral homeostasis of Ctla-4-deficient Tregs was investigated.  Previous phenotyping 
analysis of Ctla-4 knockout mice by others observed overt T cell activation as determined by 
increased CD69 and decreased CD62L expression [156, 157].  To assess the activation status 
of conventional T cells and regulatory T cells in Ctla-4-deficient mice, FOXP3 was used to 
discriminate the peripheral T cells.  Fig. 3.12 shows that both CD4+ FOXP3- Tconv (A) and 
CD4+ FOXP3+ Tregs (B) up-regulated CD69 and down-regulated CD62L in the periphery of 
Ctla-4 knockout mice compared to littermate controls.  Increased CD69 and decreased 
CD62L are consistent with a highly activated phenotype.  Additionally, expression of the 
secondary co-stimulatory molecule ICOS was analysed because it is now known that ICOS 












Figure 3.11.  CD80 and CD86 expression by CD45- EpCam+ non-thymocytes.  
Adult wild type BALB/c, CD28-/-, 15-18 day old Ctla-4+/- and Ctla-4-/- thymi were 
teased to remove thymocytes, collagenase / dispase and trypsin digested and surface 
stained with CD45, EpCam, CD80, CD86 or control antibody for analysis by flow 
cytometry.  Representative FACS plots to show CD80 (middle) and CD86 (right) 
expression by EpCam+ cells.  All FACS plots show CD45- gate.  Data representative 




















Figure 3.12.  Activation marker expression by CD4+ FOXP3- conventional T 
cells and CD4+ FOXP3+ Tregs in Ctla-4-/- mice.  Single cell suspensions from 
peripheral lymph nodes were surface stained with CD4, CD69, CD62L, ICOS and 
intracellularly with FOXP3 for analysis by flow cytometry.  (A) Representative 
FACS plots of CD69 (top), CD62L (middle) and ICOS (bottom) for CD4+ FOXP3-
gated lymphocytes of day 15-18 Ctla-4+/- (left) and day 15-18 Ctla-4-/- (right).  (B) 
Representative FACS plots of CD69 (top), CD62L (middle) and ICOS (bottom) for 
CD4+ FOXP3+ gated lymphocytes of day 15-18 Ctla-4+/- (left) and day 15-18 Ctla-
4-/- (right).  Data representative of four mice.
(Fig. 3.12 A) and CD4+ FOXP+ Tregs (Fig. 3.12 B) there was a substantial increase in ICOS 
expression.  Given the activated Treg phenotype observed above, enhanced proliferation 
could possibly explain the augmented FOXP3+ population in the periphery of 
Ctla-4-deficient mice.  The proliferation of peripheral FOXP3+ cells in mice lacking Ctla-4 
was analysed using the nuclear protein expressed by proliferating cells; Ki67.  Spleen sections 
from Ctla-4 knockout and littermate controls were stained with CD4, FOXP3 and Ki67 for 
analysis by confocal microscopy.  The confocal images in Fig. 3.13 A clearly show that many 
more FOXP3+ cells (red) in the Ctla-4-/- spleen were also Ki67+ (green) and undergoing 
proliferation (appearing yellow) compared to in the control littermate spleen.  The 
immunoflourescence data obtained was quantified by scoring the images from the spleens of a 
number of different mice for the percentage of FOXP3+ cells that were also Ki67+ (yellow) 
(Fig. 3.13 B).  There was a statistically significant increase in the percentage of proliferating 
FOXP3+ cells in Ctla-4-deficient spleens compared to littermate control spleens.  Similar data 
was obtained by flow cytometry analysis of lymphocytes isolated from the lymph nodes of 
Ctla-4 knockout mice compared to littermate controls.  Intracellular staining for FOXP3 and 
Ki67 showed that there was a statistically significant increase in the proportion of 
proliferating (Ki67+) CD4+ FOXP3- Tconv and CD4+ FOXP3+ Tregs in the absence of 
Ctla-4 (Fig. 3.14).    
 
The nuclear protein Ki67 that is present during all active phases of the cell cycle and absent in 
resting cells is becoming a more widely used cellular marker for determining the growth 
fraction of a given cell population [245].  Ki67 was the proliferation marker of choice as it is 
difficult to detect a more classical method such as 5-bromo-2-deoxyuridine (BrdU) 
incorporation along with FOXP3.  It is also not easy to administer BrdU to Ctla-4-/- mice due 
to the early, fatal disease associated with ablation of the Ctla-4 gene.  The use of Ki67 as a 
marker of proliferation was validated by comparison with BrdU in CD4+ T cells of wild type 
BALB/c mice in vivo by flow cytometry.  The representative FACS plots of Fig. 3.15 A and 
graph in Fig. 3.15 B show that Ki67 expression measured a similar proportion of proliferating 
CD4+ T cells to the detection of BrdU incorporation. 
 
In Fig. 3.14 it can be seen that Ctla-4+/- littermate control CD4+ FOXP3+ Tregs proliferate 
more than CD4+ FOXP3- Tconv.  Some may view this Treg proliferation in naïve mice as  
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Figure 3.13. CD4+ FOXP3+ Tregs in the Ctla-4-/- spleen show increased 
proliferation.  (A)  Acetone fixed, 6µm spleen sections from 15-18 day old 
littermate Ctla-4+/- controls (left) or Ctla-4-/- (right) were stained with rat anti-CD4-
647 (blue), rat anti-FOXP3-biotin, streptavidin-555 (red), rabbit anti-Ki67 and 
donkey anti-rabbit-488 (green) for analysis by confocal microscopy (x63).  
Proliferating FOXP3+ Ki67+ Tregs appear yellow.  (B)  Graph shows scoring of 
stained Ctla-4+/- (blue) and Ctla-4-/- (red) spleen sections for the percentage of 
FOXP3+ that are Ki67+.  Each symbol represents a different field of view and each 
column a different mouse.  >five fields were scored per mouse.  Lines represent 
mean value. p value calculated by two-tailed, unpaired T-test for the means.
A Ctla-4+/- Ctla-4-/-

































Figure 3.14. CD4+ FOXP3- conventional T cell and CD4+ FOXP3+ Treg 
proliferation in the peripheral lymph nodes of Ctla-4-/- mice.  Single cell 
suspensions from peripheral lymph nodes were surface stained with CD4 and 
intracellularly with FOXP3 and Ki67 for analysis by flow cytometry.  (A)  
Representative FACS plots of Ki67 expression by CD4+ FOXP3- gated lymphocytes 
(top) and CD4+ FOXP3+ gated lymphocytes (bottom) from 15-18 day old Ctla-4+/-
(left) and Ctla-4-/- (right).  (B)  Graph shows percentage of CD4+ FOXP3- (squares) 
and CD4+ FOXP3+ (circles) that expressed Ki67 for four Ctla-4+/- (blue) and four 
Ctla-4-/- (red) mice.  Lines indicate mean values. p values calculated by two-tailed, 

















































Figure 3.15. Validation of Ki67 as a marker of proliferation by comparison with 
BrdU. Two week old wild type BALB/c mice received 1mg BrdU by intra-
peritoneal injection every twenty-four hours for three days.  Twenty-four hours 
following last injection mice were harvested and single cell suspensions from 
peripheral lymph nodes were surface stained with CD4 and intracellularly with Ki67 
or BrdU for analysis by flow cytometry.  Representative FACS plots of Ki67 (A) and 
BrdU (B) expression by CD4+ gated lymphocytes.  (C)  Graph shows data for four 
































rather high considering that in vitro Tregs are anergic [57].  However, in unmanipulated mice 
the CD4+ CD25+ Treg population has been shown to exhibit a surprising capacity for 
proliferation that has been suggested to reflect their continuous encounter with self antigens 
[246].  Additionally, due to the young age at which Ctla-4-/- mice have to be sacrificed there 
may also be lymphopenic affects seen in the age-matched Ctla-4+/- littermate controls.  To 
investigate the proliferation of naïve conventional T cells and regulatory T cells, BALB/c 
mice were assessed during maturation from a neonate (1 week old) into an adult (>6 weeks 
old).  It can be seen in Fig. 3.16 that CD4+ FOXP3+ Treg proliferation, as determined by 
Ki67 expression, was generally greater than that of CD4+ FOXP3- Tconv proliferation.  The 
graph of Fig. 3.16 demonstrates that both Treg and Tconv proliferation was greater in young 
mice (1 week old) and decreased as the mice matured into adults (>6 weeks old).   
 
3.2.4 Tregs deficient in Ctla-4 undergo less cell death. 
An augmented FOXP3+ population in the absence of Ctla-4 could also be a consequence of 
decreased cell death.  Therefore, the proportion of FOXP3+ cells undergoing cell death was 
analysed in the Ctla-4 knockout mouse.  Cells undergoing apoptosis translocate 
phosphatidylserine from the inner leaflet of the plasma membrane lipid bilayer to the outer 
layer [247] where, in the presence of calcium, the ANNEXIN V protein can then detect and 
bind this phospholipid-like molecule [248].  Unfortunately, analysis of ANNEXIN V binding 
by flow cytometry cannot be carried out with intracellular staining for FOXP3.  Tregs in the 
mouse can be identified with the surface markers CD4 and CD25 as the CD4+ CD25+ 
population correlates very well with the CD4+ FOXP3+ population.  However, in the 
Ctla-4-deficient mouse CD4+ FOXP3- Tconv exhibit an activated phenotype (Fig. 3.12 A) 
with increased expression of CD25 [156, 157].  Fig. 3.17 A illustrates that the CD4+ CD25+ 
population in the Ctla-4-/- mouse consists of only 85% FOXP3+ lymphocytes.  Consequently, 
additional cell surface markers had to be indentified that could be used to represent a pure 
FOXP3+ Treg population.  In humans where the regulatory CD4+ FOXP3+ population is 
confined to just the CD4+ CD25hi cells, CD127 is frequently used as an additional cell 
surface marker to isolate a pure population of CD4+ CD25hi CD127lo FOXP3+ Tregs [249, 
250].  It has also been shown in an inflammatory environment (inflamed synovia) where 
Tconv have increased CD25 expression, that CD27 is a useful marker to distinguish Tregs 
from effector T cells.  CD27 is constitutively expressed by T cells and upon activation Tregs  
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Figure 3.16. Timecourse of CD4+ FOXP3- conventional T cell and CD4+ 
FOXP3+ Treg proliferation. Single cell suspensions from wild type BALB/c 
peripheral lymph nodes were surface stained with CD4 and intracellularly with Ki67 
and FOXP3 for analysis by flow cytometry. Graph shows percentage of gated 
population that express Ki67 for one week, two weeks, four weeks, eight weeks or 
≥twenty-two week old mice.  CD4+ FOXP3- gated lymphocytes represented by red 
squares and CD4+ FOXP3+ gated lymphocytes represented by blue circles.  Each 








































Figure 3.17. Discrimination of Tregs from activated conventional T cells using 
CD25 and CD27 cell surface markers. Single cell suspensions from 15-18 day old 
Ctla-4-/- peripheral lymph nodes were surface stained with CD4, CD25, CD27 and 
intracellularly with FOXP3 for analysis by flow cytometry. Representative FACS 
plots show (A) FOXP3 expression (right) of CD4+ CD25+ gated lymphocytes 
indicated on the left and (B) FOXP3 expression (right) of CD4+ CD25+ CD27hi 
gated lymphocytes indicated on the left.  Experiments carried out in collaboration 














maintain expression of CD27, whereas Tconv down regulate CD27 [251].  It was therefore 
investigated whether CD27 could be used in conjunction with CD4 and CD25 as cell surface 
markers to isolate a pure CD4+ FOXP3+ population from the activated environment of 
Ctla-4-deficient mice.  Fig. 3.17 B shows that when just the CD25+ CD27hi CD4+ T cell 
population was isolated it had a FOXP3+ purity of 98%.  In future when intracellular FOXP3 
cannot be used to identify Tregs, a reliable population could be identified as 
CD4+ CD25+ CD27hi.                  
 
To analyse the proportion of FOXP3+ Tregs undergoing cell death (apoptotic and necrotic), 
ANNEXIN V staining was carried out on peripheral lymphocytes along with the surface 
markers CD4, CD25 and CD27 for analysis by flow cytometry.  The representative FACS 
plots and graph in Fig. 3.18 show that there was slightly less cell death occurring within the 
Tconv population in Ctla-4-/- mice compared to wild type as indicated by reduced ANNEXIN 
V staining.  Whereas there was a statistically significant reduction in ANNEXIN V staining 
and therefore cell death occurring within the Treg population in Ctla-4-/- mice compared to 
wild type controls.  In addition to increased proliferation of peripheral Tregs in 
Ctla-4-deficient mice, decreased occurrence of cell death could also be contributing to the 
augmented FOXP3+ population observed.   
 
To investigate the mechanism behind the observed reduction in regulatory T cell death in the 
Ctla-4 knockout mice, FAS expression was analysed by flow cytometry.  FAS (CD95) is a 
death receptor up-regulated by activated T cells and the ligation of which, by FAS ligand, 
induces apoptosis [252-254].  Mechanistically, the triggering of signalling pathways can be 
regulated by the control of cell surface receptor expression.  The representative histograms 
and graph in Fig. 3.19 show that FAS expression by CD4+ FOXP3- Tconv was similar in 
lymphocytes from Ctla-4-deficient mice and littermate controls.  A reduction in the intensity 
of FAS expression by CD4+ FOXP3+ Tregs from Ctla-4 knockout mice was observed 
compared to lymphocytes from littermate controls.  Reduced FAS receptor expression by 
Tregs either due to the cell-intrinsic loss of CTLA-4 or the environment of the 
Ctla-4-deficient mouse, could potentially account for the observed decrease in proportion of 
Tregs undergoing cell death in Ctla-4-/- mice.   
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Figure 3.18. Cell Death analysis of Ctla-4-deficient CD4+ CD27low Tconv and 
CD4+ CD25+ CD27hi Tregs using ANNEXIN V. Single cell suspensions from 15-
18 day old wild type BALB/c (left) and Ctla-4-/- (right) peripheral lymph nodes 
were surface stained with CD4, CD25, CD27 and ANNEXIN V for analysis by flow 
cytometry. (A)  Representative FACS plots show ANNEXIN V expression by CD4+ 
CD27low gated Tconv (top) and CD4+ CD25+ CD27hi gated Tregs (bottom).  (B) 
Graph shows data of CD4+ CD27low Tconv (squares) and CD4+ CD25+ CD27hi 
Tregs (circles) for >five wild type BALB/c (blue) and Ctla-4-/- (red) mice.  Lines 



























































Figure 3.19. FAS expression by Ctla-4-/- CD4+ FOXP3- Tconv and CD4+ 
FOXP3+ Tregs. Single cell suspensions from 15-18 day old Ctla-4+/- (blue) and 
Ctla-4-/- (red) peripheral lymph nodes were surface stained with CD4, FAS and 
intracellularly with FOXP3 for analysis by flow cytometry. (A)  Representative 
histograms show FAS expression by CD4+ FOXP3- gated Tconv (left) and CD4+ 
FOXP3+ gated Tregs (right).  Isotype control in black.  (B) Graph shows data for 
FAS median fluorescence intensity of CD4+ FOXP3- (squares) and CD4+ FOXP3+ 




































































The amount of Tconv and Treg cell death measured in wild type mice in Fig. 3.18 could be 
considered to be relatively high.  These wild type mice were only 2-3 weeks old because they 
were age-matched to the 15-18 day old Ctla-4-/- mice.  Tconv and Treg cell death was 
consequently assessed in the naïve BALB/c mouse as it matures from a neonate (2 weeks old) 
into an adult (>6 weeks old) by ANNEXIN V staining and flow cytometry.  It can be seen in 
Fig. 3.20 that CD4+ CD27low conventional T cell death, as determined by ANNEXIN V 
binding, did not vary over the timecourse studied, if anything ANNEXIN V binding to Tconv 
slightly increased as the BALB/c mice aged.  CD4+ CD25+ CD27hi regulatory T cell death, 
as determined by ANNEXIN V binding, on the other hand decreased from 2 weeks to 4 weeks 
and then remained fairly constant. 
 
3.2.5 Induction of the Treg-specific transcription factor FOXP3. 
Natural CD4+ FOXP3+ Tregs are produced in the thymus and exported to the periphery 
where functionally they are main players in the maintenance of peripheral tolerance.  More 
recently it has been established that expression of the transcription factor FOXP3 can be 
induced in CD4+ FOXP3- Tconv in the periphery to generate adaptive Tregs (reviewed 
[106]).  To explore whether the augmented FOXP3+ population observed in the periphery of 
Ctla-4-/- mice could reflect increased induction of FOXP3 in peripheral T cells, experiments 
to test the role of CTLA-4 in FOXP3 induction were carried out.       
 
In vitro, culture of CD4+ CD25- Tconv with TCR-stimulation and CD28 co-stimulation in the 
presence of TGF-β induces FOXP3 expression [114].  However, it is difficult to determine 
whether this is true FOXP3 induction or outgrowth of any contaminating FOXP3+ cells 
present in the isolated CD4+ CD25- population before culture.  This technical problem can be 
overcome using lymphocytes from TCR-transgenic mice.  T cells within DO11.10 mice bear a 
transgenic T cell receptor specific for the model antigen OVA (KJ-126+).  However, due to 
random TCR-rearrangement during T cell development some KJ-126-negative T cells can 
develop.  The model antigen OVA is not promiscuously expressed within the thymus, 
therefore natural CD4+ FOXP3+ Tregs specific for OVA (KJ-126+) do not develop in the 
thymus and cannot be found in the periphery.  Although, it is possible that KJ-126-negative 
T cells which develop due to random TCR-rearrangement could encounter their antigen 
within the thymus and be induced to become natural CD4+ FOXP3+ Tregs.  Consequently, a  
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Figure 3.20. Timecourse of CD4+ CD27low Tconv and CD4+ CD25+ CD27hi 
Treg cell death by ANNEXIN V. Single cell suspensions from wild type BALB/c 
peripheral lymph nodes were surface stained with CD4, CD25, CD27 and 
ANNEXIN V for analysis by flow cytometry. Graphs show percentage of gated 
population that express ANNEXIN V.  Data for three two weeks, four weeks, eight 
weeks or ≥twenty-two week old mice.  CD4+ CD27low gated lymphocytes 
represented by red squares (top) and CD4+ CD25+ CD27hi gated lymphocytes 
represented by blue circles (bottom).  Lines indicate means.
Tconv
























































Figure 3.21. Analysis of antigen-specific CD4+ FOXP3+ Tregs in TCR-
transgenic mice. Single cell suspensions from peripheral lymph nodes were surface
stained with CD4, KJ-126 and intracellularly with FOXP for analysis by flow 
cytometry. Representative FACS plots of antigen-specific (KJ-126+) CD4+ FOXP3+ 
Tregs in (A) DO11.10+ mOVA-, (B) DO11.10+ mOVA+ mice, (C)  DO11.10+ 
mOVA- Rag2-/- and (D) DO11.10+ mOVA+ Rag2-/- mice.  All FACS plots CD4+ 
gated lymphocytes.      
A
C
DO11.10+ mOVA- DO11.10+ mOVA+








minority of CD4+ KJ-126- FOXP3+ lymphocytes are exported from the thymus and can be 
found in the periphery (Fig. 3.21 A).  By maintaining TCR-transgenic mice on a Rag2-/- 
background (deficiency in the recombination activating gene), random TCR-rearrangements 
are prevented and no T cells encounter their antigen in the thymus which prevents thymic 
selection of FOXP3+ Tregs.  Therefore, all T cells in the periphery are antigen-specific 
(KJ-126+) but FOXP3- (Fig. 3.21 C).  In contrast, in DO11.10 TCR-transgenic mice 
expression of the model antigen OVA under the control of the rat insulin promoter (RIP) 
means OVA is expressed in the thymus and natural CD4+ FOXP3+ Tregs specific for OVA  
(KJ-126+) develop and can be found in the periphery (Fig. 3.21 B).  Maintenance of these 
double transgenic mice on a Rag2-/- background means that only OVA antigen-specific 
(KJ-126+) CD4+ FOXP3- conventional T cells and CD4+ FOXP3+ regulatory T cells 
develop (Fig. 3.21 D).   
 
Lymphocytes from DO11.10+ mOVA- Rag2-/- mice that were either wild type, Ctla-4-/- or 
CD28-/- were used to investigate the role of CTLA-4 and CD28 in the induction of FOXP3 in 
vitro.  Fig. 3.22 A shows a representative FACS plot of the FOXP3 expression induced in 
CD4+ KJ-126+ wild type DO11.10+ mOVA- Rag2-/- lymphocytes cultured for 3 days in the 
presence of TGF-β (44%).  Addition of recombinant IL-2 augmented FOXP3 induction 
(58.2%).  Negligible FOXP3 expression was seen following culture without TGF-β, plus or 
minus rIL-2.  The graph of Fig. 3.22 B shows a similar percentage of CD4+ KJ-126+ cells 
were induced to express FOXP3 by TGF-β in both wild type and Ctla-4-deficient mice.  
FOXP3 induction by TGF-β was lower in CD4+ KJ-126+ lymphocytes that lacked CD28.  
Addition of rIL-2 slightly augmented the mean percentage of FOXP3 induced in wild type 
CD4+ KJ-126+ but had no affect on the TGF-β induction of FOXP3 by lymphocytes lacking 
Ctla-4.  The percentage of FOXP3 expression induced in lymphocytes deficient in CD28 was 
substantially increased upon addition of rIL-2.  Analysis of the absolute numbers 
(Fig. 3.22 C) of FOXP3+ CD4+ KJ-126+ CD25+ induced indicated that in the absence of 
CD28 there was decreased FOXP3 induction compared to wild type, whereas the absence of 
Ctla-4 had no affect.  Addition of rIL-2 slightly increased the absolute number of 
CD4+ KJ-126+ CD25+ FOXP3+ of wild type lymphocytes and CD28-/- lymphocytes relative 
to TGF-β induction in the absence of rIL-2.  However, rIL-2 decreased the absolute number 
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Figure 3.22. Induction of CD4+ FOXP3+ cells in vitro using TGF-β.  Single cell 
suspensions of peripheral lymph nodes were cultured with 1µg/ml plate-bound anti-
CD3, plus or minus 3ng/ml TGFβ and 100 I.U. recombinant IL-2.  On day three, 
cells were harvested and surface stained with CD4, KJ, CD25 and intracellularly 
with FOXP3 for analysis by flow cytometry.  (A)  Representative FACS plots 
showing CD25 and FOXP3 expression of CD4+ KJ+ gated lymphocytes from 
DO11.10+ mOVA- Rag2-/- mice cultured (B)  Graph shows data of the percentage 
of CD4+ KJ+ that are CD25+ FOXP3+ following culture with anti-CD3 alone 
(black), plus rIL-2 (blue), plus TGFβ (red) or plus TGFβ and rIL-2 (purple) for 
≥three wild type DO11.10+ mOVA- Rag2-/- (squares), Ctla-4-/- DO11.10+ mOVA-
Rag2-/- (circles) or CD28-/- DO11.10+ mOVA- Rag2-/- mice (triangles).  (C)  
Graph shows data of the absolute number of CD4+ KJ+ CD25+ FOXP3+ following 
culture plus TGFβ (red) or TGFβ and rIL-2 (purple) for ≥three wild type DO11.10+ 
mOVA- Rag2-/- (squares), Ctla-4-/- DO11.10+ mOVA- Rag2-/- (circles) or CD28-/-




























































































































































































for lymphocytes deficient in Ctla-4.  Overall, the results obtained suggest that CTLA-4 is not 
required for FOXP3 induction by TGF-β, but neither does CTLA-4 normally function to 
restrict the TGF-β induction of FOXP3.  The data are consistent with a role of CD28 in the 
TGF-β induction of FOXP3 expression, which could be overcome by addition of exogenous 
rIL-2.  
 
Having examined the induction of FOXP3 in vitro, the next aim was to develop a system to 
examine this phenomenon in vivo.  It has been found that in vivo sub immunogenic, 
continuous exposure to antigen induces FOXP3 expression [107].  A protocol was established 
in which DO11.10+ mOVA- Rag2-/- mice were immunised with 50µg OVA by 
intra-peritoneal injection on day 1, day 2, day 3, day 6 and day 7.  On day 8 mice were 
harvested and expression of FOXP3 by peripheral CD4+ T cells was analysed by flow 
cytometry.  Fig. 3.23 A shows that OVA immunisation induced a population of 
CD4+ FOXP3+ T cells that was not present in mice that received control PBS immunisations.  
As with the previous in vitro TGF-β FOXP3 induction experiments, 
DO11.10+ mOVA Rag2-/- mice that were wild type, Ctla-4-/- or CD28-/- were used to assess 
the role of CTLA-4 and CD28 in in vivo antigen-mediated FOXP3 induction.  The graphs in 
Fig. 3.22 B suggest that CD28 was absolutely required for in vivo FOXP3 induction as the 
percentage and absolute number of CD4+ FOXP3+ cells obtained was negligible.  In the 
absence of Ctla-4 an augmented population of CD4+ FOXP3+ cells was induced in vivo in 
terms of both percentage composition and absolute number compared to that in wild type 
mice.  The data therefore suggest that CTLA-4 normally functions to restrict the induction of 
peripheral CD4+ FOXP3+ lymphocytes in vivo in response to antigen.  
 
To further explore the role of CD28 in FOXP3 expression, in vitro assays were carried out 
using lymphocytes isolated from CD28-deficient mice and agonistic antibodies to CD3 and 
CD28.  Fig. 3.24 shows that in both wild type and CD28-deficient CD4+ T cells the intensity 
of FOXP3 expression was increased upon TCR-stimulation with anti-CD3.  As predicted, 
anti-CD28 did not affect FOXP3 expression by CD28-/- CD4+ T cells.  Similarly, wild type 
CD4+ T cell FOXP3 expression was unaltered by anti-CD28-mediated co-stimulation.  
Overall, this data suggests that increased intensity of FOXP3 expression following 



















































































































Figure 3.23. In vivo antigen-driven induction of CD4+ FOXP3+ cells.  Wild type 
DO11.10+ mOVA- Rag2-/- (squares), Ctla-4-/- DO11.10+ mOVA- Rag2-/- (circles) 
or CD28-/- DO11.10+ mOVA- Rag2-/- mice (triangles) received 50µg OVA or PBS 
alone by intra-peritoneal injection on day 1, day 2, day 3, day 6 and day 7.  Mice 
were harvested on day 8.  Single cell suspensions of peripheral nodes were surface 
stained with CD4 and intracellularly with FOXP3 for analysis by flow cytometry.  
(A)  Representative FACS plots showing FOXP3 expression of CD4+ gated 
lymphocytes from DO11.10+ mOVA- Rag2-/- mice that received PBS (left) or OVA 
(right). Graphs show data of (B) the percentage of CD4+ that are FOXP3+ (C) the 
absolute number of CD4+ FOXP3+ following PBS (blue) or OVA (red) treatment 
for ≥three wild type DO11.10+ mOVA- Rag2-/- (squares), Ctla-4-/- DO11.10+ 
mOVA- Rag2-/- (circles) or CD28-/- DO11.10+ mOVA- Rag2-/- mice (triangles).  


















































Figure 3.24. CD28-dependency of intracellular FOXP3 expression by CD4+ 
FOXP3+ Tregs. Adult BALB/c wild type or CD28-/- single cell suspensions from 
peripheral lymph nodes were cultured overnight plus or minus 500ng/ml anti-CD3 
and 1µg/ml anti-CD28.  Three wells were pooled and surface stained with CD4 and 
intracellularly with FOXP3 for analysis by flow cytometry.  (A) Representative 
FACS plots of FOXP3 expression by gated CD4+ lymphocytes from wild type 
BALB/c (left) and CD28-/- (right) mice cultured plus or minus anti-CD3 and anti-
CD28.  (B)  Graph shows FOXP3 median fluorescence intensity of gated CD4+ 
FOXP3+ Tregs.  Representative graph from three independent experiments is shown.
3.2.6 Ctla-4-deficiency and Treg pathogenicity.     
Mice in which the Ctla-4 gene has been ablated die at around 3 weeks of age from a fatal 
lymphoproliferative syndrome with multi-organ lymphocytic infiltration [156, 157].  Yet, as 
described previously the CD4+ FOXP3+ population which constitutes the regulatory T cells 
was found to be augmented.  One potential solution to this paradox is that CD4+ FOXP3+ 
Tregs that lack CTLA-4 have a pathogenic functional role as opposed to being regulatory.   
 
To assess the inherent pathogenicity of the CD4+ FOXP3+ population in Ctla-4-deficient 
mice in vivo adoptive T cell transfers into Rag2-/- mice were carried out.  Adoptive transfer of 
Ctla-4-/- lymphocytes or mo-flow sorted Ctla-4-/- CD4+ CD25- transferred disease into 
Rag2-/- recipient mice in 3-4 weeks.  This was evident by severe weight loss and 
lymphadenopathy, as shown by increased absolute lymph node cell counts (Fig. 3.25 A).  In 
addition to weight loss, organ infiltration was studied by hematoxylin and eosin (H & E) 
histology staining of heart tissue to assess the pathogenicity of Ctla-4-deficient Tregs.  Others 
have shown that Ctla-4-/- mice with fatal lymphoproliferative syndrome have significant 
lymphocytic infiltration of many organs such as heart, lung and liver [157].  It was found that 
similar lymphocytic infiltration could be identified in the heart tissue of Rag2-/- recipient 
mice of Ctla-4-/- lymphocytes and Ctla-4-/- CD4+ CD25- Tconv (Fig. 3.25 B).  In 
comparison for Rag2-/- mice that received Ctla-4-/- CD4+ CD25hi Tregs, weight loss and 
lymphadenopathy was negligible.  Likewise, transfer of wild type CD4+ CD25- and 
CD4+ CD25+ caused no weight loss or lymphadenopathy (Fig. 3.25 A).  H & E staining of 
the heart tissue from recipients of Ctla-4-/- CD4+ CD25hi Tregs showed no lymphocytic 
infiltration (Fig. 3.25 B) and was indistinguishable from heart tissue from mice that had 
received wild type CD4+ CD25- Tconv or CD4+ CD25+ Tregs (Fig. 3.25 C).  These data 
suggest that Ctla-4-deficient Tregs are not themselves pathogenic.   
 
Assessing the pathogenicity of Ctla-4-deficient Tregs by adoptive transfer into Rag2-/- mice 
does not account for interaction of Tregs with other lymphocytes such as B cells and Tconv 
via, for example, the provision of co-stimulatory ligands or the secretion of cytokines.  For 
instance, regulatory T cells normally lack CD40L [52] which activated pathogenic effector 
T cells up regulate to co-stimulate antigen-presenting cells, such as B cells, though CD40 














































































































































Figure 3.25. Ctla-4-deficient Tregs are not inherently pathogenic.  1-2 x 106
lymphocytes or mo-flow sorted CD4+ CD25- or CD4+ CD25hi lymph node cells 
from 15-18 day old Ctla-4-/- mice were intra-venially injected into Rag2-/-
recipients.  Mice were harvested 3-4 weeks following transfer.  (A) Graphs show 
percentage weight loss (top) and lymph node cellularity (bottom) of recipient mice.  
Bars indicate mean values and standard deviations are shown for three-five mice.
(B) H&E staining of fomaldehyde fixed heart tissue from recipients of Ctla-4-/-
lymphocytes (top), Ctla-4-/- CD4+ CD25- (middle) or Ctla-4-/- CD4+ CD25hi 
(bottom). (C) H&E staining of fomaldehyde fixed heart tissue from recipients of 
BALB/c CD4+ CD25- (top) or BALB/c CD4+ CD25+ (bottom). 
is by permitting the expression of CD40L.  Consequently, CD40L expression by 
Ctla-4-deficient Tregs was analysed by flow cytometry.  It can be seen in Fig. 3.26 that wild 
type CD4+ FOXP3- Tconv expressed some CD40L and this was increased in Tconv from 
Ctla-4-/- mice.  Ctla-4-deficient CD4+ FOXP3+ Tregs however did not express CD40L, 
similar to wild type Tregs.    
 
It is also possible that Ctla-4 could normally function to restrict the capacity of Tregs to make 
pro-inflammatory cytokines.  Therefore, cytokines produced by Tregs isolated from Ctla-4 
knockout mice were investigated by quantitative polymerase chain reaction (qPCR) and 
intracellular cytokine staining analysis by flow cytometry.  As described previously, the cell 
surface marker CD27 was successfully used along with CD4 and CD25 to identify 
CD4+ FOXP3+ Tregs from the activated environment of the Ctla-4 knockout mouse when 
intracellular FOXP3 could not be used.  mRNA and cDNA was obtained from mo-flow sorted 
CD4+ CD25- Tconv and CD4+ CD25+ CD27hi Tregs from Ctla-4-/- and age-matched wild 
type BALB/c lymphocytes.  By qPCR, expression of mRNA transcripts for TGF-β, IL-17 and 
IL-21 by wild type and Ctla-4-/- Tconv and Tregs were determined (Fig. 3.27).  There was 
not much change in expression of TGF-β by either Tconv or Tregs from Ctla-4-deficient mice 
compared to those T cell populations from wild type mice.  On the other hand Tconv and 
particularly Tregs from Ctla-4-/- mice showed increased IL-17 expression compared to wild 
type, whereas the only population to show any IL-21 expression were the Tconv lacking 
Ctla-4.   
 
To extend the qPCR studies above, cytokine expression was detected in FOXP3- and 
FOXP3+ CD4+ T cell populations at the protein level by intracellular cytokine staining.  
Fig. 3.28 shows representative FACS plots for the detection of IL-2 (A), IFN-γ (B), TGF-β 
(C), IL-10 (D) and IL-17 (E) expressed by CD4+ FOXP3- Tconv and CD4+ FOXP3+ Treg 
populations in Ctla-4-/- mice and littermate controls.  Flow cytometry analysis of Tconv and 
Treg cytokine expression was carried out for a number of different mice.  The 
pro-inflammatory cytokines IL-2 (F) and IFN-γ (G) showed significantly increased 
expression by Ctla-4-/- Tconv, whereas neither Ctla-4-/- or Ctla-4+/- control Tregs showed 








Figure 3.26. CD40 ligand expression by Ctla-4-deficient Tregs.  15-18 day old 
wild type BALB/c (left) or Ctla-4-/- (right) single cell suspensions from peripheral 
lymph nodes were surface stained with CD4 and intracellularly with CD40L and 
FOXP3 for analysis by flow cytometry.  Representative FACS plots of 
iCD40Lexpression by CD4+ FOXP3- gated lymphocytes (top) and CD4+ FOXP3+ 












































































































Figure 3.27. Real time qPCR for cytokine expression by Ctla-4-/- CD4+ CD25-
Tconv and CD4+ CD25+ CD27hi Tregs.  15-18 day old wild type BALB/c or Ctla-
4-/- single cell suspensions of peripheral lymph nodes were surface stained with 
CD4, CD25 and CD27 for mo-flow cell sorting.  Tconv were isolated as CD4+ 
CD25- and Tregs were isolated as CD4+ CD25+ CD27hi.  mRNA and cDNA was 
obtained from snap-frozen cell pellets and real time TaqMan qPCR carried out for 
the presence of  TGF-β, IL-17 and IL-21 relative to β-actin.  Graphs show data for 
CD4+ CD25- Tconv (squares) and CD4+ CD25+ CD27hi Treg (circles) cDNA
samples obtained from ≥six different wild type (blue) or Ctla-4-/- (red) mice.  
Relative amount was calculated as the amount of target normalised to an endogenous 













































































































































































































Figure 3.28. Intracellular cytokine staining of Ctla-4-/- CD4+ FOXP3- Tconv 
and CD4+ FOXP3+ Tregs.  15-18 day old Ctla-4+/- or Ctla-4-/- single cell 
suspensions of peripheral lymph nodes were cultured for four hours with 50ng/ml 
PMA and 1.5µM ionomycin, and 1µl/ml BD GolgiStop for the last three hours, at 
37°C, 5% CO2.  Cells were then surface stained with CD4, and intracellularly with 
CD4, FOXP3, IL-2, IFN-γ, IL-17 for analysis by flow cytometry.  For detection of 
TGF-β single cell suspensions were cultured with 2 x 106 anti-CD3/anti-CD28 
Dynabeads per ml overnight at 37°C, 5% CO2 prior to surface staining with CD4, 
TGF-β and intracellular staining with FOXP3 for analysis by flow cytometry.  For 
detection of IL-10 single cell suspensions were cultured with 2 x 106 anti-CD3/anti-
CD28 Dynabeads per ml overnight at 37°C, 5% CO2 prior to staining with CD4, IL-
10 and FOXP3 using a MACS secretion assay kit.  Representative FACS plots for 
CD4+ gated Ctla-4+/- (left) or Ctla-4-/- (right) IL-2 (A), IFN-γ (B), TGF-β (C), IL-
10 (D) and IL-17 (E) expression.  Graphs show data for percentages of IL-2 (F), 
IFN-γ (G), TGF-β (H), IL-10 (I) and IL-17 (J) expression by CD4+ FOXP3- gated 
Tconv (squares) and CD4+ FOXP3+ gated Tregs (circles) from Ctla-4+/- (blue) or 
Ctla-4-/- (red) mice.  Lines indicate mean values. p values calculated by two-tailed, 
unpaired T-test for the means.     
production by Tregs from Ctla-4-deficient mice (G).  A greater proportion of Tregs expressed 
TGF-β than Tconv, which was augmented with the lack of Ctla-4 (H).  Both IL-10 (I) and 
IL-17 (J) production by Ctla-4+/- control Tconv and Tregs was negligible, and both Tconv 
and Tregs from Ctla-4-/- mice produced statistically significant increased amounts of these 
cytokines.   
 
To qualify the CD4+ CD25- Tconv and CD4+ CD25+ CD27hi Treg populations isolated by 
mo-flow sorting for qPCR analysis of mRNA expression it was decided to investigate the 
expression of mRNA transcripts for the TH1 and TH2 lineage transcription factors T-bet [15] 
and GATA3 [16], respectively.  Fig. 3.29 shows that mRNA transcripts for both T-bet and 
GATA3 were expressed by both the isolated Tconv and Treg populations.  Tconv and Tregs 
from Ctla-4-/- mice showed increased expression of T-bet and GATA3 mRNA compared to 
the respective T cell populations from age-matched wild type control mice.                                           
 
3.2.7 Role of CTLA-4 in T cell help for B cells. 
By both qPCR and flow cytometry, increased IL-21 production was observed by Tconv from 
Ctla-4-deficient mice.  IL-21 is a cytokine associated with T follicular helper (TFH) cells 
which are present within B cell follicles and involved in the initiation of the germinal centre 
reaction as part of the humoral immune response [256].  Early studies of Ctla-4 knockout 
mice identified substantially increased serum IgE levels [156] which is consistent with the 
immunoglobulin class switching that occurs during the germinal centre B cell response [257].  
The presence of germinal centres within the spleen of Ctla-4-deficient mice was therefore 
investigated by immunohistochemistry.  In the age-matched wild type control spleen of Fig. 
3.30 A CD4+ (blue) T zones and IgD+ (brown) B zones could be identified.  In the Ctla-4 
knockout spleen, similar CD4+ (blue) T zones and IgD+ (brown) B zones could be 
determined, but also within the B zones an IgD negative area could be identified 
(Fig. 3.30 B).  It is known that germinal centre B cells loose expression of IgD [258-261] and 
the antigen peanut agglutinin (PNA) is specifically expressed by germinal centre B cells 
[262].  Using serial sections, the IgD negative areas in the Ctla-4-/- spleen were found to be 
PNA+ (Fig. 3.30 B).  No positive staining for PNA was identified in the age-matched wild 
type control spleen (Fig. 3.30 A).  In conclusion, compared to an age-matched wild type 
control spleen, spontaneous germinal centres could be identified in spleens from  
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Figure 3.29. Real time qPCR for TH1 and TH2 transcription factor expression 
by mo-flow sorted CD4+ CD25- Tconv and CD4+ CD25+ CD27hi Tregs.  15-18 
day old wild type BALB/c or Ctla-4-/- single cell suspensions of peripheral lymph 
nodes were surface stained with CD4, CD25 and CD27 for mo-flow cell sorting.  
Tconv were isolated as CD4+ CD25- and Tregs were isolated as CD4+ CD25+ 
CD27hi.  mRNA and cDNA was obtained from snap-frozen cell pellets and real time 
TaqMan qPCR carried out for the presence of  T-bet (top) and GATA3 (bottom)
relative to β-actin.  Graphs show data for CD4+ CD25- Tconv (squares) and CD4+ 
CD25+ CD27hi Treg (circles) cDNA samples obtained from ≥six different wild type 
(blue) or Ctla-4-/- (red) mice. Relative amount was calculated as the amount of 




















































































Figure 3.30.  Germinal centre histology of Ctla-4-/- spleens. Acetone fixed, 6µm 
spleen sections from 15-18 day old wild type BALB/c (A) or Ctla-4-/- (B) were 
stained with IgD (brown) and CD4 (blue) (left) or PNA (blue) (right) for analysis by 
light microscopy (x10). T – T zone (CD4+), B – B zone (IgD+), GC – germinal 
centre (PNA+). 
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Ctla-4-deficient mice.  To gain further insight into the development of spontaneous germinal 
centres in Ctla-4-deficient mice and the role of CTLA-4, the spleens of BALB/c mice 
following a timecourse of anti-CTLA-4 blocking antibody (4F10) treatment were analysed by 
immunohistochemistry for IgD, CD4 and PNA.  In Fig. 3.31 B  IgD negative areas within the 
B zones were identified at day 3 which were not present at day 1.  These IgD negative areas 
within the B zones were increased in size and number at day 14 (Fig. 3.31 C).  Analysis of 
serial sections showed the IgD negative areas were PNA+.  The mean size of the PNA+ 
germinal centres in a number of mouse spleens throughout the timecourse of anti-CTLA-4 
blocking antibody treatment was scored under the microscope (Fig. 3.31 D).  Over time, 
anti-CTLA-4 blocking antibody treatment increased the mean germinal centre size towards 
that observed in Ctla-4-deficient mice. 
 
As shown in Fig. 3.03 D, B cells do not express CTLA-4.  Therefore, the spontaneous 
germinal centres observed in Ctla-4-deficient mice could be due to dysregulated TFH cell 
homeostasis.  It has been shown that Tregs can migrate to follicles and suppress germinal 
centre TFH cells [263], it could be that in the absence of CTLA-4 there is a loss of TFH cell 
regulation by Tregs and concurrent spontaneous germinal centre formation.  The distribution 
of FOXP3+ cells within the BALB/c and Ctla-4 knockout spleen was analysed by 
immunohistochemistry.  In Fig. 3.32 A FOXP3+ cells (blue) could be identified within the 
IgD+ (brown) B zone follicle.  Similarly, within the B zone follicle and germinal centre of 
Ctla-4-deficient spleens, FOXP3+ cells (blue) could be found (Fig. 3.32 B).  If there is 
dysregulation of TFH cells by Tregs in Ctla-4-deficient mice, the data suggest this was not 
due to altered Treg trafficking and localisation.   
 
To directly assess TFH cell homeostasis within the Ctla-4-deficient mouse, flow cytometry 
was used to quantify TFH cells.  Many markers associated with the TFH cell phenotype are 
also expressed by Tregs such as ICOS and OX40, therefore the TFH cell population has 
historically been challenging to identify.  PD-1 and CXCR5 currently seem the best markers 
used to distinguish TFH cells from other CD4+ T cell subtypes by flow cytometry [264].  
Therefore CD4, PD-1 and CXCR5 cell surface expression was combined with FOXP3- 
intracellular expression to analyse the TFH cell population within the peripheral lymphocytes 
of the Ctla-4 knockout mouse.  The representative FACS plots (Fig. 3.33 A) and graph in 
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Fig. 3.33 C indicated that the CD4+ FOXP3- CXCR5+ PD-1+ TFH cell population was 
statistically significantly augmented in the absence of CTLA-4.  As well as visual 
identification of germinal centres within Ctla-4 knockout spleens and identification of an 
augmented TFH cell population within the peripheral lymphocytes of Ctla-4-deficient mice, 
in the absence of CTLA-4, CD19+ splenocytes showed increased FAS expression by flow 
cytometry (Fig. 3.33 D).  The FAS receptor is known to be highly expressed by germinal 
centre B cells [265, 266].                                      
 
 
                                       
 
 
         
    
 



































































































Figure 3.31. Analysis of germinal centre development in BALB/c spleen 
following an anti-CTLA-4 blocking antibody timecourse.  Acetone fixed, 6µm 
spleen sections from 15-18 day old wild type BALB/c following treatment with 
500µg anti-CTLA-4 blocking antibody (4F10) twice weekly by intra-peritoneal 
injection were stained with IgD (brown) and CD4 (blue) (left) or PNA (blue) (right) 
for analysis by light microscopy (x20).  Representative pictures of mice harvested on 
day 1 (A), day 3 (B) and day 14 (C) of treatment. T – T zone (CD4+), B – B zone 
(IgD+), GC – germinal centre (PNA+).  (D)  Germinal centres were sized in µm2
using a graticule and determining the area of PNA+ staining within IgD+ B cell 
follicles.  Graph shows data from three wild type BALB/c mice (blue squares), wild 
type BALB/c mice day 1 after anti-CTLA-4 blocking antibody treatment, mice day 






















Figure 3.32.  Localisation of FOXP3+ cells in BALB/c and Ctla-4-/- spleen.  
Acetone fixed, 6µm spleen sections from 15-18 day old wild type BALB/c (left) or 
Ctla-4-/- (right) were stained with IgD (brown) and FOXP3 (blue) for analysis by 
light microscopy (x10 - A and x20 - B).  Arrows indicate FOXP3+ cells in B zone / 




















































Figure 3.33. Analysis of T follicular helper cells in Ctla-4-/- mice. Single cell 
suspensions from 15-18 day old Ctla-4+/- and Ctla-4-/- splenocytes were surface 
stained with CD4, PD-1, CXCR5 and intracellularly with FOXP3 for analysis by 
flow cytometry. (A)  Representative FACS plots show CXCR5 and PD-1 expression 
of CD4+ FOXP3- gated lymphocytes in Ctla-4+/- (left) and Ctla-4-/- (right) mice. 
(B)  Representative FACS plot shows control antibody staining of CD4+ FOXP3-
gated lymphocytes.  (C)  Graph shows data of the percentage of CD4+ FOXP3- that 
are CXCR5+ PD-1+ for three Ctla-4+/- (blue) and Ctla-4-/- (red) mice.  Lines 
indicates mean value.  (D) Single cell suspensions from 15-18 day old Ctla-4+/-
(left) and Ctla-4-/- (right) splenocytes were surface stained with CD19 and FAS for 
analysis by flow cytometry.  Representative FACS plots show FAS expression of 




Analysis of Ctla-4-gene ablated mice in this present study identified an augmented FOXP3+ 
population.  This is in agreement with an investigation which found a 30-40% increase in the 
frequency of CD4+ CD25+ regulatory T cells in the peripheral blood of healthy subjects 
homozygous for a single nucleotide Ctla-4 polymorphism [267].  This finding is also 
consistent with recent data from a study in which anti-CTLA blocking antibody was used as a 
cancer immunotherapy in combination with GM-CSF to induce effector T cells to mediate 
tumour regression.  However, it was found that rather than decrease the number of Tregs or 
impair their regulatory function, CTLA-4 blockade actually increased the number of 
CD4+ FOXP3+ Tregs at a lower dose than that required to expand the activated effector 
CD4+ T cells [268].  Kavanagh et al. suggested that CTLA-4 may inhibit Treg proliferation 
similar to its role on effector T cells.  This is corroborated by the data obtained in this current 
investigation which found that CTLA-4 signalling normally functions to control the size of 
the peripheral CD4+ FOXP3+ compartment by modulating proliferation.  Additionally, it has 
recently been reported by two other groups that CTLA-4 functions to negatively regulate Treg 
homeostasis and limit their frequency in vivo [269, 270].     
 
Regulatory T cells have previously been shown to proliferate in response to self-antigen 
in vivo [52].  Therefore, it could be that upon self-antigen encounter in the periphery after 
exiting the thymus, CTLA-4 normally functions to restrict the magnitude of the 
CD4+ FOXP3+ proliferative response.  Also, at the young age that Ctla-4-/- mice have to be 
studied, there may be lymphopenia-induced, homeostatic Treg proliferation.  Consistent with 
this, the studies presented here of naïve BALB/c mice upon maturation from a neonate 
(1 week old) into an adult (>6 weeks old) found by expression of the cell cycle marker Ki67 
that CD4+ FOXP3+ Treg proliferation decreased as the mice matured into adults.  
Additionally, high levels of the cytokine IL-2 have been found to overcome Treg anergy 
in vitro and stimulate their proliferation [57].  Increased IL-2 production by CD4+ FOXP3- 
conventional T cells was detected in Ctla-4-/- mice.  It could therefore be the higher levels of 
IL-2 present in the environmental milieu that causes the increased proliferation of 
CD4+ FOXP3+ cells in Ctla-4-/- mice.   
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An altered cytokine milieu could also account for the decreased proportion of conventional 
and regulatory T cells found to be undergoing cell death in Ctla-4-deficient mice compared to 
age-matched BALB/c controls.  The cytokine milieu of the Ctla-4-/- environment could 
promote cell growth and division and protect from cell death.  For example, T cell growth 
factors such as IL-2, IL-7 and IL-15 that share a common-gamma signalling chain in their cell 
surface receptors induce viability of activated T lymphocytes, whereas mutations in the 
common-gamma chain are associated with the X-linked severe combined immunodeficiency 
(SCID) phenotype [271, 272] that appears to be due to apoptosis of developing 
T lymphocytes lacking the necessary viability inducing signals [273].    
 
In addition to alterations in the proliferation and/or cell death of peripheral CD4+ FOXP3+ 
Tregs, the augmented FOXP3+ population observed in the Ctla-4-/- mouse could be the result 
of enhanced FOXP3 induction in CD4+ FOXP3- T cells.  Others have previously identified 
an essential role for CTLA-4 in the TGF-β induction of Foxp3 and suggested that a lack of 
peripheral, adaptive Tregs in Ctla-4-/- mice may contribute to the fatal lymphoproliferative 
syndrome of Ctla-4-deficient mice [123].  In the present study a role for CTLA-4 in the 
TGF-β induction of FOXP3 in vitro was not found as using TCR-transgenic mice a similar 
proportion of CD4+ CD25- T cells from Ctla-4-/- mice were induced to express FOXP3 as 
CD4+ CD25- T cells from wild type mice.  The differences observed may be because in this 
present study TCR-transgenic Rag2-/- mice were used to ensure that the starting population of 
CD4+ CD25- T cells was naïve and truly FOXP3-.  Also, in this current investigation the 
sensitive technique of flow cytometry was used to detect FOXP3 expression at the protein 
level as opposed to detection of Foxp3 mRNA by PCR.   
 
Additionally, the complimentary in vivo FOXP3 induction experiments carried out found no 
requirement for CTLA-4 in FOXP3 induction.  If anything, the data suggests that CTLA-4 
may normally function to restrict the induction of peripheral CD4+ FOXP3+ lymphocytes 
in vivo in response to antigen.  The augmented FOXP3 induction observed in Ctla-4-/- mice 
in vivo (Fig. 3.23) could be the result of enhanced proliferation of induced FOXP3+ T cells 
upon the loss of CTLA-4 rather than increased induction of FOXP3.  It would be interesting 
in future to investigate the involvement of proliferation in the augmented FOXP3 induction 
observed in Ctla-4-/- mice in vivo by the adoptive transfer of CFSE-labelled T cells prior to 
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antigen immunisation to induce FOXP3 expression.  Upon harvest of wild type and Ctla-4-/- 
mice, the proliferation of the induced FOXP3+ T cell population could be assessed by CFSE 
dilution.  
 
The role of the CD28 co-stimulatory receptor in FOXP3 induction was also investigated.  
Both TGF-β in vitro and antigen in vivo studies found a requirement for CD28 in FOXP3 
induction.  These studies using TCR-transgenic Rag2-/- mice to ensure a truly naïve FOXP3- 
starting population of T cells corroborate previous findings by others [121].  Although 
FOXP3 was not induced in CD28-deficient CD4+ CD25- T cells, addition of exogenous IL-2 
to the in vitro TGF-β experiments induced FOXP3 which suggests the requirement of CD28 
in FOXP3 induction is mediated by IL-2.  The requirement of the CD28 receptor in FOXP3 
induction indicates a role for the co-stimulatory ligands CD80 and CD86.  The requirement of 
CD80 and CD86 in FOXP3 induction could be investigated in future by antibody-mediated 
blockade of each of these ligands during in vitro TGF-β induction or antigen induction 
in vivo.  It would also be interesting to use antigen-presenting cells from 
CD80/CD86-deficient mice for in-vitro TGF-β induction, or generate TCR-transgenic Rag2-/- 
mice lacking CD80/86 for in vivo FOXP3 induction experiments. 
 
The in vitro and in vivo experiments carried out induced FOXP3 expression in peripheral 
CD4+ CD25- (FOXP3-) T cells; however it was not determined whether the cells generated 
were fully functional regulatory T cells.  It is difficult to isolate FOXP3 induced T cells as 
each protocol activates the conventional T cells to express CD25, therefore CD25 cannot be 
used as a cell surface marker to purify FOXP3+ T cells from activated FOXP3- T cells.  
Ideally, TCR-transgenic Rag2-/- FOXP3-GFP mice would be used to induce FOXP3+ T cells 
which could then be isolated on the basis of GFP expression and used in suppression assays to 
assess the functional activity of the FOXP3 induced T cells.  It is believed that natural and 
induced / adaptive FOXP3+ regulatory T cells may differ in suppressive function due to the 
stability of Foxp3 expression as determined by the methylation state of CpG motifs within the 
Treg-specific demethylated region (TSDR) (reviewed in [106]).  Recently, it has been 
reported that instability of Foxp3 expression can lead to the generation of pathogenic memory 
T cells in vivo and the development of autoimmune disease [274].  An in vivo 
microenvironment where it is believed induced / adaptive FOXP3+ Tregs may have a 
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functional role is the gut where immune tolerance to foreign food allergens and a 
non-inflammatory environment needs to be maintained.  Within the gut-associated lymphoid 
tissue (GALT) a functionally specialised, mucosal dendritic cell population has been found to 
be important in the TGF-β induction of FOXP3+ Tregs via a retinoic acid-dependent 
mechanism [116-118].  CTLA-4 has been found to play an essential role in the function of 
regulatory cells that control intestinal inflammation [154].  Therefore, it would be interesting 
to assess the role of CTLA-4 in FOXP3 induction in vivo using TCR-transgenic Rag2-/- mice 
in a more physiological setting such as oral tolerance by oral gavage administration of 
antigen.     
 
This investigation found that there was unaltered thymic selection of natural CD4+ FOXP3+ 
Tregs in Ctla-4-deficient mice.  This suggests that the augmented peripheral CD4+ FOXP3+ 
Treg population identified in Ctla-4-/- mice is not due to increased thymic selection of Tregs 
and their export to the periphery.  If CTLA-4 plays a functional role in the thymic 
development of Tregs, the data obtained here suggests that it is not in terms of restricting the 
proportion of CD4+ FOXP3+ Tregs that are selected.  It would be interesting to analyse 
recent thymic emigrants in Ctla-4-/- mice because the augmented peripheral CD4+ FOXP3+ 
population observed could be due to altered frequency of thymocyte export.  Recent thymic 
emigrants have been studied by others using intra-thymic injection of fluorescein, however 
none of the surface proteins investigated uniquely distinguished recent thymic emigrants from 
peripheral T cells or mature thymocytes [275].  Alternatively, T cell receptor excision circles 
can be used to identify recent thymic emigrants within the peripheral T cell pool [276].  The 
results of this current investigation differ to a recent report that found enhanced thymic 
selection of FOXP3+ regulatory T cells in Ctla-4-deficient mice protected from experimental 
autoimmune encephalomyelitis (EAE) [277].  However, in these studies Verhagen et al. used 
TCR-transgenic mice in which it is not truly understood how the thymic generation of 
conventional and regulatory T cell occurs.                  
 
The augmented FOXP3+ population observed in Ctla-4 knockout mice raises a paradox as 
these mice suffer a fatal lymphoproliferative disease; however the regulatory T cell 
population is increased.  It is possible that CD4+ FOXP3+ regulatory T cells lacking CTLA-4 
have a pathogenic functional role as opposed to being regulatory.  Assessment of the ability of 
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CD4+ CD25hi Tregs from Ctla-4 knockout mice to transfer disease by adoptive transfer into 
Rag2-/- recipients did not identify an inherent pathogenic function within the FOXP3+ 
population.  However, this experimental setup did not allow for the interaction of Tregs with 
other lymphocytes such as conventional T cells and B cells, for example via the secretion of 
cytokines.   
 
Analysis of the cytokines produced by CD4+ FOXP3+ regulatory T cells in Ctla-4-/- mice 
identified an altered cytokine profile compared to CD4+ FOXP3+ Tregs in Ctla-4+/- 
littermate controls.  This could modulate the homeostatic balance towards pathogenic effector 
T cells.  A small, but reproducible increase in production of the TH1 pro-inflammatory 
cytokine IFN-γ by Ctla-4-/- CD4+ FOXP3+ Tregs was observed.  Thus, rather than having a 
regulatory function, CD4+ FOXP3+ Tregs in Ctla-4-/- mice may contribute to the initiation 
and amplification of immune activation.  Additionally, increased production of TGF-β by 
CD4+ FOXP3+ Tregs in Ctla-4-/- mice was found.  As discussed above, T cells activated 
with TGF-β can be induced to become FOXP3+ regulatory T cell [114].  Therefore, the 
increased TGF-β observed could contribute to the augmented FOXP3+ population in Ctla-4-/- 
mice.  However, TGF-β has been found to be able to promote both regulatory and effector cell 
differentiation pathways depending on the other cytokines present in the local environment.  
Activation of T cells with TGF-β along with IL-6 or IL-21 results in the generation of TH17 
cells [278, 279].  TH17 cells are a relatively newly classified CD4+ T cell subset distinct from 
TH1, TH2 and Tregs that produce IL-17 and express the lineage transcription factor RORγt 
[17, 18, 280].  TH17 cells are believed to play a pro-inflammatory role in some autoimmune 
diseases as certain mouse models such as experimental autoimmune encephalomyelitis (EAE) 
and collagen-induced arthritis are mediated mostly by TH17 cells [281, 282].  An increase in 
IL-17 production by CD4+ FOXP3+ regulatory T cells was observed in Ctla-4 knockout 
mice.  Studies in mice initially found that TGF-β-induced CD4+ FOXP3+ Tregs were 
resistant to TH17 conversion by IL-6 [283].  However, more recently human Tregs have been 
found to differentiate into IL-17-producing cells with the addition of other cytokines such as 
IL-1β or IL-21 rather than IL-6 [284, 285].        
 
Expression of the TH1 and TH2 lineage transcription factors T-bet and GATA3 was detected 
in both wild type BALB/c and Ctla-4-/- CD4+ CD25- Tconv and CD4+ CD25+ CD27hi Treg 
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populations.  This could be due to contamination of the mo-flow sorted cell preparations from 
which mRNA was extracted and analysed by qPCR.  In future it would therefore be 
interesting to analyse expression of multiple transcription factors such as T-bet, GATA3 and 
RORγt in wild type and Ctla-4-/- CD4+ FOXP3- conventional T cells and CD4+ FOXP3+ 
regulatory T cells by flow cytometry.  Recently, evidence has started to accumulate that 
suggests differentiation of CD4+ T cells into effector lineages is more plastic than previously 
appreciated (reviewed in [286]).  For example, FOXP3+ Tregs have been shown to up 
regulate the TH1-specifying transcription factor T-bet during type 1 inflammation [287].           
 
Analysis of cytokines produced by CD4+ T cells in Ctla-4 knockout mice found an increase 
in IL-21 production.  IL-21 is the most recently described member of the common gamma 
chain signalling family of cytokines, which also includes IL-2, IL-4, IL-7, IL-9 and IL-15.  A 
broad range of actions have been implicated for IL-21 from the expansion of CD8+ T cells, 
apoptosis of NK cells to the differentiation of B cells [288].  In recent years, a fundamental 
role for IL-21 in the generation of T follicular helper (TFH) cells has been established [289, 
290].  Consistent with the substantially increased serum IgE levels identified in early studies 
of Ctla-4 knockout mice [156], which indicates immunoglobulin class switching has occurred 
during the germinal centre B cell response [257], and increased IL-21 production by 
CD4+ FOXP3- Tconv measured in this study, spontaneous germinal centres were identified in 
the spleens of Ctla-4-/- mice.  Few mouse strains have been described that develop 
spontaneous germinal centres, those that do typically develop an autoimmune, lupus-like 
disease or Type 1 diabetes [46].  Studies using sanroque mice, which exhibit a lupus-like 
phenotype, have identified excessive TFH cell numbers and aberrant germinal centre 
formation as a pathway to systemic autoimmunity [291].  In line with this, increased numbers 
of CD4+ FOXP3- CXCR5+ PD-1+ TFH cells were found in Ctla-4-/- mice.  A role for 
CTLA-4 in the regulation of T cell help for germinal centre B cells has previously been 
suggested by others [292].  Thus, the fatal lymphoproliferative syndrome of Ctla-4-deficient 
mice is likely to be pathologically manifested by an aberrant B cell response and autoantibody 
production. 
 
The augmented CD4+ FOXP3- CXCR5+ PD-1+ population and spontaneous germinal 
centres found in Ctla-4-/- mice suggests a role for CTLA-4 in the regulation of T cell help for 
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germinal centre B cells as discussed above.  However, it is not clear whether TFH cells 
express CTLA-4 themselves, which is required to maintain their homeostasis, or if in the 
absence of CTLA-4 there is a loss of TFH cell regulation by Tregs.  In this study it was found 
that in the absence of CTLA-4, FOXP3+ cells still traffic to and localise within the T zones 
and B zones in a similar manner to in wild type mice.  It would be interesting in future to 
analyse CTLA-4 expression by CD4+ FOXP3- CXCR5+ PD-1+ TFH cells.  A mouse model 
that may be suitable for this would be the DO11.10 x RIP-mOVA transgenic mouse model of 
autoimmune diabetes as our laboratory has previously found elevated levels of IL-21 [53] and 
























4.0 Role of CTLA-4 in the Suppressive Function of 
Regulatory T Cells 
 
4.1 Introduction 
Regulatory T cells actively control effector T cell populations to maintain peripheral 
tolerance.  It is now considered that loss of Treg function is a major factor in the development 
of autoimmune disease.  Due to the constitutive expression of the CTLA-4 receptor by Tregs 
[154, 155] and the fatal lymphoproliferative syndrome observed in Ctla-4-deficient mice 
[156, 157], a role for CTLA-4 as an effector molecule in Treg function has been suggested.  
Furthermore, polymorphisms in the Ctla-4 gene are linked with several autoimmune diseases 
such as type 1 diabetes, thyroiditis, systemic lupus erythematosus and rheumatoid arthritis 
(reviewed in [228, 229]).   
  
A role for CTLA-4 as an effector molecule in Treg suppressive function would be consistent 
with the ability of Ctla-4-expressing cells to exert dominant tolerance over Ctla-4-deficient 
cells in mixed bone marrow chimeras [220].  Early studies with anti-CTLA-4 blocking 
antibodies abrogated disease protection by Tregs [154, 155], although in these experiments 
effector T cells could have also been affected by the CTLA-4 blockade treatment.  
Additionally, antibody-mediated CTLA-4 modulation studies have yielded conflicting results 
where in some instances Treg suppression is abrogated [155, 231, 232], but in other 
investigations Tregs retain suppressive function [56, 293].  It has even been reported that 
different batches of monoclonal antibody preparations sometimes yielded opposite results 
[294].  In studies where the role of CTLA-4 was specifically assessed in the Treg population, 
generation of Ctla-4-deficient Tregs relied on the simultaneous abrogation of CD28 signalling 
by CD80/86 blockade or deficiency [231, 232].  It is not clear whether or not Tregs that 
develop in the absence of CD28 are functionally equivalent to wild type Tregs, therefore the 
results of these studies cannot be solely attributed to a lack of CTLA-4.   
 
To analyse the suppressive function of Ctla-4-deficient Tregs in a setting not complicated by 
lymphoproliferation or CD28 deficiency, a TCR-transgenic system was used to generate 
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antigen-specific Tregs lacking CTLA-4.  The functional activity of Ctla-4-deficient Tregs was 































4.2.1 In vivo evidence for a role of the CTLA-4 receptor in Treg suppressive function.    
Due to the fatal lymphoproliferative disease in mice where the Ctla-4 gene has been ablated 
[156, 157] and the finding that CTLA-4 is constitutively expressed by regulatory T cells [154, 
155], a role for CTLA-4 in Treg suppressive function has been hypothesised for some years.  
Over a decade ago, Bachmann et al. carried out elegant bone marrow chimera studies in 
which Rag2-/- mice reconstituted with a mixture of wild type C57BL/6 bone marrow and 
Ctla-4-/- bone marrow remained healthy and did not develop disease like Rag2-/- recipients of 
Ctla-4-/- bone marrow alone.  These experiments showed that the lethal lymphoproliferative 
syndrome of Ctla-4-deficient mice was not T cell autonomous and could be prevented by 
factors produced by normal T cells [220].   
 
To assess the cell-extrinsic role of CTLA-4 for ourselves using our Ctla-4-/- mice on the 
BALB/c genetic background, similar bone marrow chimera experiments to those performed 
by Bachmann et al. were carried out.  As illustrated in Fig. 4.01 A, T cell-depleted (THY1 
negative) bone marrow from wild type BALB/c, Ctla-4-/- or a 50:50 mix was adoptively 
transferred into irradiated Rag2-deficient recipient mice.  Five weeks following transfer, 
recipient mice of Ctla-4-deficient bone marrow had lost a substantial percentage of body 
weight, whereas mice that had received wild type BALB/c bone marrow or a 50:50 mix of 
wild type and Ctla-4-/- bone marrow had not lost weight and remained healthy (Fig. 4.01 B).  
In fact mixed bone marrow chimeras showed no signs of disease (such as weight loss of 
lymphoproliferation) at any time point examined.   
 
When the recipient mice were sacrificed five weeks after transfer, the reconstitution of the 
peripheral lymphocyte compartment was analysed by flow cytometry using congenic markers.  
It was possible to distinguish lymphocytes derived from wild type BALB/c or Ctla-4-/- bone 
marrow on the basis of their expression of variants of the THY1 protein (THY1.1 and 
THY1.2, respectively).  The CD4+ lymphocytes of recipient mice of wild type BALB/c bone 
marrow alone were THY1.1+, and THY1.1- in recipient mice of Ctla-4-/- bone marrow alone.  










































Figure 4.01. BALB/c : Ctla-4-/- Mixed Bone Marrow Chimeras.  (A) THY1 
depleted bone marrow from BALB/c or Ctla-4-/- mice was adoptively transferred 
into Rag2-/- mice (8 x 106 cells) either alone or as a 50:50 mix.  Mice were harvested 
5 weeks following transfer.  (B)  Graph shows the percentage weight loss of 
recipients mice for a representative experiment.  (C)  Histograms illustrate recipient 
peripheral lymph node composition of THY1.1+ BALB/c and THY1.1- Ctla-4-/-
CD4+ gated lymphocytes.  Data shown is representative of three independent 
adoptive transfer experiments.  Experiments carried out in collaboration with C. 
Wang.
THY1.1-:THY1.1+ composition (Fig. 4.01 C).  The THY1.1-:THY1.1+ ratio within the 
mixed bone marrow chimeras consistently ranged from 35:65 to 58:42.    
 
The experiments carried out above, like those by Bachmann et al. suggest that wild type cells 
are capable of controlling the fatal lymphoproliferative disease associated with the loss of 
Ctla-4 by gene ablation.  This could be due to the presence of functional Tregs that express 
CTLA-4 in the wild type lymphocyte compartment that develops.  To examine this in more 
detail and assess Treg control of Ctla-4-deficient lymphoproliferative disease, lymphocytes 
from Ctla-4-/- mice were adoptively transferred into wild type BALB/c mice which have a 
full complement of functional Tregs, or CD28 knockout mice which have a deficient 
peripheral Treg population [131, 238, 295] (illustrated in Fig. 4.02 A).  Four weeks following 
adoptive transfer, CD28 knockout recipients of Ctla-4-deficient lymphocytes had lost greater 
than 15% of their body weight, whereas wild type BALB/c recipients of Ctla-4-/- 
lymphocytes and control BALB/c and CD28-/- mice remained healthy with no weight loss 
(Fig. 4.02 B).  In conclusion, when Ctla-4-/- lymphocytes were transferred into BALB/c mice 
with a full complement of functional Tregs the recipient mice remained healthy, whereas 
CD28-/- recipients with a compromised peripheral Treg population succumbed to a severe 
wasting disease.                         
 
The adoptive transfer experiments carried out above imply that wild type CD4+ FOXP3+ 
Tregs can control the fatal lymphoproliferative syndrome of Ctla-4 knockout mice.  To 
directly test the capacity of Tregs to control disease induced by Ctla-4-deficiency, further 
in vivo adoptive transfer experiments were carried out.  As illustrated in Fig. 4.03 A, 
CD4+ CD25- lymphocytes from Ctla-4-deficient mice were adoptively transferred into Rag2-
deficient mice either alone or with the co-transfer of wild type BALB/c CD4+ CD25- 
conventional T cells or wild type CD4+ CD25+ regulatory T cells.  Two to three weeks 
following transfer, Rag2-/- recipients of Ctla-4-/- lymphocytes alone or plus wild type 
CD4+ CD25- Tconv had lost greater than 15% body weight (Fig. 4.03 B).  Importantly, 
Rag2-/- recipient mice of Ctla-4-/- lymphocytes plus wild type CD4+ CD25+ Tregs remained 




















































Figure 4.02.  Adoptive transfer of Ctla-4-/- lymphocytes causes disease in Treg-
deficient CD28-/- mice. (A) Single cell suspensions from peripheral lymph nodes of 
Ctla-4-/- mice were adoptively transferred into BALB/c or CD28-/- mice (50 x 106
cells).  Mice were harvested 4 weeks following transfer.  (B)  Graph shows the 
percentage weight loss of recipients mice for a representative experiment.  Data 
shown is representative of two independent adoptive transfer experiments.  



























































Figure 4.03.  Wild type BALB/c CD4+ CD25+ Tregs protect Rag2-/- from 
disease following adoptive transfer of Ctla-4-/- lymphocytes.  (A) MACS 
separated CD4+ CD25- from peripheral lymph nodes of Ctla-4-/- mice were 
adoptively transferred into Rag2-/- mice (0.6 x 106 cells) alone or plus 0.6 x 106
BALB/c MACS separated CD4+ CD25- Tconv or CD4+ CD25+ Tregs.  Mice were 
harvested 2-3 weeks following transfer.  (B)  Graph shows the percentage weight 
loss of recipients mice for a representative experiment.  (C)  Single cell suspensions 
from peripheral lymph nodes of recipient mice were surface stained with CD4, ICOS 
and intracellular with FOXP3 and Ki67 for analysis by flow cytometry.  
Representative FACS plots are shown for Ki67 (left) and ICOS (right) expression by 
CD4+ FOXP3- gated lymphocytes for recipients of Ctla-4-/- CD4+ CD25- alone 
(top), plus BALB/c CD4+ CD25- Tconv (middle) or plus BALB/c CD4+ CD25+ 
Tregs (bottom).  (D)  Histograms of Ki67 (left) and ICOS (right) expression by 
CD4+ FOXP3- gated lymphocytes for recipients of Ctla-4-/- CD4+ CD25- alone 
(black), plus BALB/c CD4+ CD25- Tconv (red) or plus BALB/c CD4+ CD25+ 
Tregs (blue). Data shown is representative of three independent adoptive transfer 
experiments.
When the recipient mice were sacrificed the phenotype of congenically marked (THY1.1-) 
Ctla-4-deficient CD4+ FOXP3- Tconv was analysed by flow cytometry.  Differences were 
only small, however, the CD4+ FOXP3- Tconv in Rag2-/- recipient mice of Ctla-4-deficient 
lymphocytes alone or co-transferred with wild type CD4+ CD25- Tconv expressed higher 
levels of the cell cycle marker Ki67 and secondary co-stimulatory molecule ICOS compared 
to the Ctla-4-deficient CD4+ FOXP3- Tconv in Rag2-/- recipients with co-transferred wild 
type CD4+ CD25+ Tregs (Fig. 4.03 C and D).  Overall, the fatal lymphoproliferative disease 
of Ctla-4-deficient mice was adoptively transferred by CD4+ CD25- lymphocytes to Rag2-/- 
hosts.  Co-transfer of wild type CD4+ CD25+ Tregs prevented disease transfer, whereas wild 
type CD4+ CD25- Tconv did not provide protection.              
 
4.2.2 Ctla-4-deficient Tregs exert suppressive function in vitro. 
The in vivo bone marrow chimera and adoptive transfer data in 4.2.1 suggests that Tregs in 
Ctla-4-deficient mice could be functionally defective, leading to the severe 
lymphoproliferative syndrome observed.  The function of regulatory T cells is frequently 
assessed in vitro by their ability to suppress the proliferation and / or cytokine production of 
conventional T cells.  To test the suppressive capacity of Tregs from Ctla-4-deficient mice, 
suppression of conventional T cell growth in vitro was analysed.     
 
It was decided that a conventional tritiated thymidine-based in vitro suppression assay could 
not be used due to the spontaneous proliferation of Ctla-4-deficient Tregs observed in chapter 
3. Instead a flow cytometry-based assay was developed in which congenically marked wild 
type CD4+ CD25- effector T cells (THY1.1+) were co-cultured with congenically marked 
wild type or Ctla-4-/- Tregs (THY1.2+) and flow cytometry was used to then quantify the 
absolute number of effector T cells after three days incubation.  When Tregs were isolated 
from Ctla-4 knockout mice using the cell surface markers CD4 and CD25 (CD4+ CD25+ 
lymphocytes), no suppression of effector T cell growth was observed (Fig. 4.04 A).  However, 
as discussed in chapter 3, the use of CD27 as an additional cell surface marker to CD25 
allows better discrimination of FOXP3+ cells in Ctla-4-/- mice.  When Tregs were isolated 
from Ctla-4 knockout mice using the additional cell surface marker CD27 


































































































































Figure 4.04.  In vitro analysis of Ctla-4-deficient Treg suppressive function.  
Single cell suspensions from BALB/c and Ctla-4-/- peripheral lymph nodes were mo 
flow sorted to obtain CD4+ CD25- Tconv and CD4+ CD25+ or CD4+ CD25+ 
CD27hi Tregs. 2.5 x 104 BALB/c Tconv were co-cultured in 96 well, U-bottomed 
plates with 15 x 104 MACS separated CD19+ from BALB/c spleen, 1µg/ml anti-
CD3 and BALB/c or Ctla-4-/- Tregs at the indicated ratio for 3 days at 37°C, 5% 
CO2. Cells were then surface stained with CD4, THY1.1 and intracellular for 
FOXP3 for analysis by flow cytometry.  (A) Graph shows percentage of maximum 
THY1.1+ CD4+ FOXP3- effector T cell number following culture with indicated 
ratios of BALB/c or Ctla-4-/- CD4+ CD25+. (B) Graph shows percentage of 
maximum THY1.1+ CD4+ FOXP3- effector T cell number following culture with 
indicated ratios of BALB/c or Ctla-4-/- CD4+ CD25+ CD27hi Tregs. (C) Graph 
shows absolute number of THY1.1+ CD4+ FOXP3- effector T cells following 
culture with indicated ratios of BALB/c or Ctla-4-/- CD4+ CD25+ CD27hi Tregs. 
(D) Graph shows percentage of maximum THY1.1+ CD4+ FOXP3- effector T cell 
number following culture with indicated ratios of BALB/c or Ctla-4-/- CD4+ CD25-
Tconv. Data shown is representative of four independent in vitro suppression assay 
experiments.
growth to a similar extent as wild type Tregs (Fig. 4.04 B and C).  The difference in Treg 
suppressive function observed when CD27 was additionally used to isolate Tregs is likely to 
reflect the presence of activated (CD25+) CD4+ FOXP3- conventional T cells when Tregs 
were isolated solely using CD25.   
 
As a control for the possibility that increasing the number of cells per well with the addition 
of Tregs suppresses effector T cell growth, CD4+ CD25- conventional T cells were added to 
the assay as mock ‘suppressor’ cells.  Fig. 4.04 D shows that no suppression of effector T cell 
growth was observed in the presence of wild type or Ctla-4 knockout CD4+ CD25- Tconv.  
Overall, Tregs from Ctla-4 knockout mice exert suppressive function in vitro when isolated as 
a pure population free from contaminating, activated conventional T cells [241].   
 
The in vitro analyses above suggest that Tregs lacking CTLA-4 can still function to suppress 
effector T cells.  If Tregs in Ctla-4-deficient mice are functional, another possible explanation 
for the severe lymphoproliferative syndrome in CTLA-4 knockout mice is that the 
conventional T cells are resistant to Treg-mediated suppression.  This hypothesis was tested 
by carrying out an in vitro suppression assays using CD4+ CD25- conventional T cells from 
Ctla-4-/- mice as effector cells (THY1.2+) and wild type BALB/c CD4+ CD25+ Tregs 
(THY1.1+).  It was found that CD4+ CD25- conventional T cells from Ctla-4-deficient mice 
were susceptible to suppression by wild type CD4+ CD25+ Tregs in vitro (Fig. 4.05).  This 
corroborates the in vivo data obtained in 4.2.1 where wild type Tregs protected Rag2-/- 
recipients from disease upon adoptive transfer of Ctla-4-/- lymphocytes.  Overall, the in vitro 
suppression assays carried out suggest that Tregs from Ctla-4-deficient mice have suppressive 
function and conventional T cells from Ctla-4-/- mice are capable of being suppressed.   
 
There is debate over whether regulatory T cells directly suppress effector T cells, or indirectly 
control them via modulation of antigen-presenting cells.  Therefore, another potential 
explanation for the severe lymphoproliferative disease observed in Ctla-4-deficient mice is 
that the antigen-presenting cells in these mice are unable to support Treg-mediated 
suppression.  To investigate Treg-mediated suppression of Tconv in the presence of antigen 
presenting cells from Ctla-4 knockout mice, in vitro suppression assays were carried out.  In  
 
 141
Figure 4.05. In vitro suppression of Ctla-4-deficient CD4+ CD25- Tconv. Single 
cell suspensions from BALB/c and Ctla-4-/- peripheral lymph nodes were MACS 
separated into CD4+ CD25- Tconv and CD4+ CD25+ Tregs. 2.5 x 104 BALB/c or 
Ctla-4-/- CD4+ CD25- Tconv were co-cultured in 96 well, U-bottomed plates with 
15 x 104 MACS separated CD19+ from BALB/c spleen, 1µg/ml anti-CD3 and 
BALB/c CD4+ CD25+ Tregs at the indicated ratio for 3 days at 37°C, 5% CO2.
Cells were then surface stained with CD4, THY1.1, THY1.2 and intracellular for 
FOXP3 for analysis by flow cytometry.  Graph shows percentage of maximum 
THY1.1+ or THY1.2+ CD4+ FOXP3- effector T cell number following culture with 
indicated ratio of BALB/c Tregs. Data shown is representative of two independent in 




























the presence of CD19+ B cells isolated from Ctla-4-/- mice, both wild type BALB/c and 
Ctla-4-deficient Tregs suppressed conventional T cell growth to the same extent (Fig. 4.06).  
In conclusion the data suggest that CD19+ B cells from Ctla-4 knockout mice support in vitro 
Treg-mediated suppression of conventional T cells.    
 
4.2.3 Effect of Ctla-4-deficiency on the generation and function of antigen-specific 
regulatory T cells.   
It was found in 4.2.2 above that Ctla-4-deficient Tregs exert suppressive function in vitro.  
In vitro suppression assays are a useful tool for determining Treg suppressive activity, 
however; where possible, further insight can be obtained using in vivo mouse models to assess 
the suppressive function of Tregs.  Our laboratory has developed an adoptive transfer mouse 
model of autoimmune diabetes.  CD4+ antigen-specific (KJ-126+) CD25- conventional 
T cells from DO11.10 TCR-transgenic Rag2-/- mice are adoptively transferred into Rag2-/- 
mice that express the membrane form of OVA (DO11.10 antigen) under the control of the rat 
insulin promoter, and hence in the pancreatic islets (RIP-mOVA).  This causes pancreatic islet 
destruction and development of overt diabetes with 100% penetrance.  Co-transfer of 
antigen-specific (KJ-126+) CD4+ CD25+ regulatory T cells suppresses the induction of 
diabetes [53, 296].  As discussed in 3.2.5, in DO11.10 Rag2-/- mice all peripheral T cells are 
antigen-specific (KJ-126+) and FOXP3-negative.  If DO11.10 Rag2-/- mice are crossed with 
RIP-mOVA Rag2-/- mice, antigen-specific (KJ-126+) CD4+ FOXP3+ Tregs are also 
generated in the thymus and exported to the periphery due to promiscuously expressed OVA 
antigen under the control of the autoimmune regulator AIRE in medullary thymic epithelial 
cells [32, 52, 242, 297] (Fig. 3.21).  Therefore, antigen-specific Tregs can be generated by 
crossing DO11.10 Rag2-/- mice with RIP-mOVA Rag2-/- mice.  By also introducing mice 
deficient in Ctla-4 to the breeding colonies, antigen-specific Ctla-4-/- Tregs can be obtained.   
 
To test whether Ctla-4-deficiency altered the frequency of antigen-specific FOXP3+ Tregs 
generated in the thymus, flow cytometry was used to analyse thymocyte FOXP3 expression.  
Fig. 4.07 A shows that no CD4+ KJ-126+ FOXP3+ Tregs were present in the thymus or 
periphery of wild type or Ctla-4-/- DO11.10 Rag2-/- mice.  In DO11.10 RIP-mOVA Rag2-/- 
mice CD4+ KJ-126+ FOXP3+ Tregs were present in the thymus and periphery.  Introduction  
 
 143
Figure 4.06.  CD19+ B cells from Ctla-4-/- mice support in vitro suppression.   
Single cell suspensions from BALB/c and Ctla-4-/- peripheral lymph nodes were 
mo-flow sorted into CD4+ CD25- Tconv and CD4+ CD25+ CD27hi Tregs. 2.5 x 
104 BALB/c Tconv were co-cultured in 96 well, U-bottomed plates with 15 x 104
MACS separated CD19+ from Ctla-4-/- spleen, 1µg/ml anti-CD3 and BALB/c or 
Ctla-4-/- Tregs at the indicated ratios for 3 days at 37°C, 5% CO2. Cells were then 
surface stained with CD4, THY1.1 and intracellular for FOXP3 for analysis by flow 
cytometry.  Graph shows percentage of maximum THY1.1+ or THY1.2+ CD4+ 
FOXP3- effector T cell number following culture with indicated ratio of BALB/c or 




























































































































Figure 4.07.  CD4+ FOXP3+ Tregs in TCR-Tg mice. Single cell suspensions from 
thymus and spleen were surface stained with CD4, KJ-126 and intracellular with 
FOXP3 for analysis by flow cytometry.  (A)  Representative FACS plots of antigen-
specific (KJ-126+) CD4SP FOXP3+ Tregs in thymus (left) and CD4+ FOXP3+ 
Tregs in spleen for wild type and Ctla-4-/- DO11.10 mOVA- and DO11.10 mOVA+ 
mice.  All FACS plots CD4+ KJ-126+ gated lymphocytes.  (B)  Graphs show 
absolute number of CD4+ CD8- KJ-126+ FOXP3+ (thymus) or CD4+ KJ-126+ 
FOXP3+ (spleen) in 6 week old mice of the indicated genotype.  Experiments 
carried out in collaboration with C. Wang.
of Ctla-4-deficiency did not alter the absolute number of CD4+ KJ-126+ FOXP3+ Tregs 
generated in the thymus or then present in the periphery (Fig. 4.07 B).         
 
Introducing the Ctla-4-deficiency to the TCR-transgenic mice did not alter the generation of 
antigen-specific regulatory T cells.  Therefore, the adoptive transfer mouse model of diabetes 
described above was used to investigate the suppressive function of antigen-specific 
Ctla-4-deficient Tregs generated in a setting not complicated by lymphoproliferation.  Wild 
type antigen-specific (KJ-126+) CD4+ CD25- conventional T cells were adoptively 
transferred into RIP-mOVA Rag2-/- mice either alone or co-transferred with wild type or 
Ctla-4-/- antigen-specific (KJ-126+) CD4+ CD25+ regulatory T cells (illustrated in 
Fig. 4.08 A).  Diabetes progression was monitored by regularly obtaining blood glucose 
readings.  The graph of Fig. 4.08 B shows that adoptive transfer of CD4+ CD25- Tconv alone 
(black lines) led to high blood glucose readings greater than 250mg/dL by 22 days post 
transfer.  Consistent blood glucose readings of greater than 250mg/dL are indicative of overt 
diabetes.  Co-transfer of wild type CD4+ CD25+ Tregs maintained low, normal blood glucose 
readings around 100-150mg/dL and suppressed the development of diabetes (blue lines of 
graph in Fig. 4.08 B).  On the other hand, co-transfer of Ctla-4-deficient CD4+ CD25+ Tregs 
(red lines of graph in Fig. 4.08 B) did not maintain low blood glucose readings, and the blood 
glucose increased to give readings of greater than 250mg/dL by 22 days post transfer in a 
similar manner to the adoptive transfer of CD4+ CD25- Tconv alone.  Overall, 
Ctla-4-deficient Tregs did not control the induction of diabetes in an adoptive transfer mouse 
model of diabetes as measured by blood glucose readings [241].   
 
One possible explanation for the difference in blood glucose readings observed upon co-
transfer of wild type or Ctla-4-/- Tregs is that the Ctla-4-deficient Tregs may not have 
survived as well as wild type Tregs after transfer or trafficked appropriately to the antigen-
expressing tissue (pancreas) and draining lymph node.  To investigate this hypothesis, when 
the mice were sacrificed, the presence of CD4+ FOXP3+ Tregs in the pancreas and draining 
pancreatic lymph node was analysed by flow cytometry.  In mice that received Ctla-4-/- 
Tregs, CD4+ FOXP3+ Tregs could be detected in the pancreas and pancreatic lymph node as 
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Figure 4.08. Antigen-specific Tregs deficient in Ctla-4 lack regulatory function 
in vivo. (A) Single cell suspensions from peripheral lymph nodes of wild type and 
Ctla-4-/- DO11.10 mOVA+ Rag2-/- mice were mo-flow sorted into CD4+ CD25-
Tconv and CD4+ CD25+ Tregs.  WT CD4+ CD25- were adoptively transferred into 
RIP-mOVA Rag2-/- mice (0.2 x 106 cells) alone or plus 0.2 x 106 WT or Ctla-4-/-
CD4+ CD25+.  (B)  Blood glucose was monitored throughout.  Mice were harvested 
3 weeks following transfer when recipients of WT CD4+ CD25- alone or plus Ctla-
4-/- CD4+ CD25+ gave blood gluocose readings of 600mg/dL according to home 
office regulations.   (C)  Single cell suspension from pancreas (top) and pancreatic 
lymph node (bottom) of recipient mice were surface stained with CD4 and 
intracellular with FOXP3 for analysis by flow cytometry.  Representative FACS 
plots are shown for recipients of WT (left) and Ctla-4-/- (right) CD4+ CD25+ Tregs.  
Experiments carried out in collaboration with C. Wang.
observed in the survival and trafficking to the antigen-expressing tissue or draining lymph 
node by wild type and Ctla-4-/- Tregs following adoptive transfer [241].  
 
4.2.4 Induction of anergy in CD4+ CD25- conventional T cells following co-culture with 
Ctla-4-deficient Tregs. 
The in vivo data obtained in 4.2.3 suggests that CTLA-4 is required by regulatory T cells in 
the suppression of pancreatic islet autoimmunity.  Although, in 4.2.2 Ctla-4-deficient Tregs 
were found to exert suppressive function in vitro.  This raises the possibility that there may be 
redundancy in the manner in which regulatory T cells suppress conventional T cells.  Maybe 
Ctla-4-/- Tregs use a different mechanism to compensate for the lack of CTLA-4.  Many 
mechanisms have been proposed for how the CTLA-4 receptor functions in conventional 
T cells.  The CTLA-4 receptor binds the same ligands CD80 and CD86 as the CD28 
co-stimulatory receptor.  Many hypotheses for the effector function of CTLA-4 on Tregs 
involve the prevention of ligand binding to CD28 thereby interrupting CD28-mediated   
co-stimulation.  This could act as a mechanism of conventional T cell regulation as upon 
encounter with antigen via the TCR a second co-stimulatory signal through the CD28 receptor 
is thought to be required for full T cell activation [36, 298, 299].  Furthermore, T cell 
stimulation via TCR binding of antigen in the absence of the CD28 co-stimulatory signal has 
been reported to induce an anergic state of unresponsiveness in the conventional T cell [35-
38].     
 
To assess the hypothesis that the CTLA-4 receptor functions on Tregs by preventing 
CD28-mediated co-stimulation of conventional T cells thereby inducing a state of anergy; 
congenically marked (THY1.1+) CD4+ CD25- Tconv were co-cultured with wild type or 
Ctla-4-deficient Tregs in the presence of TCR-stimulation provided by soluble anti-CD3 and 
CD80/CD86-expressing CD19+ B cells, then re-isolated using the congenic marker and 
proliferation measured by tritiated thymidine incorporation in response to re-stimulation with 
irradiated splenocytes and soluble anti-CD3 plus or minus recombinant IL-2 (Fig. 4.09 A).  
With reference to Fig. 4.09 C, re-stimulation of Tconv, previously cultured without any 
Tregs, with anti-CD3 and antigen presenting cells induced proliferation (top graph, second bar 
from left) which was augmented with the addition of IL-2.  Whereas, re-stimulation of Tconv, 
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Figure 4.09. CD4+ CD25- Tconv co-cultured with Ctla-4-/- CD4+ CD25+ 
CD27hi Tregs are anergic upon re-stimulation.  Single cell suspensions from 
THY1.1+ BALB/c peripheral lymph nodes were MACS separated to obtain CD4+ 
CD25- Tconv.  Single cell suspensions from THY1.2+ BALB/c and THY1.2+ Ctla-
4-/- peripheral lymph nodes were mo-flow sorted to obtain CD4+ CD25+ CD27hi 
Tregs. (A) 2.5 x 104 THY1.1+ BALB/c Tconv were co-cultured in 96 well, U-
bottomed plates with 15 x 104 MACS separated CD19+ from BALB/c spleen, 
1µg/ml anti-CD3 alone or plus THY1.2+ BALB/c or THY1.2+ Ctla-4-/- Tregs at a 
1:1 ratio for 3 days. THY1.1+ CD4+ CD25- Tconv were then re-isolated by MACS 
separation and 2.5 x104 cells cultured in 96 well, U-bottomed plates with 1 x 105
irradiated BALB/c splenocytes plus or minus 1µg/ml anti-CD3 and 100I.U. rIL-2 for 
3 days.  Tritiated thymidine was added for the last 6hours of culture. (B) Co-
cultured cells were surface stained with CD4 and THY1.1 for analysis by flow 
cytometry.  Histograms show CD4+ THY1.1 purity before (black line) and after 
(coloured line) MACS re-isolation.  (C) Graphs show tritiated thymidine 
incorporation of THY1.1+ CD4+ CD25- Tconv that were previously cultured alone 
(top), with WT Tregs (middle) or with Ctla-4-/- Tregs (bottom).  (D) Graph to show 
tritiated thymidine incorporation of THY1.1+ CD4+ CD25- Tconv re-stimulated 
with irradiated splenocytes and anti-CD3.  (E) Graph shows tritiated thymidine 
incorporation by irradiated splenocytes (APCs) plus or minus anti-CD3 and IL-2.  
Data shown is representative of two independent in vitro assay experiments.
induce proliferation (middle graph, second bar from left).  This putative anergic state was 
overcome by the addition of IL-2 as seen by the proliferation induced.  Similarly, 
re-stimulation of Tconv, previously cultured with Ctla-4-/- Tregs, with anti-CD3 and 
antigen-presenting cells did not induce proliferation (bottom graph, second bar from left) and 
IL-2 overcame the anergy by induction of proliferation (summarised in Fig. 4.09 D).  Culture 
of the re-isolated Tconv alone or re-stimulation with anti-CD3 or antigen-presenting cells 
alone did not induce proliferation in any of the Tconv populations.  This suggests that 
reasonably pure Tconv populations were re-isolated after the initial co-culture as also 
indicated by flow cytometric analysis for the THY1.1 congenic marker following Tconv 
re-isolation (Fig. 4.09 B).  Under all re-stimulation conditions, addition of exogenous IL-2 
induced a similar amount of proliferation in all the Tconv populations.  Additionally, 
Fig. 4.09 E shows that the contribution of the irradiated splenocytes to the tritiated thymidine 
cell counts was minimal plus or minus anti-CD3 and IL-2.               
 
4.2.5 Modulation of CD80/CD86 expression on antigen-presenting cells by CTLA-4 on 
Tregs. 
The in vivo suppression of diabetes experiment in 4.2.3 revealed a clear role of CTLA-4 on 
regulatory T cells for suppression, at least in this disease setting.  Even if there is redundancy 
in the Treg mode of action in vitro, the requirement of CTLA-4 by Tregs for suppression of 
pancreatic islet autoimmunity in vivo suggests that CTLA-4 nonetheless represents a key 
effector molecule in Treg suppressive function.  The main mechanism that has been proposed 
as a cell-extrinsic effector function of CTLA-4 on regulatory T cells is the induction of 
indoleamine 2,3-dioxygenase (IDO) in dendritic cells (reviewed in [226]).  However, not 
everyone agrees because functional evidence of the IDO pathway remains to be identified 
[300].  Colleagues within our institution (Dr. O. Qureshi and Dr. D. Sansom) have found 
evidence that CTLA-4 can remove its ligands from antigen-presenting cells in a 
trogocytosis-like manner.  This could represent a mechanism of suppression by rendering 
APCs deficient in the co-stimulatory ligands needed to drive full T cell activation. 
 
To investigate trogocytosis as a potential mechanism for CTLA-4 function, modulation of 
ligand (CD80 and CD86) expression on dendritic cell and B cell antigen-presenting cells by 
CTLA-4 on Tregs was explored.  To assess modulation of dendritic cell CD80/CD86 
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expression by CTLA-4 on Tregs, CD11c+ dendritic cells were co-cultured with Tconv and/or 
Tregs plus or minus anti-CTLA-4 blocking antibody.  CD86 expression by the CD11c+ 
dendritic cells was then analysed by flow cytometry.  The representative histograms and 
graphs in Fig. 4.10 show that the presence of Tregs in the co-culture down regulated CD86 
expression by CD11c+ dendritic cells, and addition of anti-CTLA-4 blocking antibody 
abrogated this decrease in CD11c+ dendritic cell CD86 expression.  By flow cytometry, 
expression of MHC class II by the CD11c+ dendritic cells was unaltered in all co-culture 
conditions.  In conclusion, Tregs specifically down regulated CD86 expression by CD11c+ 
dendritic cells in a CTLA-4-dependent manner.   
 
To investigate modulation of CD80/CD86 expression on antigen-presenting cells by CTLA-4 
on Tregs in vivo, confocal microscopy was used to analyse CD86 expression by CD11c+ 
dendritic cells in the spleen of Ctla-4 knockout mice.  Fig. 4.11 A clearly shows that the 
intensity of CD86 expression in the spleen of Ctla-4-/- mice was higher than that in Ctla-4+/- 
littermate control spleens.  From a number of fields of view of three Ctla-4-/- spleens and 
three Ctla-4+/- littermate control spleens, the median fluorescence intensity of CD86 
expression by CD11c+ cells was quantified.  It was found that the level of CD86 expression 
by CD11c+ cells in the spleens of Ctla-4-deficient mice was higher than that in Ctla-4+/- 
littermate controls spleens (Fig. 4.11 B).   
 
To further analyse CD80/CD86 expression by antigen-presenting cells in Ctla-4-deficient 
mice flow cytometry was used.  The representative histograms show that on both CD19+ B 
cells and CD3- CD11c+ MHC II+ dendritic cells the intensity of CD80 and CD86 expression 
was increased in Ctla-4-/- mice compared to Ctla-4+/- littermate controls (Fig. 4.12 A).  
Quantification of CD80 and CD86 median fluorescent intensity on CD19+ B cells (Fig. 4.12 
B) and CD3- CD11c+ MHC II+ dendritic cells (Fig. 4.12 C) in a number of different mice 
found expression of both ligands was significantly increased in Ctla-4-/- mice compared to 
Ctla-4+/- littermate controls. 
                  
 




Figure 4.10. CTLA-4-dependent down-regulation of CD11c+ DC CD86 by 
Tregs.  4 x 104 MACS separated BALB/c splenic CD11c+ were cultured for 48hours 
with 8 x 104 CD4+ CD25- Tconv, CD4+ CD25+ Tregs or both plus or minus 
50µg/ml anti-CTLA-4 blocking antibody (4F10).  Cells were surface stained with 
CD11c, CD86 and MHC Class II for analysis by flow cytometry.  (A)  
Representative histograms of CD86 (left) and MHC II (right) expression by CD11c+ 
gated cells.  Black line = isotype control, Blue line = Tconv plus Tregs and red line = 
Tconv alone.  (B)  Graphs of CD86 (left) and MHC II (right) median fluorescence 
intensity on CD11c+ gated cells. Data shown is representative of three independent 
in vitro assay experiments.
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Figure 4.11.  Comparison of CD86 expression by CD11c+ DCs in Ctla-4+/- and 
Ctla-4-/- spleen. Acetone fixed, 6µm spleen sections from 15-18 day old littermate 
Ctla-4+/- controls or Ctla-4-/- were stained with FOXP3 (red), CD11c  (blue) and 
CD86 (green) for analysis by confocal microscopy (x63).  (A) Representative images 
of Ctla-4+/- (left) and Ctla-4-/- (right) spleen. (B) Graph shows CD86 median 
fluorescence intensity of CD11c+ cells in Ctla-4+/- and Ctla-4-/- spleen. Each circle 
represents a different CD11c+ cell and lines indicate median.  Data shown is 
representative of six fields of view from three tissue sections of three Ctla-4+/-




















































































































































Figure 4.12.  Analysis of CD80 and CD86 expression by CD19+ B Cells and 
CD3- CD11c+ MHC II+ DCs in Ctla-4+/- and Ctla-4-/- spleen.  Single cell 
suspensions from Ctla-4+/- and Ctla-4-/- spleens were surface stained with CD3, 
CD19, CD11c, MHC Class II, CD80 and CD86 for analysis by flow cytometry. (A)  
Representative histograms show CD80 (left) and CD86 (right) expression by CD19+ 
B cells (top) and CD3- CD11c+ MHC II+ DCs (bottom) from Ctla-4+/- (blue) and 
Ctla-4-/- (red) mice.  Isotype controls shown in black.  Graphs show pooled data for 
CD80 and CD86 expression by CD19+ B cells (B) and CD3- CD11c+ MHC II+ DCs




Using Ctla-4-/- mice on the BALB/c genetic background, mixed bone marrow chimera 
experiments confirmed the cell-extrinsic protective role of CTLA-4 previously demonstrated 
by Bachmann et al. using Ctla-4-/- mice on the C57BL/6 genetic background [220].  Others 
have also previously found that radiation chimeras reconstituted with a mixture of Ctla-4+/+ 
and Ctla-4-/- bone marrow retained a normal phenotype when circumventing the experimental 
limitations associated with the fatal lymphoproliferative disease of Ctla-4 knockout mice in 
order to study long term T cell immunity in the absence of CTLA-4 [221].  In this present 
study, two different in vivo adoptive transfer approaches found that CTLA-4-expressing, wild 
type CD4+ FOXP3+ regulatory T cells could control the lethal lymphoproliferative disease 
associated with Ctla-4-deficiency.  These findings extend previous work carried out by Tivol 
and Gorski in which the adoptive transfer of Ctla-4-deficient splenocytes into Rag2-deficient 
mice resulted in fatal inflammation and tissue destruction similar to that seen in Ctla-
4-deficient mice, whereas the co-transfer of an equivalent number of splenocytes from wild 
type animals allowed the recipient mice to survive indefinitely [301].   
 
Overall, this suggests that the role of CTLA-4 in the maintenance of peripheral tolerance is 
more complex than the provision of an inhibitory signal into self-reactive CD4+ FOXP3- 
conventional T cells.  Rather, the evidence indicates that CTLA-4 functions on CD4+ 
FOXP3+ regulatory T cells in the maintenance of peripheral tolerance.  This is consistent with 
the recent demonstration by Friedline et al. using mixed stem cell chimeras and T cell transfer 
systems, that CTLA-4 was essential for Treg dominant control of a large pool of self-reactive 
T cells in vivo [302].  A role for CTLA-4 in Treg suppressive function would be consistent 
with the observation that CTLA-4 and FOXP3 need to be expressed on the same cell to 
provide optimal protection from the lethal lymphoproliferative disease associated with 
deficiency of either pathway [227].   
 
It was found that Tregs from Ctla-4 knockout mice exert suppressive function in vitro when 
isolated as a pure population free from contaminating, activated conventional T cells.  
Alternatively, within the Ctla-4-deficient mice, the self-reactive CD4+ FOXP3- conventional 
T cells could be resistant to suppression.  Our laboratory has previously found that in a mouse 
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model of spontaneous autoimmune diabetes, over time the ability of Tregs to control 
autoimmunity is overcome by the acquisition of resistance to suppression within the 
auto-reactive, conventional T cell population [53].  Similar findings have been reported by 
others using non-obese diabetic (NOD) mice [303, 304].  Our laboratory found that resistance 
to Treg-mediated suppression was associated with the induction of IL-21 [53], furthermore, in 
chapter 3 of this present study, an increase in IL-21 mRNA was observed in conventional 
T cells from Ctla-4-deficient mice compared to wild type controls.  However, it was also 
found that CD4+ CD25- conventional T cells from Ctla-4-deficient mice were susceptible to 
suppression by wild type CD4+ CD25+ Tregs in vitro that is consistent with the in vivo data 
obtained in which wild type Tregs protected Rag2-/- recipients from disease upon co-transfer 
with Ctla-4-/- lymphocytes.      
 
The function of antigen-specific, Ctla-4-deficient regulatory T cells was assessed in vivo 
using an adoptive transfer mouse model of autoimmune diabetes.  The generation of 
TCR-transgenic regulatory T cells lacking CTLA-4 allowed the role of this pathway in Treg 
suppressive function to be tested for the first time in a setting uncomplicated by 
lymphoproliferation or interrupted CD28-signalling.  Ctla-4-deficient Tregs did not control 
the induction of diabetes in this adoptive transfer mouse model of diabetes as measured by 
blood glucose readings.  It is likely that the requirement for CTLA-4 in Treg function varies 
depending on the disease setting because others have previously shown that Ctla-4-deficient 
Tregs were capable of preventing colitis induced by the transfer of CD4+ CD45RBhi cells 
into Rag-deficient recipients [232].  Interestingly, suppression of colitis by Ctla-4-/- Tregs, 
but not wild type Tregs, in this setting was highly dependent on IL-10.  This suggests that 
pathological responses that can be controlled by IL-10 may not require expression of CTLA-4 
by regulatory T cells.  Consistent with this hypothesis, it has been shown that mice lacking 
IL-10 specifically in Tregs develop colitis but do not exhibit lymphoproliferation or systemic 
autoimmunity [305].  This implicates IL-10 as an important effector molecule for Treg 
function within the colon, but suggests that other effector mechanisms such as CTLA-4 could 
be essential for Treg function at other tissue sites.  Consistent with this, knockdown of 
CTLA-4 by RNA interference triggers focused autoimmunity of the pancreas [306].   
 
 161
Consistent with a role for CTLA-4 in the negative regulation of the CD4+ T cell 
compartment, indicated by the lethal lymphoproliferative disease of Ctla-4-deficient mice, a 
requirement for CTLA-4 in Treg suppressive function in vivo was identified using an adoptive 
transfer mouse model of autoimmune diabetes.  In line with this, Wing et al. recently 
generated Ctla-4 conditional knockout mice in which Ctla-4 was specifically deleted in 
CD4+ FOXP3+ T cells by crossing mice expressing Cre under the control of the Foxp3 
promoter with mice expressing a floxed Ctla-4 gene.  These Ctla-4 conditional knockout mice 
succumbed to a similar fatal lymphoproliferative syndrome as that seen in Ctla-4-deficient 
mice, furthermore Treg-specific Ctla-4 deficiency was found to impair the suppressive 
function of Tregs in vitro and in vivo [307].  Although it has been hypothesised for some 
years that CTLA-4 has a role in regulatory T cell suppressive function, the mechanism(s) of 
action are not well defined and remain a subject of debate.   
 
There is also debate over whether Tregs function to suppress by direct contact with effector 
T cells, or via interaction with antigen-presenting cells.  Two-photon laser-scanning 
microscopy studies have shown in situ that Tregs directly interact with antigen-presenting 
cells rather than effector T cells in order to control T cell priming by dendritic cells [150].  
This could be mediated by the constitutively expressed CTLA-4 in Tregs as its ligands CD80 
and CD86 are expressed by antigen-presenting cells.  However, the control of Treg 
aggregation around dendritic cells has been found to critically depend on LFA-1 rather than 
CTLA-4 [308].  On the other hand, preferential affinity of CD80 and CD86 ligand binding of 
CTLA-4 compared with CD28 [158] has led to a ligand competition model of CTLA-4 
function on Tregs.  Tregs with constitutive expression of CTLA-4 could preferentially bind 
CD80 and CD86 ligands on antigen-presenting cells, thereby depriving effector T cells of 
CD28 co-stimulatory signals [185].  Furthermore, direct contact between Tregs and APCs has 
been shown to induce the down-modulation of co-stimulatory CD80 and CD86 molecules 
[159] which was then later found to be CTLA-4-dependent [160].  It has also been proposed 
that CTLA-4 on Tregs can alter APC function by inducing the production of the enzyme 
indoleamine 2,3-dioxygenase (IDO) through CD80/CD86 back-signalling [161, 162].  It has 
been suggested that as the enzyme IDO breaks down tryptophan, which is an essential amino 
acid for T cell proliferation, induction of active IDO would be dominantly 
immunosuppressive [163].  In addition to these Treg-extrinsic mechanisms of CTLA-4 
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function, a Treg-intrinsic role of CTLA-4 has recently been reported.  Similar to the indicated 
role of CTLA-4 ligation dampening signalling pathways downstream of the TCR in 
conventional T cells [309], CTLA-4 was found to play an analogous role in altering Treg 
signalling responses [310].    
 
Ligand competition and down-modulation of co-stimulatory molecules as hypotheses for the 
effector function of CTLA-4 on Tregs both involve the prevention of CD80/CD86 ligand 
binding to CD28 thereby interrupting CD28-mediated co-stimulation.  This could act as a 
mechanism of conventional T cell regulation as upon encounter with antigen via the TCR a 
second co-stimulatory signal through the CD28 receptor is thought to be required for full 
T cell activation [36, 298, 299].  Furthermore, T cell stimulation via TCR binding of antigen 
in the absence of the CD28 co-stimulatory signal has been reported to induce an anergic state 
of unresponsiveness in the conventional T cell [35-38].  In this present study, in vitro assays 
found that effector T cells were anergic upon re-stimulation following co-culture with both 
wild type Tregs and Ctla-4-deficient Tregs.  This experimental setup suggests that induction 
of an anergic state of unresponsiveness in conventional T cells following co-culture with 
regulatory T cells is not dependent upon CTLA-4 expression by the Treg population.  Anergy 
is assessed as the inability to proliferate upon re-stimulation with TCR-stimulation and CD28 
co-stimulation which is overcome with the addition of IL-2.  This is difficult to analyse 
specifically as proliferation of the same T cells cannot be measured before and after addition 
of IL-2, therefore the IL-2 could be keeping cells alive rather than overcoming anergy in 
response to TCR-stimulation and CD28 co-stimulation.  It has been reported by others that the 
induction of T cell anergy in vivo requires engagement of CTLA-4 on effector T cells to 
induce an abortive response [311].               
 
Down-modulation of CD80/CD86 co-stimulatory molecules on APCs as an effector 
mechanism of Tregs was first hypothesised nearly ten years ago.  Cederbom et al. 
demonstrated that in the presence of stimuli that would normally increase the expression of 
co-stimulatory molecules by dendritic cells, CD4+CD25+ T cells down-regulated the 
expression of CD80 and CD86 on dendritic cells in vitro [159].  This was later shown to be 
dependent upon CTLA-4 and furthermore the extent of down-modulation was functionally 
significant because Treg-cell conditioned dendritic cells induced poor T-cell proliferation 
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responses [160].  More recently, using conditional knockout mice, Wing et al. found that 
Treg-specific CTLA-4 deficiency impaired Treg-mediated down-regulation of CD80 and 
CD86 expression on dendritic cells [307].  As mentioned previously, colleagues within our 
institution (Dr. O. Qureshi and Dr. D. Sansom) have found evidence that CTLA-4 can remove 
its ligands from antigen-presenting cells in a trogocytosis-like manner.  This could represent a 
mechanism of co-stimulatory molecule down-regulation by CTLA-4-expressing regulatory 
T cells.   
 
Modulation of ligand (CD80 and CD86) expression on dendritic cell and B cell APCs by 
CTLA-4 on Tregs was explored in this investigation.  In this study it was similarly found that 
following in vitro co-culture, Tregs specifically down regulated CD86 expression by CD11c+ 
dendritic cells and this was dependent upon CTLA-4.  Consistent with this, confocal 
microscopy and flow cytometry analysis identified augmented CD80 and CD86 expression by 
CD11c+ dendritic cells and CD19+ B cells in Ctla-4-deficient mice.  However, due to the 
lethal lymphoproliferative disease of Ctla-4-deficient mice the cellular environment is 
pro-inflammatory, therefore the increased expression of CD80 and CD86 by APCs observed 
could be due to cellular activation.  In future it would be interesting to assess CD80 and CD86 
expression by APCs in the adoptive transfer model of diabetes following co-transfer of wild 
type or Ctla-4-deficient Tregs.  Removal of CD86 by CTLA-4 could then be assessed in vivo 














5.0 Role of Additional Accessory Pathways in Regulatory 
T Cell Homeostasis 
 
5.1 Introduction 
The data obtained in chapter 3 (role of CTLA-4 in regulatory T cell development and 
homeostasis) suggested that CTLA-4 plays a role in the homeostasis of peripheral regulatory 
T cells.  However, it was unclear from the data obtained using Ctla-4 knockout mice, with a 
severe lymphoproliferative syndrome, whether the altered Treg homeostasis observed was a 
direct cell-intrinsic result of the loss of CTLA-4 in the regulatory T cells, or in response to 
cell-extrinsic changes in the environment within the diseased mice. 
 
To compliment the Ctla-4 knockout mouse studies in chapter 3 and further dissect the 
mechanism by which CTLA-4 controls Treg homeostasis, anti-CTLA-4 blocking antibody 
in vivo experiments were carried out with Ctla-4-sufficient mice.  The involvement of factors 
which are known to modulate regulatory T cell homeostasis, such as IL-2 signalling [57, 80], 
CD28 co-stimulation [131, 238, 295] and encounter with antigen [52] was investigated.   
 
Additionally, accessory pathways such as those mediated by other CD28-superfamily 
members and tumor necrosis factor (TNF) receptors have been suggested to be functionally 
involved in the development and homeostasis of regulatory T cells [125, 312-316].  The 
involvement of the CD28-superfamily, secondary co-stimulatory molecule ICOS and TNF 
receptors OX40, CD30 and RANK, in the context of the role of the CTLA-4 pathway in Treg 












5.2.1 Mechanistic analysis of regulatory T cell proliferation resulting from a lack of 
CTLA-4.    
In chapter 3, analysis of CD4+ FOXP3+ regulatory T cells in Ctla-4-deficient mice identified 
a potential role for the CTLA-4 receptor in the peripheral homeostasis of Tregs.  Prior to the 
revival in the concept and existence of regulatory T cells, the CTLA-4 receptor had been 
found to function opposite the CD28 co-stimulatory receptor to negatively control T cell 
activation and proliferation [199, 200].  As it is now known CD4+ FOXP3+ regulatory T cells 
constitutively express CTLA-4 whereas CD4+ FOXP3- conventional T cells up regulate 
CTLA-4 only upon activation, the augmented Treg proliferation observed in Ctla-4 knockout 
mice could be due to the cell-intrinsic loss of CTLA-4 in regulatory T cells.  However, it is 
also possible that the lymphoproliferative environment within diseased Ctla-4-deficient mice 
alters peripheral CD4+ FOXP3+ Treg homeostasis in Ctla-4 gene ablated mice.  For example, 
high levels of cytokines such as IL-2 could be present which could potentially alter regulatory 
T cell proliferation.     
 
To assess the loss of CTLA-4 signalling on CD4+ FOXP3+ Treg homeostasis in a healthy 
mouse, wild type BALB/c mice were treated with anti-CTLA-4 blocking antibody.  On day 
eight, following twice weekly treatment with anti-CTLA-4 blocking antibody, 
CD4+ FOXP3+ Treg proliferation was assessed by flow cytometry analysis of Ki67 
expression.  Increased Ki67 expression by CD4+ FOXP3+ regulatory T cells was observed in 
mice treated with anti-CTLA-4 blocking antibody compared to controls.  Expression of Ki67 
by CD4+ FOXP3- conventional T cells was also increased, but proportionally not by as much 
as Ki67 expression by CD4+ FOXP3+ Tregs (Fig. 5.01 A).  To explore whether it was 
possible to distinguish which T cell subset (CD4+ FOXP3- conventional T cells or 
CD4+ FOXP3+ regulatory T cells) responded to anti-CTLA-4 treatment, a time course 
analysis was undertaken.  Three days following initiation of anti-CTLA-4 antibody-mediated 
blockade, CD4+ FOXP3+ Tregs showed a statistically significant increase in Ki67 expression 
(p=0.0019), whereas Ki67 expression by CD4+ FOXP3- Tconv at this time point was not 
significantly different from that in control treated mice (p=0.3393) (Fig. 5.01 B).  The 







































Figure 5.01.  Antibody-mediated CTLA-4 blockade augments CD4+ FOXP3+ 
Treg proliferation in vivo.  BALB/c mice received 500µg of anti-CTLA-4 blocking 
antibody (4F10) or control twice weekly by intra-peritoneal injection.  Single cell 
suspensions from peripheral lymph nodes were surface stained with CD4 and 
intracellular with FOXP3 and Ki67 for analysis by flow cytometry. (A)  
Representative FACS plots of Ki67 expression by CD4+ FOXP3+ Tregs (top) and 
CD4+ FOXP- Tconv (bottom) from mice harvested on day 8.  (B) Graph shows data 
for ≥3 mice harvested at each time point.  Bars represent mean value and standard 
deviation is shown. p value calculated by two-tailed, unpaired T-test for the means.
blocking antibody treatment; however this manifested later than for the CD4+ FOXP3+ Treg 
population.  The graph of Fig. 5.01 B shows that by day eight there was a trend toward 
slightly increased Ki67 expression by CD4+ FOXP3- cells in mice that had received 
anti-CTLA-4 blocking antibody, but this trend was not significant until day fourteen 
(p=0.0006).   
 
Although the proliferation of conventional T cells was not altered at early time points by 
anti-CTLA-4 blocking antibody treatment, it remained possible that treatment induced a 
non-proliferative change in these cells that indirectly altered regulatory T cell homeostasis.  In 
this regard it is known that upon activation, CD4+ FOXP3- conventional T cells produce the 
T cell growth factor cytokine IL-2 [317].  IL-2 has been found to overcome Treg anergy 
in vitro [57] and IL-2 signalling has since been identified as a critical requirement for Treg 
homeostasis in vivo [80].  Therefore, in both the Ctla-4 gene ablated mice and wild type 
BALB/c mice treated with anti-CTLA-4 blocking antibody, the augmented proliferation of 
peripheral CD4+ FOXP3+ Tregs observed could be due to enhanced IL-2 production by 
CD4+ FOXP3- conventional T cells.  On day three of the anti-CTLA-4 blocking antibody 
time course when CD4+ FOXP3+ Tregs, but not CD4+ FOXP3- Tconv, Ki67 expression was 
significantly increased, production of IL-2 by CD4+ non-Tregs was measured by intracellular 
cytokine staining and analysis by flow cytometry.  IL-2 production by CD4+ non-Tregs was 
detected (Fig. 5.02 A) and this was unaltered following antibody-mediated CTLA-4 blockade 
(Fig. 5.02 A and B).  The FACS plots of Fig. 5.02 A show that with and without anti-CTLA-4 
blocking antibody treatment, CD4+ CD25+ CD27hi Tregs produced negligible IL-2.  Overall, 
this data shows that antibody-mediated CTLA-4 blockade did not detectably affect IL-2 
production by conventional T cells at day three of a time course of treatment, and therefore 
suggests that the augmented CD4+ FOXP3+ Treg proliferation observed was not dependent 
on enhanced IL-2 production by conventional T cells. 
 
IL-2 is required to overcome the profound unresponsiveness regulatory T cells exhibit to TCR 
engagement in vitro [57], however it has previously been shown that Tregs proliferate in 
response to self-antigen in vivo [52].  It was therefore hypothesised in chapter 3 that upon 
self-antigen encounter in the periphery, after exiting the thymus, CTLA-4 could potentially 































Figure 5.02.  Antibody-mediated CTLA-4 blockade does not affect IL-2 
production by conventional T cells at day 3.  BALB/c mice received 500µg of 
anti-CTLA-4 blocking antibody (4F10) or control twice weekly by intra-peritoneal 
injection.  Single cell suspensions from peripheral lymph nodes were cultured for 
four hours with PMA and ionomycin.  Cells were then surface stained with CD4, 
CD25, CD27 and intracellular with IL-2 for analysis by flow cytometry. (A)  
Representative FACS plots of IL-2 production by CD4+ CD25+ CD27hi Tregs (top) 
and CD4+ non-Treg Tconv (bottom) from mice harvested on day 3.  (B) Graph 
shows data for a number of different mice harvested on day 3.  Lines represent mean 
value.
studies on the role of CTLA-4 in regulatory T cell homeostasis, Ki67 expression was 
investigated in transgenic mice (DO11.10 RIP-mOVA Rag2-/-) to analyse proliferation of a 
single clone of Tregs in response to antigen in vivo, in the presence or absence of CTLA-4.  
As mentioned previously, mice with germ line deletion of Ctla-4 succumb to a severe 
lymphoproliferative syndrome.  Therefore, TCR-transgenic mice 
(DO11.10 RIP-mOVA Rag2-/-) were used in chapter 4 to study the functional activity of Tregs 
lacking the CTLA-4 receptor in a setting uncomplicated by lymphoproliferation, but with an 
intact CD28 pathway.  A key feature of this transgenic mouse model used is that antigen 
availability is restricted anatomically to the pancreas by the rat insulin promoter (RIP), such 
that T cells at most peripheral sites do not encounter antigen.  This differs from the situation 
in the non-transgenic Ctla-4-/- mice that exhibit global polyclonal T cell activation in the 
periphery.  Accordingly, CD4+ FOXP3+ regulatory T cells in the peripheral, inguinal lymph 
nodes of DO11.10 RIP-mOVA Rag2-/- mice remained largely undivided, even in the absence 
of CTLA-4, as indicated by expression of the cell cycle marker Ki67 (Fig. 5.03).  To examine 
Tregs that had been exposed to antigen, lymphocytes were isolated from digested pancreata.  
Very few T cells could be recovered from the pancreata of these transgenic mice.  However, 
CD4+ FOXP3+ Tregs isolated from the pancreas exhibited greater expression of Ki67 in mice 
that lacked CTLA-4.  This data supports the idea that CTLA-4 signalling controls regulatory 
T cell proliferation in response to encounter with self-antigen. 
 
Each mouse system used in this present study (Ctla-4-/-, TCR-transgenic and anti-CTLA-4 
blocking antibody) to investigate Tregs lacking the CTLA-4 receptor has an intact CD28 
co-stimulatory pathway.  The CD28 receptor is a co-stimulatory molecule required for T cell 
activation and proliferation [182].  It has previously been established by others that CD28 
co-stimulation supports the survival and promotes the self-renewal of peripheral regulatory 
T cells [86, 131].  Additionally, as discussed above, prior to the revival in the concept and 
existence of regulatory T cells, the CTLA-4 receptor had been found to function opposite the 
CD28 co-stimulatory receptor to negatively control T cell activation and proliferation [199, 
200].    A key mechanism of action proposed for CTLA-4 is the binding and sequestering of 
its ligands, which are also common to the co-stimulatory receptor CD28, namely CD80 and 
CD86.  In this model CTLA-4 essentially serves as a competitive inhibitor of the CD28 
pathway.  However, it has also been proposed that following ligation CTLA-4 can transmit a  
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Figure 5.03.  Antigen-specific CD4+ FOXP3+ Tregs deficient in CTLA-4 show 
augmented proliferation at the site of antigen expression.  Wild type (left) and 
Ctla-4-/- (right) DO11.10 x RIP-mOVA Rag2-/- single cell suspensions from non-
draining inguinal lymph nodes (top) and pooled, digested pancreata (≥2) were 
surface stained with CD4 and intracellular with FOXP3 and Ki67 for analysis by 
flow cytometry.  Representative FACS plots of Ki67 expression with respect to 
FOXP3 expression by CD4+ lymphocytes.  Data is representative of two 
independent experiments.    
FOXP3
Ki67







negative signal [213, 318, 319].  In addition, in a small number of instances it has been 
suggested that CTLA-4 can function in a ligand-independent manner [43, 320].  In these latter 
two scenarios, CD28 would not need to be present for the effects of CTLA-4 blockade to 
manifest.  However, CD28 would need to be present if CTLA-4 was working by limiting 
access of CD28 to its ligands.  In an attempt to distinguish between these possibilities 
CD28-/- mice were used to ask whether the ability of anti-CTLA-4 blocking antibody 
treatment to augment Treg proliferation depended on CD28.  Fig. 5.04 A shows the increased 
Ki67 expression observed previously (Fig. 5.01) by both CD4+ FOXP3- conventional T cells 
and CD4+ FOXP3+ regulatory T cells in wild type BALB/c mice on day eight of 
anti-CTLA-4 blocking antibody treatment.  However, on day eight of anti-CTLA-4 blocking 
antibody treatment of CD28 knockout mice, both CD4+ FOXP3- Tconv and CD4+ FOXP3+ 
Tregs showed unaltered Ki67 expression (Fig. 5.04 B).  The data obtained of Ki67 expression 
by CD4+ FOXP3+ Tregs (Fig. 5.04 C) and CD4+ FOXP3- Tconv (Fig. 5.04 D) for a number 
of control and anti-CTLA-4 antibody treated wild type BALB/c and CD28-/- mice is also 
shown graphically.  These data suggest that the augmented CD4+ FOXP3+ Treg proliferation 
upon antibody-mediated CTLA-4 blockade is CD28-dependent.   
 
5.2.2 Role of the secondary co-stimulatory molecule ICOS in CTLA-4 modulation of 
regulatory T cell homeostasis. 
It was found in 5.2.1 above that the augmented CD4+ FOXP3+ Treg proliferation upon 
antibody-mediated CTLA-4 blockade was CD28-dependent, and CD28 co-stimulation has 
been previously implicated in the maintenance of peripheral Treg homeostasis [86, 131].  
However, analysis of Ki67 expression by flow cytometry in Fig. 5.04 identified some 
CD4+ FOXP3+ Tregs in the periphery of CD28-/- mice that expressed Ki67 and were 
therefore undergoing cell cycling (7.81% in CD28-/- versus 11.6% in wild type, in the 
experiment shown).  Therefore, there may be some other molecule(s) involved in peripheral 
CD4+ FOXP3+ regulatory T cell proliferation and homeostasis.  A good candidate molecule 
is the inducible T cell co-stimulator (ICOS).  The secondary co-stimulatory molecule ICOS is 
expressed upon T cell upon activation and has been found to enhance T cell responses such as 
proliferation and IL-10 production [243, 321] as indicated by the defects in T cell activation 






























































Figure 5.04.  Augmented CD4+ FOXP3+ Treg proliferation upon antibody-
mediated CTLA-4 blockade is CD28-dependent.  BALB/c and CD28-/- mice 
received 500µg of anti-CTLA-4 blocking antibody (4F10) or control twice weekly 
by intra-peritoneal injection.  Single cell suspensions from peripheral lymph nodes 
were surface stained with CD4 and intracellular with FOXP3 and Ki67 for analysis 
by flow cytometry.  Representative FACS plots of Ki67 expression by CD4+ 
FOXP3+ Tregs (top) and CD4+ FOXP- Tconv (bottom) from BALB/c (A) and 
CD28-/- (B) mice harvested on day 8.  Graphs show data for ≥2 BALB/c (C) and 
CD28-/- (D) mice.  Lines represent mean value. Experiments carried out in 
collaboration with C. Wang.
proportion of CD4+ FOXP3+ regulatory T cells than CD4+ FOXP3- conventional T cells in 
the steady state, and has been implicated in Treg homeostasis [313].   
 
In chapter 3 it was found that expression of ICOS by both CD4+ FOXP3- Tconv and 
CD4+ FOXP3+ Tregs was substantially increased in Ctla-4 knockout mice (Fig. 3.12).  This 
further highlights the potential involvement of the ICOS pathway in the augmented regulatory 
T cell proliferation upon the loss of CTLA-4 signalling.  First, ICOS expression by 
conventional T cells and regulatory T cells was analysed following antibody-mediated 
CTLA-4 blockade in wild type BALB/c mice.  On day eight of anti-CTLA-4 blocking 
antibody treatment, ICOS expression by CD4+ FOXP3+ Tregs was substantially increased, 
and there was a slight increase in the expression of ICOS by CD4+ FOXP3- Tconv 
(Fig. 5.05).  This data shows that ICOS expression on CD4+ FOXP3+ regulatory T cells is 
augmented upon antibody-mediated blockade of the CTLA-4 pathway in vivo.   
 
In 15-18 day old Ctla-4 knockout mice a substantial increase in ICOS expression by 
conventional T cells and regulatory T cells was observed in chapter 3.  However, as discussed 
above, after only a relatively short time (day 8) following antibody-mediated blockade of the 
CTLA-4 pathway, increased expression of ICOS by Tregs was observed.  Therefore, 
CD4+ FOXP3+ regulatory T cells in one week old Ctla-4-deficient mice were analysed.  As 
seen previously for the 15-18 day old Ctla-4-/- mice, the percentage of CD4+ T cells that 
expressed FOXP3 was increased in the lymph nodes and spleen of one week old Ctla-4-/- 
mice (Fig. 5.06 A).  Interestingly, in one week old Ctla-4-/- mice, Ki67 expression by 
CD4+ FOXP3+ Tregs was increased, but in contrast to the data obtained for 15-18 day old 
Ctla-4-/- mice, Ki67 expression by CD4+ FOXP3- Tconv in one week old Ctla-4-/- mice was 
similar to that in Ctla-4+/- littermate controls (Fig. 5.06 B).  ICOS expression by 
CD4+ FOXP3+ Tregs in one week old Ctla-4-/- mice was substantially increased, whereas the 
percentage of CD4+ FOXP3- Tconv that expressed ICOS was only slightly increased 
compared to Ctla-4+/- littermate controls (Fig. 5.06 C).  Overall that data suggest that 
increased proliferation and expression of ICOS by CD4+ FOXP3+ regulatory T cells upon 
loss of the CTLA-4 pathway occurs before the increased proliferation and activation of 











Figure 5.05. ICOS expression on CD4+ FOXP3+ Tregs is augmented upon 
CTLA-4 blockade in vivo. BALB/c mice received 500µg of anti-CTLA-4 blocking 
antibody (4F10) or control twice weekly by intra-peritoneal injection.  Single cell 
suspensions from peripheral lymph nodes were surface stained with CD4, ICOS and 
intracellular with FOXP3 for analysis by flow cytometry.  Representative FACS 
plots of ICOS expression by CD4+ FOXP3+ Tregs (top) and CD4+ FOXP- Tconv 













































































































































Figure 5.06.  Analysis of CD4+ FOXP3+ Tregs in one week old Ctla-4-deficient 
mice. Day 6 Ctla-4+/- and Ctla-4-/- single cell suspensions from peripheral lymph 
nodes were surface stained with CD4, ICOS and intracellular with FOXP3 and Ki67 
for analysis by flow cytometry.  (A)  Graph shows the percentage of CD4+ T cells 
that express FOXP3 in Ctla-4+/- littermate controls (blue) and Ctla-4-/- (red). (B) 
Graph shows the percentage of CD4+ FOXP3- Tconv (squares) and CD4+ FOXP3+ 
Tregs (circles) that express Ki67 in Ctla-4+/- littermate controls (blue) and Ctla-4-/-
(red). (C)  Graph shows the percentage of CD4+ FOXP3- Tconv (squares) and 
CD4+ FOXP3+ Tregs (circles) that express ICOS in Ctla-4+/- littermate controls 
(blue) and Ctla-4-/- (red).  Lines represent mean value.  
Along with altered receptor expression, the activity of a signalling pathway is also modulated 
by expression of the ligand(s).  To obtain an indication of the potential activity of the ICOS 
signalling pathway in Ctla-4-deficient mice, ICOS ligand (ICOSL) expression by CD19+ 
B cells was analysed by flow cytometry.  In Fig. 5.07 A and B it can be seen that the median 
fluorescent intensity (MFI) of ICOSL expression on the surface of CD19+ B cells was slightly 
decreased in Ctla-4-/- mice compared to age-matched BALB/c controls.  In some instances, 
upon receptor-ligand interaction there is a concurrent down regulation of ligand expression as 
a means of modulating the activity of signalling via the receptor.  Therefore, intracellular 
expression of ICOSL by CD19+ B cells was also analysed by flow cytometry.  It was found 
that the MFI of intracellular ICOSL expression by CD19+ B cells in Ctla-4-/- mice was 
slightly increased compared to age-matched BALB/c controls (Fig. 5.07).  However, these 
shifts in the intensity of ICOSL expression are only very small and more data is required to 
determine if these represent significant changes.    
 
Upon T cell activation, the up regulation of ICOS has been reported to be CD28-dependent 
[244].  However, the mechanistic control of ICOS expression in Tregs is not known.  Using 
lymphocytes isolated from CD28-deficient mice and agonistic antibodies to CD3 and CD28, 
the CD28-dependency of ICOS expression by CD4+ FOXP3- Tconv and CD4+ FOXP3+ 
Tregs was investigated by in vitro overnight culture.  Fig. 5.08 shows that fewer 
CD28-deficient CD4+ FOXP3- conventional T cells (Tconv) expressed ICOS compared to 
wild type.  ICOS expression in Tconv increased in response to TCR-stimulation by anti-CD3 
in wild type and slightly in CD28-deficient lymphocytes.  In wild type Tconv, CD28 
co-stimulation with anti-CD28 in conjunction with TCR-stimulation with anti-CD3 further 
increased ICOS expression, although CD28 co-stimulation alone had no affect.  As predicted, 
the anti-CD28 antibody had no affect on CD28-/- lymphocytes.  Collectively, these data 
suggest that a combination of TCR and CD28 signalling drive the up regulation of ICOS in 
conventional T cells.    
 
Parallel analyses were carried out on the CD4+ FOXP3+ regulatory T cell subset.  ICOS 
expression by CD28-deficient CD4+ FOXP3+ Tregs (Fig. 5.08) was similar to wild type.  
Similar to conventional T cells, Treg ICOS expression increased upon TCR-stimulation with 







































Figure 5.07.  Analysis of ICOSL expression by CD19+ B cells in Ctla-4-deficient 
mice. Day 15-18 BALB/c and Ctla-4-/- single cell suspensions from peripheral 
lymph nodes were surface stained with CD19, ICOSL and intracellular with ICOSL 
for analysis by flow cytometry.  (A)  Representative histograms for surface (left) and 
intracellular (right) expression of ICOSL by CD19+ gated lymphocytes of day 15-18 
BALB/c mice (blue) and Ctla-4-/- mice (red).  Isotype controls in black.  (B)  Graph 
shows data for surface (circles) and intracellular (squares) ICOSL median 
fluorescent intensity (MFI) on CD19+ B cells for a number of BALBC/c (blue) and 








































































































Figure 5.08. CD28-dependency of ICOS expression by CD4+ FOXP3- Tconv 
and CD4+ FOXP3+ Tregs. Adult BALB/c wild type or CD28-/- single cell 
suspensions from peripheral lymph nodes were cultured overnight plus or minus 
500ng/ml anti-CD3 and 1µg/ml anti-CD28.  Three wells were pooled and surface 
stained with CD4, ICOS and intracellular with FOXP3 for analysis by flow 
cytometry.  (A)  Graphs show ICOS expression by gated CD4+ FOXP3- Tconv (top) 
and CD4+ FOXP3+ Tregs (bottom).  Representative graph from three independent 
experiments is shown.  Representative FACS plots of ICOS expression by CD4+ 
FOXP3- Tconv (B) and CD4+ FOXP3+ Tregs (C) following culture with anti-CD3 
and/or anti-CD28 are also shown.   
antibody had no affect on CD28-/- lymphocytes.  Overall, the data suggest that up regulation 
of ICOS expression by both CD4+ FOXP3- Tconv and CD4+ FOXP3+ Tregs is augmented 
by CD28 signalling.   
 
From the ICOS and ICOSL expression patterns observed upon loss of the CTLA-4 pathway in 
this study, and the generally accepted role of ICOS as a secondary co-stimulatory molecule, it 
could be hypothesised that the ICOS signalling pathway may be involved in the augmented 
Treg proliferation observed in Ctla-4-/- mice and anti-CTLA-4 blocking antibody treated 
mice.  To investigate the role of ICOSL-ICOS signalling in the augmented Treg proliferation 
observed upon loss of CTLA-4 signalling, in vivo experiments were carried out in which wild 
type BALB/c mice were treated with anti-CTLA-4 blocking antibody in the presence or 
absence of anti-ICOSL blocking antibody.  The graphs of Fig. 5.09 show increased Ki67 (A) 
and ICOS (B) expression by CD4+ FOXP3+ Tregs (top) and CD4+ FOXP3- Tconv (bottom) 
day five after anti-CTLA-4 blocking antibody treatment, as seen previously.  Treatment with 
anti-ICOSL blocking antibody alone had no affect on Ki67 or ICOS expression by either 
CD4+ FOXP3- Tconv or CD4+ FOXP3+ Tregs.  Combined blockade of both the CTLA-4 
and ICOS pathways by treatment with anti-CTLA-4 and anti-ICOSL blocking antibodies did 
not abrogate the increase in Ki67 expression by both CD4+ FOXP3- Tconv and 
CD4+ FOXP3+ Tregs caused by anti-CTLA-4 blocking antibody treatment alone.  Overall, 
the data suggest that the ICOSL-ICOS pathway is not responsible for the augmented Treg 
proliferation observed upon loss of the CTLA-4 pathway following antibody-mediated 
blockade.   
 
The increased ICOS expression observed on CD4+ FOXP3- Tconv and CD4+ FOXP3+ Tregs 
in Ctla-4-deficient mice and following anti-CTLA-4 blocking antibody treatment of wild type 
BALB/c mice could be a cell-intrinsic result of the loss of CTLA-4 signalling, or it could be 
due to factors in the local environment.  In an attempt to distinguish between these 
possibilities in vitro experiments were carried out in which wild type BALB/c lymphocytes 
were cultured in control medium or supernatants obtained from the in vitro culture of wild 
type BALB/c or Ctla-4-/- lymphocytes.  ICOS expression on CD4+ FOXP3- Tconv was 
similar following culture in control medium, wild type-derived supernatant or 






















































































































































































Figure 5.09. In vivo analysis of the ICOS-dependency of augmented CD4+ 
FOXP3+ Treg proliferation upon antibody-mediated CTLA-4-blockade.
BALB/c mice received 500µg of anti-CTLA-4 blocking antibody (4F10) plus or 
minus 200µg of anti-ICOSL blocking antibody (HK5.3) or control twice weekly by 
intra-peritoneal injection.  Mice were harvested on day 5.  Single cell suspensions 
from peripheral lymph nodes were surface stained with CD4, ICOS and intracellular 
with FOXP3 and Ki67 for analysis by flow cytometry. Graphs show Ki67 (A) and 
ICOS (B) expression by CD4+ FOXP3+ Tregs (top) and CD4+ FOXP3- Tconv 
(bottom).  Lines represent mean value.
was increased following culture in Ctla-4-/--derived supernatant compared to control medium 
or wild type-derived supernatant (Fig. 5.10).  Overall, the in vitro data suggest that 
lymphocytes in Ctla-4-deficient mice produce some factor(s) that can up regulate ICOS 
expression by CD4+ FOXP3+ Tregs.   
 
5.2.3 Role of the TNF receptors OX40 and CD30 in CTLA-4 modulation of regulatory T 
cell homeostasis. 
In addition to ICOS, the tumor necrosis factor (TNF) receptor OX40 is also known as a 
secondary co-stimulatory molecule expressed by activated T cells [323].  It has been found 
that OX40 is involved in the T cell-dependent humoral response [324], CD4 T cell memory 
[325] and, along with another TNF receptor expressed by activated T cells CD30, T cell 
survival (reviewed in [326, 327]).  Additionally, OX40 is expressed by regulatory T cells and 
it has been proposed that OX40 is involved in Treg induction and function [125, 314].  
Therefore, following the studies on ICOS above, the TNF receptors OX40 and CD30 were 
other good candidate molecules to be involved in the modulation of regulatory T cell 
homeostasis.  First, CD4+ FOXP3+ regulatory T cells were analysed in OX40-/- CD30-/- 
mice to assess the role of these two TNF receptors in Treg development and homeostasis.  
The graph of Fig. 5.11 A indicates that in the peripheral lymph nodes of mice lacking OX40 
and CD30 there was no difference in the percentage of CD4+ T cells that were FOXP3+ 
compared to C57BL/6 controls.  However, the data show that a slightly increased proportion 
of CD4+ T cells expressed FOXP3 in the thymi of OX40-/- CD30-/- compared to in wild type 
control thymi.  To examine whether the OX40 and CD30 pathways influence the proliferation 
of mature Tregs in the periphery, Ki67 expression was analysed by flow cytometry.  The 
FACS plots of Fig. 5.11 B show that there was not really any change in Ki67 expression by 
peripheral CD4+ FOXP3- conventional T cells or CD4+ FOXP3+ regulatory T cells lacking 
OX40 or both OX40 and CD30 compared to wild type C57BL/6 controls. 
 
To test whether deficiency in the OX40 or CD30 pathways altered the augmented Treg 
proliferation upon antibody-mediated blockade of the CTLA-4 pathway, mice lacking OX40 
(OX40-/-) or both OX40 and CD30 (OX40-/- CD30-/-) were treated with anti-CTLA-4 
blocking antibody.  On day eight after treatment with anti-CTLA-4 blocking antibody, Ki67 




















































Figure 5.10. In vitro analysis of CD4+ FOXP3- Tconv and CD4+ FOXP3+ Treg 
ICOS expression in a ‘Ctla-4-/- environment’. 2 x 105 wild type BALB/c 
lymphocytes were cultured in control medium (C10), wild type supernatant (WT) or 
Ctla-4-/- supernatant (KO) overnight.  The next day cells were analysed by flow 
cytometry for ICOS expression by CD4+ FOXP3- Tconv and CD4+ FOXP3+ Tregs.  
Supernatants were obtained from culture of 3 x 105 wild type BALB/c or Ctla-4-/-
lymphocytes for two days.  (A)  Graph to show ICOS expression by CD4+ FOXP3-
Tconv and CD4+ FOXP3+ Tregs following culture in control medium (C10), wild 
type supernatant (WT) or Ctla-4-/- supernatant (KO).  Bars on graphs represent 
mean and standard deviation is shown.  (B)  Representative FACS plots of FOXP3 
and ICOS expression by CD4+ gated lymphocytes following culture in control 




































































Figure 5.11.  Analysis of CD4+ FOXP3+ Tregs in mice lacking OX40 and CD30. 
Single cell suspensions from thymi and peripheral lymph nodes of wild type 
C57BL/6 (WT), OX40-/- and OX40-/- x CD30-/- mice were surface stained with 
CD4 and intracellular with FOXP3 and Ki67 for analysis by flow cytometry.  (A)  
Graph shows the percentage of CD4+ that were FOXP3+ in the thymi and peripheral 
lymph nodes of wild type C57BL/6 or OX40-/- x CD30-/- mice.  (B)  Representative 
FACS plots of Ki67 expression by CD4+ FOXP3- Tconv (left) and CD4+ FOXP3+ 
Tregs (right) from the lymph nodes of wild type C57BL/6 (top), OX40-/- (middle) 
and OX40-/- x CD30-/- (bottom) mice.  Data are representative of 2 mice. p values 
calculated by two-tailed, unpaired T-test for the means.
previously with BALB/c mice.  Anti-CTLA-4 blocking antibody treatment also increased 
Ki67 expression by Tconv and Tregs in OX40-/- and OX40-/- CD30-/- mice (Fig. 5.12).  
Overall, the data suggest that regulatory T cell proliferation upon the loss of the CTLA-4 
pathway by anti-CTLA-4 blocking antibody treatment is not OX40/CD30-dependent.    
 
5.2.4 Role of the TNF receptor RANK in regulatory T cell development and homeostasis. 
Another TNF receptor that is of interest with respect to regulatory T cell development and 
homeostasis is receptor activator of NF-κB (RANK).  RANK was originally identified to be 
expressed by dendritic cells [328] and interaction with RANKL on activated T cells 
established a role for the RANKL-RANK pathway in DC function and survival [329].  
Additionally, the RANKL-RANK pathway was found to be involved in bone physiology 
following the identification of RANK expression on chondrocytes and osteoclasts [330].  
RANK is also expressed by endothelial cells, specifically medullary thymic epithelial cells 
(mTECs), and a role for RANK in positive selection-mediated thymic medulla formation has 
been proposed [315, 331].  mTECs, that promiscuously express self-antigen under the control 
of the autoimmune regulator AIRE, have been proposed to functionally determine whether 
thymocytes develop into FOXP3+ regulatory T cells [79].  This consequently infers a role for 
the RANKL-RANK pathway in regulatory T cell development. 
 
In addition to dendritic cells, osteoclasts and mTECs, RANK has also been reported to be 
expressed by activated T cells [328, 329].  It is technically difficult to study the cellular 
distribution of RANK expression as good monoclonal antibodies are not available.  Due to the 
activated cellular phenotype in Ctla-4-deficient mice with severe lymphoproliferative disease, 
it was decided to investigate Rank expression by SYBR green qPCR using sorted cell 
populations from these mice.  Some Rank expression was detected in both wild type and 
Ctla-4-/- whole lymphocyte and purified CD4+ cell preparations (Fig. 5.13 A).  The relative 
amount of Rank expression detected in wild type and Ctla-4-/- lymphocytes and CD4+ was 
two logs lower than that expressed by the foetal thymic organ culture cells used as a positive 
control.  Rank expression was also detected in wild type and Ctla-4-/- purified CD4+ CD25- 
conventional T cell and CD4+ CD25+ CD27hi regulatory T cell preparations (Fig. 5.13 B).  
With the purified Tconv and Treg populations a three log lower relative amount of Rank was 



















































Figure 5.12. Augmented CD4+ FOXP3+ Treg proliferation upon antibody-
mediated CTLA-4 blockade is not OX40 / CD30-dependent.  C57BL/6, OX40-/-
and OX40-/- x CD30-/- mice received 500µg of anti-CTLA-4 blocking antibody 
(4F10) or control twice weekly by intra-peritoneal injection.  Single cell suspensions 
from peripheral lymph nodes were surface stained with CD4 and intracellular with 
FOXP3 and Ki67 for analysis by flow cytometry.  Graphs show Ki67 expression by 














































































Figure 5.13. Real time qPCR for RANK expression.  15-18 day old wild type 
BALB/c or Ctla-4-/- single cell suspensions of pooled lymph nodes were surface 
stained with CD4, CD25 and CD27 for mo-flow cell sorting.  CD4+ T cells were 
isolated and Tconv were isolated as CD4+ CD25- and Tregs were isolated as CD4+ 
CD25+ CD27hi.  mRNA and cDNA was obtained from snap-frozen cell pellets and 
real time SYBR Green qPCR carried out for the presence of  RANK relative to β-
actin.  Graphs show pooled data for triplicates of cDNA samples obtained from three 
different wild type (blue) or Ctla-4-/- (red) mice.  Relative amount was calculated as 
the amount of target normalised to an endogenous β-actin reference. Experiments 
carried out in collaboration with S. Parnell.
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In contrast to RANK, good RANK ligand (or TRANCE) monoclonal antibodies are available.  
To compliment the RANK expression studies above, the cellular distribution of TRANCE 
(RANKL) expression was analysed by flow cytometry in Ctla-4-deficient mice and littermate 
controls.  In Ctla-4-/- mice a substantially increased proportion of CD4+ T cells expressed 
TRANCE (Fig. 5.14 B).  Therefore, TRANCE expression by CD4+ FOXP3- conventional 
T cells and CD4+ FOXP3+ regulatory T cells within the CD4+ T cell population was 
investigated.  Some CD4+ FOXP3- Tconv expressed TRANCE in Ctla-4+/- littermate 
controls; strikingly, this was greatly increased in Ctla-4-/- mice (Fig. 5.14 C).  No difference 
was observed in the TRANCE expression by CD4+ FOXP3+ regulatory T cells in Ctla-4-/- 
mice compared to Ctla-4+/- littermate controls (Fig. 5.14 D).            
 
The increased TRANCE expression observed above on CD4+ T cells from Ctla-4-/- mice 
could be due to the cell-intrinsic loss of CTLA-4, or it could be a result of the 
lymphoproliferative environment within the diseased Ctla-4-deficient mice.  To examine the 
effect of CTLA-4 blockade in mice not experiencing lymphoproliferation, the cellular 
distribution of TRANCE (RANKL) expression was analysed by flow cytometry in wild type 
BALB/c mice treated with anti-CTLA-4 blocking antibody.  Fig. 5.15 shows that in control 
treated mice similar TRANCE expression was detected on both CD4+ FOXP3- conventional 
T cells and CD4+ FOXP3+ regulatory T cells, as previously found in Ctla-4+/- littermate 
controls.  On day eight after antibody-mediated CTLA-4 blockade, TRANCE expression only 
slightly increased on the FOXP3- conventional CD4+ T cell population (Fig. 5.15 C).  The 
TRANCE expression after anti-CTLA-4 blocking antibody treatment was lower than that 
previously observed in Ctla-4-deficient mice (Fig. 5.14).  As seen in Ctla-4 knockout mice, 
there was not really any change in TRANCE expression on CD4+ FOXP3+ Tregs following 
anti-CTLA-4 blocking antibody treatment (Fig. 5.15 D).   
 
The data obtained above suggest that TRANCE expression by CD4+ FOXP3- T cells is 
increased upon loss of CTLA-4 signalling.  Since CTLA-4 functions to antagonise CD28 
signalling, the CD28-dependency of TRANCE expression by CD4+ FOXP3- conventional 
T cells and CD4+ FOXP3+ regulatory T cells was investigated using lymphocytes isolated 
from CD28-deficient mice and agonistic antibodies to CD3 and CD28 by in vitro overnight 











Figure 5.14. Cellular distribution of TRANCE (RANKL) expression in Ctla-4-
deficient mice.  Single cell suspensions from peripheral lymph nodes were surface
stained with CD4, CD19, TRANCE and intracellular with FOXP3 for analysis by 
flow cytometry. Representative FACS plots for CD19+ (A), CD4+ (B), CD4+ 
FOXP3- (C) and CD4+ FOXP3+ (D) gated lymphocytes of 15-18 day old Ctla-4+/-
and Ctla-4-/- mice (right) and for secondary antibody alone (left).  Data 





















Figure 5.15. TRANCE (RANKL) expression upon antibody-mediated CTLA-4 
blockade in vivo. BALB/c mice received 500µg of anti-CTLA-4 blocking antibody 
(4F10) or control twice weekly by intra-peritoneal injection.  Single cell suspensions 
from peripheral lymph nodes were surface stained with CD4, CD19, TRANCE and 
intracellular with FOXP3 for analysis by flow cytometry.  Representative FACS 
plots of TRANCE expression by CD19+ B cells (A), CD4+ T cells (B), CD4+ 










































































































Figure 5.16. CD28-dependency of TRANCE (RANKL) expression by CD4+ 
FOXP3- Tconv and CD4+ FOXP3+ Tregs. Adult BALB/c wild type or CD28-/-
single cell suspensions from peripheral lymph nodes were cultured overnight plus or 
minus 500ng/ml anti-CD3 and 1µg/ml anti-CD28.  Three wells were pooled and 
surface stained with CD4, TRANCE and intracellular with FOXP3 for analysis by 
flow cytometry.  Graphs show TRANCE expression by gated CD4+ FOXP3- Tconv 
(top) and CD4+ FOXP3+ Tregs (bottom).  Representative graph from three 
independent experiments is shown.
(Tconv) expressed TRANCE compared to wild type.  TRANCE expression in Tconv 
increased in response to TCR-stimulation by anti-CD3 in wild type and CD28-deficient 
lymphocytes.  In wild type Tconv, TRANCE expression following CD28 co-stimulation with 
anti-CD28 in conjunction with TCR-stimulation with anti-CD3 was similar to 
TCR-stimulation with anti-CD3 alone.  As predicted, the anti-CD28 antibody had no affect on 
CD28-/- lymphocytes.  Collectively, these data suggest that the up regulation of TRANCE in 
conventional T cells is CD28-independent.    
 
Parallel analyses were carried out on the CD4+ FOXP3+ regulatory T cell subset.  TRANCE 
expression by CD28-deficient CD4+ FOXP3+ Tregs (Fig. 5.16 B) was increased compared to 
wild type.  In wild type and CD28-/- Tregs TCR-stimulation or CD28 co-stimulation did not 
alter TRANCE expression.  Overall, the data suggest that TRANCE expression by 
CD4+ FOXP3+ regulatory T cells is not augmented by anti-CD3 or anti-CD28 treatment.   
 
To investigate the role of the TNF receptor RANK in regulatory T cell development and 
homeostasis in vivo, Rank knockout mice were analysed by flow cytometry.  No difference in 
the proportions of the CD4/CD8 T cell populations within the thymus were observed in 
Rank-deficient mice compared to C57BL/6 age-matched controls (Fig. 5.17 A and D).  
However, the proportion of CD4 single positive thymocytes that expressed FOXP3 was 
slightly decreased (Fig. 5.17 B and E).  This suggests that the thymic development of 
CD4+ FOXP3+ regulatory T cells is negatively affected in Rank-deficient mice, but 
CD4+ FOXP3+ Tregs are not absent altogether.  Rank knockout mice lack lymph nodes, 
therefore splenocytes were analysed to assess the peripheral homeostasis of CD4+ FOXP3+ 
Tregs.  Fig. 5.17 C and F show that in the periphery the proportion of CD4+ T cells that 
expressed FOXP3 was decreased in Rank-/- mice compared to age-matched wild type 
controls.  Even with the decreased proportion of CD4+ FOXP3+ Tregs in Rank-/- mice, the 
absolute number of peripheral CD4+ FOXP3+ Tregs was increased compared to C57BL/6 
age-matched controls (Fig. 5.17 G).  This could be due to the splenomegaly in Rank-deficient 
mice as shown by the greater spleen mass (Fig. 5.17 H) and increased overall number of 
splenocytes (Fig. 5.17 I) in the Rank-/- spleen compared to the spleen of a C57BL/6 














































































































































































































Figure 5.17. CD4+ FOXP3+ cells are present in the thymus and peripheral 
spleen of Rank-/- mice. Single cell suspensions from the thymi and spleens of 15 
day old Rank-/- mice and age-matched wild type C57BL/6 control mice were 
analysed by flow cytometry.  Representative FACS plots for (A) CD4 and CD8 
expression by thymocytes, (B) FOXP3 expression by CD4 single positive 
thymocytes and (C) FOXP3 expression by CD4+ gated splenocytes.  (D) Graph 
shows CD4/CD8 percentage composition of the thymus for a number of mice.  (E) 
Graph to show FOXP3 expression by CD4 single positive thymocytes.  (F) Graph 
shows FOXP3 expression by CD4+ gated splenocytes.  (G) Graph to show the 
absolute number of CD4+ FOXP3+ splenocytes. (H)  Graph shows weight of 15 day 
old C57BL/6 and Rank-/- spleens.  (I)  Graph to show absolute cell counts of 15 day 
old C57BL/6 and Rank-/- spleens.  Each point on the graphs represents a different 
mouse and lines indicate mean values. 
The data above suggest that CD4+ FOXP3+ Treg homeostasis is negatively affected in 
Rank-deficient mice.  This might be accounted for by the reduced selection of CD4+ FOXP3+ 
Tregs in the thymi of Rank knockout mice or altered Treg proliferation and/or survival in the 
periphery of Rank-/- mice.  To further explore peripheral CD4+ FOXP3+ regulatory T cell 
homeostasis in Rank-deficient mice, CD4+ T cells in Rank-/- splenocytes were phenotyped by 
flow cytometry.  The proportion of CD4+ FOXP3- Tconv and CD4+ FOXP3+ Tregs 
undergoing proliferation, as indicated by expression of the cell cycle marker Ki67, was 
decreased in Rank-deficient mice compared to age-matched wild type controls (Fig. 5.18 A).  
Additionally, expression of the cell death marker ANNEXIN V was also decreased in both 
Rank-/- conventional T cells and regulatory T cells (Fig. 5.18 B).  Consistent with the reduced 
T cell death in Rank-deficient mice, Tconv and Tregs expressed increased amounts of the 
anti-apoptotic Bcl-2 protein compared to their wild type counterparts (Fig. 5.18 C).   
 
In this study it has previously been discussed how the co-stimulatory receptor CD28 has a 
major role in regulatory T cell homeostasis.  Similarly, the CTLA-4 receptor which shares the 
common ligands CD80 and CD86 with CD28 has been found to function in the control of 
peripheral Treg homeostasis.  As discussed above, the peripheral homeostasis of Tregs was 
found to be altered in Rank-/- mice.  Therefore, the expression of the CD28 and CTLA-4 
receptors was analysed in Rank-deficient mice.  In CD4+ FOXP3- conventional T cells and 
CD4+ FOXP3+ regulatory T cells from Rank knockout mice expression of both CD28 and 
CTLA-4 was similar to that in C57BL/6 age-matched controls (Fig. 5.18 D and E).  To 
further examine the peripheral homeostasis of T cells in Rank-deficient mice flow cytometry 
was used to phenotype the activation status of T cells by investigating CD69, CD62L and 
ICOS expression.  CD69 expression by CD4+ FOXP3+ Tregs in Rank-/- mice was increased 
compared to age-matched wild type controls (Fig. 5.18 F).  However, no change in the 
proportion of Tconv or Tregs that down regulated CD62L was observed in Rank knockout 
mice (Fig. 5.18 G).  Similarly, ICOS expression was unchanged, or if anything slightly 
decreased on CD4+ FOXP3- Tconv and CD4+ FOXP3+ Tregs from Rank-deficient mice 
(Fig. 5.18 H).  Also, expression of RANK ligand (TRANCE) by conventional T cells and 
regulatory T cells was increased in Rank-/- mice compared to C57BL/6 age-matched controls 
(Fig. 5.18 I).  Overall, the CD4+ T cells in the periphery of Rank-deficient mice did not 



























































































































































































































































































































































































Figure 5.18. CD4+ FOXP3- Tconv and CD4+ FOXP3+ Treg phenotype in Rank-
/- mice. Day 15 C57BL/6 and Rank-/- splenocytes were analysed by flow cytometry 
for Ki67 (A), ANNEXIN V (B), Bcl-2 (C), CD28 (D), CTLA-4 (E), CD69 (F), 
CD62L (G), ICOS (H) and TRANCE (I) expression by CD4+ FOXP3- Tconv and 
CD4+ FOXP3+ Tregs.  Each point on the graphs represents a different mouse and 
lines indicate mean values.  
Having identified a population of CD4+ FOXP3+ cells in the periphery of Rank-deficient 
mice it is of interest to investigate the suppressive function of these regulatory T cells.  
CD4+ CD25+ Tregs were sorted from wild type and Rank-/- splenocytes and assayed for 
suppressive function in an in vitro assay.  It was found that CD4+ CD25+ Tregs from Rank-/- 
mice suppressed the growth of CD4+ CD25- effector T cells to the same extent as wild type 
CD4+ CD25+ Tregs (Fig. 5.19).  In summary, CD4+ FOXP3+ regulatory T cells develop in 
the thymus of Rank-deficient mice and are exported to the periphery.  These peripheral 
CD4+ CD25+ Tregs in Rank knockout mice exert suppressive function in vitro.    
 








                
                               
 
 




















































































Figure 5.19. CD4+ CD25+ Tregs from Rank-/- mice suppress effector T cell 
proliferation in vitro. Single cell suspensions from C57BL/6 and Rank-/- spleens 
were MACS separated to obtain CD4+ CD25- Tconv and CD4+ CD25+ Tregs. 2.5 x 
104 C57BL/6 Tconv were co-cultured with 15 x 104 MACS separated CD19+ from 
C57BL/6 spleen, 1µg/ml anti-CD3 and C57BL/6 or Rank-/- Tregs at a 1:1 ratio for 3 
days. Cells were then surface stained with CD4, CD45.1 and intracellular for 
FOXP3 for analysis by flow cytometry.  (A)  Graph shows absolute number of 
CD45.1+ CD4+ FOXP3- effector T cells following culture with C57BL/6 or Rank-/-
Tregs.  (B) Graph shows the percentage suppression as determined using the 
absolute number of effector T cells when cultured with and without Tregs.  Bars 
represent means and standard deviations are shown.  Data shown is representative of 




A potential role for the CTLA-4 receptor in the peripheral homeostasis of Tregs was 
previously identified in chapter 3 of this study.  However, it was unclear from the data 
obtained using Ctla-4 knockout mice, with a severe lymphoproliferative syndrome, whether 
the altered Treg homeostasis observed was a direct cell-intrinsic result of the loss of CTLA-4 
in the regulatory T cells, or in response to cell-extrinsic changes in the environment within the 
diseased mice.  Antibody-mediated CTLA-4 blockade studies in healthy adult mice triggered 
an increase in CD4+ FOXP3+ regulatory T cell proliferation.  CD4+ FOXP3+ Tregs would be 
expected to be the initial cellular target of anti-CTLA-4 blocking antibody since they 
constitutively express CTLA-4 [154, 155], whereas CTLA-4 is activation induced in 
CD4+ FOXP3- conventional T cells.  The delayed kinetics of the CD4+ FOXP3- conventional 
T cell proliferative response to anti-CTLA-4 blocking antibody could be because CTLA-4 is 
up regulated only upon activation in CD4+ FOXP3- Tconv.  Alternatively, the data obtained 
in chapter 4 of this study identified a role for CTLA-4 in Treg function.  Thus, anti-CTLA-4 
blocking antibody treatment may alter the function of the targeted Treg population which 
could lead to the expansion of uncontrolled effector T cells.  It would be interesting to 
continue anti-CTLA-4 blocking antibody treatment for a longer period of time to see if upon 
long term blockade of the CTLA-4 pathway, healthy adult mice succumb to a similar 
lymphoproliferative disease as gene-ablated mice. 
 
Although the proliferation of conventional T cells was not altered at early time points by anti-
CTLA-4 blocking antibody treatment, a non-proliferative change in these cells could be 
induced that indirectly affects regulatory T cell homeostasis.  For instance, it is known that 
upon activation, CD4+ FOXP3- conventional T cells produce the T cell growth factor 
cytokine IL-2 [317].  IL-2 has been found to overcome Treg anergy in vitro [57] and IL-2 
signalling has since been identified as a critical requirement for Treg homeostasis in vivo [80].  
Furthermore, augmented production of IL-2 by CD4+ FOXP3- conventional T cells in Ctla-4 
knockout mice was observed in chapter 3 (Fig. 3.26 F).  However, the short-term 
anti-CTLA-4 blockade experiments in normal mice did not identify any alterations in IL-2 
production by CD4+ non-Tregs; rather, they suggest that the steady-state Treg turnover seen 
in vivo [246] is subject to continuous inhibition via CTLA-4.  It is possible that the 
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dysregulated Treg homeostasis is exacerbated in the setting of Ctla-4-deficiency given the 
global lymphocyte activation and production of cytokines that further affect Treg 
homeostasis.       
 
STAT5 activation has been identified as crucial for signal transduction downstream of the 
IL-2 receptor and therefore maintenance of regulatory T cells [332, 333].  Consequently, it is 
possible that other common gamma chain cytokines, such as IL-7 and IL-15, which also 
activate STAT5, may additionally contribute to the maintenance of Treg homeostasis.  The 
number of FOXP3+ Tregs is not altered by IL-7 or IL-15 deficiency, however disrupted IL-2 
receptor signalling plus the loss of IL-7 or IL-15-induced signalling results in a greater 
decrease in Tregs compared to absence of IL-2-induced signalling alone (reviewed in [334]).  
It would therefore be interesting to analyse IL-7 and IL-15 production in Ctla-4-deficient 
mice and in wild type BALB/c mice following antibody-mediated CTLA-4 blockade.  
Although, it has been reported that other common gamma chain cytokines can promote the 
survival of Tregs, but only IL-2 induces their proliferation and clonal expansion [335].            
 
The CD28 co-stimulatory receptor is a second signal required for T cell activation and 
proliferation following TCR stimulation by antigen [182].  It has also been established that 
CD28 co-stimulation supports the survival and promotes the self-renewal of peripheral 
regulatory T cells [86, 131].  Data was obtained in this present study which supports the idea 
that CTLA-4 signalling controls regulatory T cell proliferation in response to encounter with 
self-antigen.  Furthermore, the augmented CD4+ FOXP3+ Treg proliferation upon 
antibody-mediated CTLA-4 blockade was found to be CD28-dependent.  This is as would be 
predicted from the maintenance of Ctla-4-deficient mice on a CD80/CD86-/- background or 
anti-CD80/86 blocking antibody treatment to overcome the lethal lymphoproliferative 
syndrome that develops in Ctla-4 gene-ablated mice and hinders their study.     
 
The secondary co-stimulatory molecule ICOS was not found to be involved in the augmented 
Treg proliferation observed upon loss of the CTLA-4 pathway following antibody-mediated 
blockade.  Although, others have previously shown that ICOS critically controls the pool size 
of FOXP3+ regulatory T cells, as well as effector-memory T cells, in the steady-state and in 
antigen-specific immune reactions [313].  However, in this study by Burmeister et al. analysis 
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of the CD4+ T cell population as a whole found that ICOS did not influence cell cycle 
progression, but rather promoted cell survival.  Consequently, the decreased occurrence of 
peripheral Treg cell death observed in Ctla-4-deficient mice (chapter 3.4) could be the result 
of the substantially increased ICOS expression by CD4+ FOXP3+ Tregs in Ctla-4-/- mice.  
 
Additionally, the role of the TNF receptor RANK in regulatory T cell development and 
homeostasis was investigated.  A role for the RANKL-RANK pathway in regulatory T cell 
development has been inferred because RANK has been proposed to be required for positive 
selection-mediated thymic medulla formation [315, 331], and it has been suggested that 
medullary thymic epithelial cells (mTECs), that promiscuously express self-antigen under the 
control of the autoimmune regulator AIRE, functionally determine whether thymocytes 
develop into FOXP3+ regulatory T cells [79].  The data obtained in this study found that 
RANK was not absolutely required for regulatory T cell development, as CD4+ FOXP3+ 
T cells were identified in the thymus and periphery of Rank-deficient mice.  This could be 
because the thymic medulla may not necessarily be the exclusive site of central tolerance 
induction.  Liston et al. have shown that cortical thymic epithelial cells (cTECs) are sufficient 
for supporting FOXP3+ Treg lineage differentiation [84].  Furthermore, it has recently been 
reported by Wirnsberger, Mair and Klein that FOXP3+ regulatory T cell development does 
not require a dedicated antigen-presenting cell, but rather there is T cell-intrinsic control of 
thymocyte Treg lineage differentiation [85].   
 
In the present study the peripheral Tregs that developed in Rank-deficient mice were found to 
exert suppressive function in vitro.  As highlighted in this investigation, it is still not clear 
whether or not CD4+ FOXP3+ Tregs express RANK and therefore whether it is directly or 
indirectly required for Treg function.  In future, the RANK signal detected by the SYBR 
green qPCR could be verified by analysis of cDNA obtained from Rank-/- cell preparations.  
Recently, Totsuka et al. found that the RANK-RANKL pathway was not required for 
CD4+ CD25+ Tregs to suppress the proliferation of CD4+ responder cell in vitro, but was 
critically involved in Treg-mediated suppression of colitis in vivo [316].  It was hypothesised 
that RANK may indirectly modulate Tregs via the interaction of RANKL (TRANCE) on 
Tregs with RANK-expressing dendritic cells.  Consistent with this, in this present study 
TRANCE expression by CD4+ T cells was augmented upon the loss of the CTLA-4 pathway.  
 210
This could possibly induce dendritic cell production of T cell growth and differentiation 
factors such as IL-15 [329] which has surprisingly been shown to induce dose-dependent Treg 
proliferation in a similar manner to IL-2 [336].  In line with this, Loser et al. reported that in 
the skin, epidermal TRANCE modulated regulatory T cell homeostasis via the activation of 
dendritic cells, although the molecular mechanisms underlying this control of Treg numbers 
was not determined [337].  Similarly, it has recently been reported that dendritic cells 
feedback to control regulatory T cell homeostasis in vivo as it was found loss of dendritic cells 
lead to a loss of Tregs and vice versa [338].  RANK is also expressed by chondrocytes and 
osteroclasts and been found to be involved in bone physiology [330].  These studies by Kong 
et al. used Ctla-4-deficient mice as a source of spontaneously activated T cells that expressed 
TRANCE, and found that all Ctla-4-/- mice displayed severe osteoporosis compared with 
littermate controls.  This suggests that the augmented TRANCE expression by CD4+ T cells 
in Ctla-4-deficient mice is significant enough to have a physiological effect via RANK.   
 
In future, it would be interesting to compliment the Rank-/- studies with analysis of 
Trance-deficient mice.  Also, it would be useful to generate Rank-/- foetal liver chimeras due 
to the multiple bone and lymphoid developmental defects in Rank-deficient mice which lead 
to a very short life-expectancy.  Additionally, the affect of positively and negatively 
modulating the RANK-RANKL pathway on regulatory T cell homeostasis could be 
investigated in vitro and in vivo with agonistic and antagonistic reagents, for example 












6.0 General Discussion 
 
In the periphery, regulatory T cells function to maintain immune homeostasis by suppressing 
the activation of any self-reactive T cells that avoided thymic central tolerance.  It is now well 
established that loss of peripheral tolerance leads to autoimmunity.  With the relatively recent 
revival in the concept of regulatory T cells, there has been renewed excitement in the possible 
therapeutic applications of Tregs for autoimmune diseases.  However, clinical implementation 
has proved challenging.  For treatment of autoimmune diseases and maintenance of tolerance 
following transplantation, the main aim is to boost regulatory T cell numbers and function.  
However, this therapeutic augmentation of tolerance does not want to be at the expense of 
protective immunity to infection.  Additionally, when developing treatments to suppress 
effector T cells, a simultaneous negative effect on the regulatory T cell population is not 
desirable.  On the other hand, regulatory T cell maintained tolerance is one of the main 
barriers to overcome in cancer therapy.   
 
The CTLA-4 receptor has long been thought to be important in the maintenance of peripheral 
tolerance since the observation that gene ablation of Ctla-4 in mice leads to the development 
of a lethal lymphoproliferation syndrome [156, 157].  The data obtained in this investigation 
extend knowledge and understanding of the Ctla-4 knockout mouse phenotype to include 
dysregulated Treg homeostasis and function.  This is in line with the constitutive expression 
of the CTLA-4 receptor by regulatory T cells and the hypothesis of a role for CTLA-4 in Treg 
suppressive function.  Overall, it was found that defects in the CTLA-4 receptor may 
uncouple Treg number and function.  This could potentially account for the enhanced 
regulatory T cell numbers sometimes observed in autoimmune diseases [249, 339] as 
polymorphisms in Ctla-4 are associated with autoimmunity [228, 229].  CTLA-4 blockade 
has recently been shown to increase regulatory T cell numbers in a mouse melanoma model 
[340] and in prostate cancer patients [268].  These findings could be viewed as discouraging 
since they suggest regulation is boosted alongside anti-tumor immunity following CTLA-4 
blockade.  However, in this present study it was found that Treg suppression in vivo was 
compromised in the absence of CTLA-4.  This raises the possibility that Tregs expanded by 
CTLA-4 blockade may show impaired regulation.  Thus, CTLA-4 blockade may enhance 
anti-tumor responses both by increasing effector T cell activation and simultaneously 
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decreasing Treg function.  This was recently assessed in a study using a transgenic mouse 
model of melanoma that expressed human CTLA-4 to evaluate the independent contributions 
of CTLA-4 blockade on the conventional and regulatory T cell compartments during cancer 
immunotherapy [341].  It was found that CTLA-4 blockade on conventional T cells, but not 
regulatory T cells enhanced anti-tumor responses, whereas CTLA-4 blockade of both T cell 
populations had synergistic anti-tumor activity.  It is possible that enhanced proliferation of 
regulatory T cells impairs their suppressive function.  However, it has previously been 
demonstrated by others that congenically marked, antigen-specific Tregs tracked in vivo 
exhibit efficient suppression despite extensive proliferation [342]. 
 
If in the future Tregs were to be used in the clinic as an immunotherapy for autoimmune 
diseases, the ex-vivo expansion of Tregs would be required to obtain sufficient numbers as 
natural Tregs constitute only 5-10% of peripheral blood lymphocytes.  Investigations such as 
this present study into the role of various pathways in Tregs homeostasis are critical in the 
development of a robust ex-vivo Treg expansion protocol.  For example, the data obtained 
here suggest that blockade of the CTLA-4 pathway could potentially be used to expand 
regulatory T cells.  However, it was also found that loss of the CTLA-4 pathway impaired 
regulatory T cell suppressive function in an adoptive transfer mouse model of autoimmune 
diabetes.  Therefore, further work is required to determine whether short-term blockade of the 
CTLA-4 pathway affects the function of regulatory T cells in the long-term, which could 
depend on the mechanism by which CTLA-4 functions in Treg suppressive activity.         
 
To obtain sufficient numbers of regulatory T cells to use as immunotherapy, expression of 
FOXP3 could also be induced in CD4+ FOXP3- conventional T cells.  As discussed 
previously in this study, various in vitro experiments and in vivo mouse models have clearly 
demonstrated that CD4+ FOXP3- conventional T cells can be effectively induced to express 
FOXP3.  However, little is known about the physiological occurrence of FOXP3+ regulatory 
T cell induction in humans.  Nadkarni et al. have found that anti-TNF-α antibody (infliximab) 
therapy gives rise to a newly generated CD4+ CD25hi FOXP3+ Treg population in 
rheumatoid arthritis patients responding to treatment.  The data obtained was consistent with 
the TGF-β-dependent differentiation of CD62L- CD4+ CD25hi FOXP3+ regulatory T cells 
with potent suppressor activity from CD4+ CD25- T cells [343].  The data obtained in this 
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present study found that the CTLA-4 receptor may function to restrict the induction of 
FOXP3 expression in CD4+ FOXP3- conventional T cells.  Modulation of CTLA-4 could 
therefore possibly be used in future to therapeutically induce FOXP3+ regulatory T cells.  
However, this current investigation found using an in vivo mouse model that upon loss of the 
CTLA-4 receptor, regulatory T cell suppressive function was impaired.  Relatively little is 
understood about the underlying mechanisms of induced Treg suppression.  TGF-β-induced 
FOXP3+ regulatory T cells have previously been shown to exert suppressive function in vivo 
[344, 345].  The data is consistent with antigen-specific Tregs being more potent suppressors 
than polyclonal Tregs [346, 347], and it has also been demonstrated that TGF-β-induced 
Tregs can function by inhibiting the stimulatory capacity of dendritic cells [113].                        
 
In order to make significant progress in the therapeutic modulation of regulatory T cells it is 
therefore important to fully understand the cellular and molecular mechanisms underlying 
Treg homeostasis and function.  A major therapeutic goal in the modulation of immune 
responses is manipulation of the CTLA-4 pathway.  However, the initial rationale for this 
approach (blockade of effector T cell inhibition [348]) has been complicated by the 
emergence of regulatory T cells which constitutively express the CTLA-4 receptor.  The 
design of strategies to target the CTLA-4 pathway needs to take into account potential effects 
on both the effector and regulatory T cell populations.  Some pathways have been found to 
possibly differentially regulate regulatory T cells and conventional T cells, but no single 
pathway has been found to regulate either Tregs or Tconv exclusively.  For example, 
superagonistic anti-CD28 antibodies were identified as a promising novel treatment for 
autoimmune disease due to the preferential expansion and activation of regulatory T cells over 
conventional T cells (reviewed in [349]).  However, the phase one human clinical trial 
resulted in a life-threatening cytokine release syndrome [350] as regulatory T cells did not 
rapidly control the conventional T cell response to the CD28 superagonist stimulation [351].  
Comprehensive understanding of regulatory T cell homeostasis and function is particularly 
important with respect to the plasticity between T cell subsets which has recently become 
evident, for example, the reciprocal relationship between adaptive Tregs and 
pro-inflammatory TH17 cells (reviewed in [352, 353]).  For instance, it has recently been 
demonstrated that FOXP3+ regulatory T cells can be induced to express the pro-inflammatory 
cytokine IL-17 [285, 354, 355].  Similarly, under the inflammatory conditions of the 
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Ctla-4-deficient mouse phenotype, it was found in this present study that CD4+ FOXP3+ 
regulatory T cells were capable of producing IL-17.     
 
Intriguingly, in this present study it was found that Ctla-4-deficient Tregs were capable of 
suppressing effector T cells in vitro, but were unable to control the development of 
autoimmune diabetes in vivo.  Thus, the capacity to regulate immune responses in vivo is not 
always accurately predicted from in vitro suppression assays.  This has previously been 
documented for IL-10 and TGF-β [141, 147].  The discrepancy between in vitro and in vivo 
suppression assays may reflect the fact that regulatory T cells are clearly equipped with 
multiple modes of action [134-137, 356], any of which may be sufficient for suppression in a 
controlled in vitro environment.  Consistent with this, it has previously been shown that the 
ability of Ctla-4-/- Tregs to suppress in vitro is partially dependent on TGF-β [231], 
suggesting that this pathway can compensate for the lack of CTLA-4.  In chapter 3 of this 
study it was found that CD4+ FOXP3+ Tregs from Ctla-4-deficient mice produced increased 
TGF-β compared to littermate controls.  In contrast, the mechanistic requirements for in vivo 
suppression may vary depending on the nature of the immune response and the tissue site.  
In vivo the trafficking of regulatory T cells to the appropriate target site to mediate 
suppression can be affected by many things, for example chemokine gradients that direct 
cellular movement or the crossing of the blood vessel endothelium.  Furthermore, it is 
difficult to manipulate and analyse in vivo the process of suppression, such as the active 
number of regulatory T cells, effector T cells and antigen-presenting cells.  In addition there is 
still the continued debate over where regulatory T cells exert suppressive function in vivo; the 
target tissue or draining lymph node.  Finally, over the last decade in vitro suppression assays 
have been widely used to investigate the suppressive function of regulatory T cells, however, 
no standard, uniform method has been employed with different groups developing and 
utilising diverse assays.               
 
Overall, the data obtained in this investigation shed new light on why defects in the CTLA-4 
receptor could be linked to the onset of autoimmunity and how therapeutic modulation of 
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